Document:

Asset Purchase Agreement and Plan of Reorganization

 EXHIBIT 10.1 
 ASSET PURCHASE AGREEMENT AND PLAN OF REORGANIZATION 
 This Asset Purchase Agreement and Plan
of Reorganization (this “Agreement”), dated as of July 25, 2008 (the “Effective Date”), is by and among Certified Diabetic Services, Inc., a Delaware corporation with a mailing address of 3030
Horseshoe Drive South, Suite 200, Naples, Florida 34104 (“CDIP”); Andover Medical, Inc., a Delaware corporation with a mailing address of 510 Turnpike Street, Suite 204, N. Andover, Massachusetts 01845
(“Andover,” collectively with CDIP, the “Target Companies” and sometimes each individually referred to as a “Target Company”); and Medical Solutions Management Inc., a Nevada
corporation with a mailing address of 237 Cedar Hill Street, Marlboro, Massachusetts 01752 (“MSMT”). MSMT and the Target Companies are each sometimes referred to individually as a “Constituent Company”
and collectively as the “Constituent Companies.” All capitalized terms used in this Agreement without definition shall have the respective meanings ascribed to such terms in Section 7.12 hereof. 
 BACKGROUND 
 The Board of
Directors of each Constituent Company has, by resolutions duly adopted, determined that it is in the best interests of its respective Constituent Company and its respective stockholders to consolidate the operations of CDIP and Andover with and into
MSMT (the “Reorganization”). In furtherance of the same, MSMT will issue shares of its capital stock to each Target Company in exchange for substantially all of the assets of each Target Company other than the Excluded
Assets. Upon consummation of the Reorganization, the parties intend that the stockholders of CDIP will own forty-five percent (45.0%) of the outstanding voting common stock, par value $0.0001, of MSMT (the “MSMT Common
Stock”); the stockholders of Andover will own thirty-five percent (35.0%) of the outstanding MSMT Common Stock; and the existing stockholders of MSMT will own twenty percent (20.0%) of the outstanding MSMT Common Stock (in
each case calculated immediately following the Closing and after giving effect to the conversion or exercise of all outstanding shares of MSMT Preferred Stock and all convertible debentures of MSMT which are convertible into shares of MSMT Common
Stock, but excluding any shares of MSMT Common Stock issuable upon the exercise of warrants or options of MSMT). In order to accomplish the above and enable the parties to receive the consideration set forth in this Agreement without having to
recognize income for federal income tax purposes, the transactions contemplated by this Agreement are being structured to qualify as a tax-free reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended
(the “Code”). In consideration of the foregoing and the mutual representations, warranties, covenants and agreements contained herein, the parties hereto agree as follows: 
 OPERATIVE PROVISIONS 
 ARTICLE I 
 EXCHANGE OF ASSETS FOR STOCK; CLOSING 
  

 -1- 

 1.1. Purchase and Sale. 
 (a) CDIP Purchase and Sale. Upon the terms and subject to the conditions of this Agreement, and in reliance upon the representations and warranties
contained herein, at the Closing, CDIP shall sell, transfer, convey, assign and deliver to MSMT, and MSMT shall purchase from CDIP, free and clear of all Liens and subject to the exclusions set forth in Section 1.2(a), all of the assets of CDIP
(the “CDIP Purchased Assets”) which shall include, without limitation: 
 (i) those shares of capital stock or other
equity interests of each subsidiary of CDIP set forth on Schedule 1.1(a)(i) hereto (each subsidiary, a “CDIP Subsidiary” and collectively, the “CDIP Subsidiaries”); 
 (ii) title to all of the property used or held for use in CDIP’s business, including without limitation, all furniture, fixtures, computers, office
equipment and miscellaneous assets of every kind and nature owned by CDIP or used in or necessary for the operation of its business; 
 (iii) all right, title and interest of CDIP in and to all contracts (expressly including unfilled contracts for services), agreements, leases, commitments, arrangements or understandings pertaining to the operation of CDIP’s business;

 (iv) all right, title and interest in and to all of the following: patents and patent rights, trademarks and trademark rights (whether
registered or not), including any goodwill therein, trade names and trade name rights, domain names, service marks and service mark rights, service names and service name rights, brand names, inventions, processes, formulae, copyrights and copyright
rights (whether registered or not), trade dress, business and product names, logos, slogans, trade secrets, industrial models, processes, designs, methodologies, computer programs, software (whether in source or object code) and related
documentation, technical information, manufacturing, engineering and technical drawings, know-how and all pending applications for and registrations of patents, trademarks, service marks and copyrights; the foregoing shall include, without
limitation, all software under development owned by CDIP and listed on Schedule 1.1(a)(iv) (including the software development schedule included therein) and all licenses, agreements and other arrangements under which CDIP has the right to
use any of the intangible or proprietary rights of a third party to the extent used or held for use by CDIP in the conduct of the business; 
 (v) all lists of present customers and lists of former customers and other customer-related records of CDIP’s business; 
 (vi) all goodwill associated with CDIP’s business or the CDIP Purchased Assets; 
 (vii) all books, files and records of CDIP
(including, without limitation, all surveys, schematics, flow charts, permit filings, mailing lists, customer lists, equipment maintenance records, warranty information, records of operations, payroll history, standard forms of documents, manuals of
operation or business procedures, training manuals and training aids and other proprietary or confidential information to the extent the same may be necessary or 

  

 -2- 

 
desirable for the operation of CDIP’s business) relating to CDIP’s business (other than minutes of corporate meetings, capital stock ledger and
purely corporate records); provided that any of the foregoing which CDIP reasonably deems necessary to CDIP’s continued operation, proper accounting and record keeping functions following the Closing shall not constitute part of the CDIP
Purchased Assets and shall be retained by CDIP; 
 (viii) all of the governmental permits, licenses, certificates of inspection, approvals
or other authorizations issued to CDIP and used in CDIP’s business (collectively, the “CDIP Governmental Permits”) (and to the extent any such permits are not assignable or transferable to MSMT, CDIP will use its best
efforts to cooperate with MSMT as may be reasonably requested to enable MSMT to apply for and obtain the CDIP Governmental Permits or to receive the benefits of the CDIP Governmental Permits); and 
 (ix) except as specifically provided in Section 1.2(a), all other assets of CDIP that exist on the Closing Date, whether tangible or intangible,
real or personal. 
 (b) Andover Purchase and Sale. Upon the terms and subject to the conditions of this Agreement, and in reliance
upon the representations and warranties contained herein, at the Closing, Andover shall sell, transfer, convey, assign and deliver to MSMT, and MSMT shall purchase from Andover, free and clear of all Liens and subject to the exclusions set forth in
Section 1.2(b), all of the assets of Andover (the “Andover Purchased Assets”) which shall include, without limitation: 
 (i) those shares of capital stock of each subsidiary of Andover set forth on Schedule 1.1(b)(i) hereto (each subsidiary, an “Andover Subsidiary” and collectively, the “Andover
Subsidiaries”); 
 (ii) title to all of the property used or held for use in Andover’s business, including without
limitation, all furniture, fixtures, computers, office equipment and miscellaneous assets of every kind and nature owned by Andover or used in or necessary for the operation of its business; 
 (iii) all right, title and interest of Andover in and to all contracts (expressly including unfilled contracts for services), agreements, leases,
commitments, arrangements or understandings pertaining to the operation of Andover’s business; 
 (iv) all right, title and interest in
and to all of the following: patents and patent rights, trademarks and trademark rights (whether registered or not), including any goodwill therein, trade names and trade name rights, domain names, service marks and service mark rights, service
names and service name rights, brand names, inventions, processes, formulae, copyrights and copyright rights (whether registered or not), trade dress, business and product names, logos, slogans, trade secrets, industrial models, processes, designs,
methodologies, computer programs, software (whether in source or object code) and related documentation, technical information, manufacturing, engineering and technical drawings, know-how and all pending applications for and registrations of
patents, trademarks, service marks and copyrights; the foregoing shall include, without limitation, all software under development owned by Andover and listed on Schedule 1.1(b)(iv) and all licenses, agreements 

  

 -3- 

 
and other arrangements under which Andover has the right to use any of the intangible or proprietary rights of a third party to the extent used or held for
use by Andover in the conduct of the business; 
 (v) all lists of present customers and lists of former customers and other
customer-related records of Andover’s business; 
 (vi) all goodwill associated with Andover’s business or the Andover Purchased
Assets; 
 (vii) all books, files and records of Andover (including, without limitation, all surveys, schematics, flow charts, permit
filings, mailing lists, customer lists, equipment maintenance records, warranty information, records of operations, payroll history, standard forms of documents, manuals of operation or business procedures, training manuals and training aids and
other proprietary or confidential information to the extent the same may be necessary or desirable for the operation of Andover’s business) relating to Andover’s business (other than minutes of corporate meetings, capital stock ledger and
purely corporate records); provided that any of the foregoing which Andover reasonably deems necessary to Andover’s continued operation, proper accounting and record keeping functions following the Closing shall not constitute part of the
Andover Purchased Assets and shall be retained by Andover; 
 (viii) all of the governmental permits, licenses, certificates of inspection,
approvals or other authorizations issued to Andover and used in Andover’s business (collectively, the “Andover Governmental Permits”) (and to the extent any such permits are not assignable or transferable to MSMT,
Andover will use its best efforts to cooperate with MSMT as may be reasonably requested to enable MSMT to apply for and obtain the Andover Governmental Permits or to receive the benefits of the Andover Governmental Permits); and 
 (ix) except as specifically provided in Section 1.2(b), all other assets of Andover that exist on the Closing Date, whether tangible or intangible,
real or personal. 
 1.2. Excluded Assets. 
 (a) CDIP Excluded Assets. Notwithstanding the provisions of Section 1.1(a), it is hereby agreed that the CDIP Purchased Assets shall not include, and CDIP is not selling to MSMT, and MSMT is not purchasing
or acquiring from CDIP, the assets listed on Schedule 1.2 (a) (collectively, the “CDIP Excluded Assets”). 
 (b) Andover Excluded Assets. Notwithstanding the provisions of Section 1.1(b), it is hereby agreed that the Andover Purchased Assets shall not include, and Andover is not selling to MSMT, and MSMT is not purchasing or acquiring
from Andover, the assets listed on Schedule 1.2(b) (collectively, the “Andover Excluded Assets”). 
 1.3.
Assumed Liabilities. 
 (a) CDIP Assumed Liabilities. In further consideration of the transfers contemplated hereby, MSMT shall
assume, effective as of the Closing Date, and shall satisfy or perform as they come due, all liabilities and obligations of CDIP (collectively, the “CDIP  

  

 -4- 

 
Assumed Liabilities”) except for the CDIP Excluded Liabilities. For purposes of this Agreement, the term “CDIP Excluded
Liabilities” shall mean (i) any liability arising out of or related to the CDIP Excluded Assets; (ii) any liability arising out of or related to the negotiation, consummation or performance of the Reorganization, including,
without limitation, any suit filed by a stockholder or creditor of CDIP (whether directly or in the nature of a derivative action) against CDIP, any member of its Board of Directors or any of its officers alleging a breach of fiduciary duty (or any
claims of a similar nature) by any member of such Board of Directors or any officer; and (iii) any liability set forth on Schedule 1.3(a). 
 (b) Andover Assumed Liabilities. In further consideration of the transfers contemplated hereby, MSMT shall assume, effective as of the Closing Date, and shall satisfy or perform as they come due, all
liabilities and obligations of Andover (collectively, the “Andover Assumed Liabilities”) except for the Andover Excluded Liabilities. For purposes of this Agreement, the term “Andover Excluded
Liabilities” shall mean (i) any liability arising out of or related to the Andover Excluded Assets; (ii) any liability arising out of or related to the negotiation, consummation or performance of the Reorganization, including,
without limitation, any suit filed by a stockholder or creditor of Andover (whether directly or in the nature of a derivative action) against Andover, any member of its Board of Directors or any of its officers alleging a breach of fiduciary duty
(or any claims of a similar nature) by any member of such Board of Directors or any officer; and (iii) any liability set forth on Schedule 1.3(b). 
 1.4. Purchase Price. 
 (a) CDIP Purchase Price. In consideration of the sale, transfer,
assignment, conveyance and delivery by CDIP of the CDIP Purchased Assets to MSMT and of the other agreements of CDIP stated herein, MSMT shall issue the following shares of its voting capital stock to CDIP: 
 (i) Common Stock. MSMT shall issue to CDIP shares of MSMT Common Stock equal to the product of (a) the number of shares of CDIP voting common
stock, par value $0.001 (the “CDIP Common Stock”), issued and outstanding immediately prior to the Closing, and (b) the CDIP Pricing Ratio. 
 (ii) Preferred Stock. MSMT shall issue to CDIP Four Hundred Sixty- Six Thousand (466,000) shares of its Series B Voting Convertible Preferred Stock, par value $0.0001, in the form set forth in the MSMT
Charter Amendment (the “Series B Preferred Stock”) and Eleven Million Two Hundred Seventy-Two Thousand Three Hundred Fifty-Six (11,272,356) shares of its Series C Voting Convertible Preferred Stock, par value $0.0001, in
the form set forth in the MSMT Charter Amendment (the “Series C Preferred Stock”). 
 (b) Andover Purchase
Price. In consideration of the sale, transfer, assignment, conveyance and delivery by Andover of the Andover Purchased Assets to MSMT and of the other agreements of Andover stated herein, MSMT shall issue the following shares of its voting
capital stock to Andover: 
 (i) Common Stock. MSMT shall issue to Andover shares of MSMT Common Stock equal to the product of
(a) the number of shares of Andover voting common 

  

 -5- 

 
stock, par value $0.001 (the “Andover Common Stock”) issued and outstanding immediately prior to the Closing, and (b) the
Andover Pricing Ratio. The Andover Common Stock and CDIP Common Stock are sometimes referred to herein collectively as the “TC Common Stock.” 
 (ii) Preferred Stock. MSMT shall issue to Andover Five Million Sixty-Five Thousand Eight Hundred (5,065,800) shares of its Series A Voting Convertible Preferred Stock, par value $0.0001, in the form set
forth in the MSMT Charter Amendment (the “Series A Preferred Stock,” collectively with the Series B Preferred Stock and Series C Preferred Stock, the “MSMT Preferred Stock” and collectively with the
MSMT Common Stock, the “MSMT Securities”) and Two Million Six Hundred Seventy-Seven Thousand Six Hundred Forty-Four (2,677,644) shares of Series C Preferred Stock. 
 1.5. Common Stock Purchase Warrants of the Target Companies. 
 (a) Common Stock Purchase Warrants of CDIP. At the Closing, each outstanding warrant to purchase CDIP Common Stock set forth on Schedule 1.5(a) (the “CDIP Warrants”), shall be
assumed by MSMT and the holder thereof shall be entitled to be issued a new MSMT warrant to purchase a number of shares of MSMT Common Stock equal to the product (rounded up to the nearest whole number) of (a) the number of shares of CDIP
Common Stock subject to the CDIP Warrant immediately prior to the Closing and (b) the CDIP Pricing Ratio; at an exercise price per share (rounded down to the nearest whole cent) equal to (x) the exercise price per share of such CDIP
Warrant immediately prior to the Closing divided by (y) the CDIP Pricing Ratio (all of the foregoing collectively, the “Assumed CDIP Warrants”). MSMT shall assume the CDIP Warrants and the terms (as in effect as of the
Closing) of such agreements by which such CDIP Warrants are evidenced. CDIP shall, as promptly as reasonably practicable but in any event not later than ten (10) days following the Closing, furnish to each holder of the Assumed CDIP Warrants a
notice of the consummation of the Reorganization, which notice shall set forth such assumption of the CDIP Warrants and include the amount of MSMT Common Stock into which each Assumed CDIP Warrant is exercisable. At the request of a holder and upon
surrender of each Assumed CDIP Warrant, MSMT shall deliver to the holder a new MSMT warrant evidencing the rights of the holder to purchase MSMT Common Stock, which new MSMT warrant shall in all other respects be identical to the surrendered Assumed
CDIP Warrant. 
 (b) Common Stock Purchase Warrants of Andover. At the Closing, each outstanding warrant to purchase Andover Common
Stock set forth on Schedule 1.5(b) (the “Andover Warrants”), shall be assumed by MSMT and the holder thereof shall be entitled to be issued a new MSMT warrant to purchase a number of shares of MSMT Common Stock equal
to the product (rounded up to the nearest whole number) of (a) the number of shares of Andover Common Stock subject to the Andover Warrant immediately prior to the Closing and (b) the Andover Pricing Ratio; at an exercise price per share
(rounded down to the nearest whole cent) equal to (x) the exercise price per share of such Andover Warrant immediately prior to the Closing divided by (y) the Andover Pricing Ratio (all of the foregoing collectively, the
“Assumed Andover Warrants,” and collectively with the CDIP Assumed Warrants, the “Assumed Warrants”). MSMT shall assume the Andover Warrants and the terms (as in effect as of the Closing) of such
agreements by which such Andover Warrants are evidenced. Andover shall, as promptly as reasonably practicable but in any event not later than ten (10) days 

  

 -6- 

 
following the Closing, furnish to each holder of the Assumed Andover Warrants a notice of the consummation of the Reorganization, which notice shall set
forth such assumption of the Andover Warrants and include the amount of MSMT Common Stock into which each Andover Warrant is exercisable. At the request of a holder and upon surrender of each Assumed Andover Warrant, MSMT shall deliver to the holder
a new MSMT warrant evidencing the rights of the holder to purchase MSMT Common Stock, which new MSMT warrant shall in all other respects be identical to the surrendered Assumed Andover Warrant. 
 1.6. Stock Options of Target Companies. 
 (a) Stock Options of CDIP. At the Closing, each option to purchase CDIP Common Stock set forth on Schedule 1.6(a) (collectively, the “CDIP Options”) that is outstanding and unexercised immediately prior
to the Closing (collectively, the “Assumed CDIP Options”), whether or not vested, shall be assumed by MSMT (such assumption inclusive of the terms of the option agreement by which such option is evidenced as in effect as of
the Closing Date) and the holder thereof shall be entitled to be issued a new MSMT option to purchase the number of shares of MSMT Common Stock equal to the product of (a) the number of shares of CDIP Common Stock that were subject to such
Assumed CDIP Option immediately prior to the Closing and (b) the CDIP Pricing Ratio, and rounding the resulting number up to the nearest whole number of MSMT Common Stock; at a per share exercise price equal to the quotient of (x) the per
share exercise price of CDIP Common Stock subject to such Assumed CDIP Option, as in effect immediately prior to the Closing and (y) the CDIP Pricing Ratio, and rounding the resulting exercise price down to the nearest whole cent. Any remaining
restrictions on the exercise of any Assumed CDIP Option shall continue in full force and effect and the term, exercisability, remaining vesting schedule and other provisions of such Assumed CDIP Option shall otherwise remain unchanged as a result of
the assumption of such Assumed CDIP Option. CDIP shall, as promptly as reasonably practicable but in any event not later than ten (10) days following the Closing, furnish to each holder of the Assumed CDIP Options a notice of the consummation
of the Reorganization, which notice shall set forth such assumption of the CDIP Options and include the amount of MSMT Common Stock into which each CDIP Option is exercisable. At the request of a holder and upon surrender of each Assumed CDIP
Option, MSMT shall deliver to the holder a new MSMT option evidencing the rights of the holder to purchase MSMT Common Stock, which new MSMT option shall in all other respects be identical to the surrendered Assumed CDIP Option. 
 (b) Stock Options of Andover. At the Closing, each option to purchase Andover Common Stock set forth on Schedule 1.6(b) (collectively, the
“Andover Options”) that is outstanding and unexercised immediately prior to the Closing (collectively, the “Assumed Andover Options” and collectively with the Assumed CDIP Options, the
“Assumed Options”), whether or not vested, shall be assumed by MSMT (such assumption inclusive of the terms of the option agreement by which such option is evidenced as in effect as of the Closing Date) and the holder thereof
shall be entitled to be issued a new MSMT option to purchase the number of shares of MSMT Common Stock equal to the product of (a) the number of shares of Andover Common Stock that were subject to such Assumed Andover Option immediately prior
to the Closing and (b) the Andover Pricing Ratio, and rounding the resulting number up to the nearest whole number of MSMT Common Stock; at a per share exercise price equal to the quotient of (x) the per share exercise price of Andover
Common Stock subject to such Assumed Andover 

  

 -7- 

 
Option, as in effect immediately prior to the Closing and (y) the Andover Pricing Ratio, and rounding the resulting exercise price down to the nearest
whole cent. Any remaining restrictions on the exercise of any Assumed Andover Option shall continue in full force and effect and the term, exercisability, remaining vesting schedule and other provisions of such Assumed Andover Option shall otherwise
remain unchanged as a result of the assumption of such Assumed Andover Option. Andover shall, as promptly as reasonably practicable but in any event not later than ten (10) days following the Closing, furnish to each holder of the Assumed
Andover Options a notice of the consummation of the Reorganization, which notice shall set forth such assumption of the Andover Options and include the amount of MSMT Common Stock into which each Andover Option is exercisable. At the request of a
holder and upon surrender of each Assumed Andover Option, MSMT shall deliver to the holder a new MSMT option evidencing the rights of the holder to purchase MSMT Common Stock, which new MSMT option shall in all other respects be identical to the
surrendered Assumed Andover Option. 
 1.7. Escrow of Additional MSMT Common Stock. At the Closing, MSMT shall issue shares of MSMT
Common Stock in an amount equal to eight percent (8%) of the issued and outstanding MSMT Common Stock (calculated immediately following the Closing and after giving effect to the conversion or exercise of all outstanding shares of MSMT
Preferred Stock and all convertible debentures of MSMT which are convertible into shares of MSMT Common Stock, but excluding any shares of MSMT Common Stock issuable upon the exercise of warrants or options of MSMT) (the “Escrow
Shares”) to the Escrow Agent (as such term is defined in the Escrow Agreement) pursuant to an escrow agreement by and among the Constituent Companies and the Escrow Agent, the form of which is attached hereto as Exhibit
1.7 (the “Escrow Agreement”). The Escrow Shares shall be distributed in accordance with the terms of the Escrow Agreement. 
 1.8. Distribution of MSMT Securities. 
 (a) CDIP Distribution of MSMT Securities. CDIP hereby
covenants and agrees that, as soon as practicable after the Closing Date and no later than forty-five (45) days following the Closing Date, CDIP shall distribute the MSMT Securities received by it pursuant to Section 1.4(a) and the notices
referenced in Sections 1.5 and 1.6 regarding the Assumed CDIP Warrants and Assumed CDIP Options as follows: 
 (i) MSMT Common Stock received
by CDIP pursuant to Section 1.4(a)(i) shall be distributed by CDIP on a pro-rata basis to the holders of record of CDIP Common Stock existing on the Closing Date; 
 (ii) Series B Preferred Stock received by CDIP pursuant to Section 1.4(a)(ii) shall be distributed by CDIP on a pro-rata basis to the holders of record of CDIP Series B Preferred Stock existing on the Closing
Date; 
 (iii) Series C Preferred Stock received by CDIP pursuant to Section 1.4(a)(ii) shall be distributed by CDIP on a pro-rata
basis to the holders of record of CDIP Series C Preferred Stock and CDIP Series D Preferred Stock existing on the Closing Date; 
  

 -8- 

 (iv) notices regarding the Assumed CDIP Warrants received by CDIP pursuant to Section 1.5(a) shall
be distributed to the holders of record thereof; and 
 (v) notices regarding the Assumed CDIP Options received by CDIP pursuant to
Section 1.6(a) shall be distributed to the holders of record thereof. 
 (b) Andover Distribution of MSMT Securities. Andover
hereby covenants and agrees that, as soon as practicable after the Closing Date and no later than forty-five (45) days following the Closing Date, Andover shall distribute the MSMT Securities received by it pursuant to Section 1.4(b) and
the notices referenced in Section 1.5 and 1.6 regarding the Assumed Andover Warrants and Assumed Andover Options as follows: 
 (i) MSMT
Common Stock received by Andover pursuant to Section 1.4(b)(i) shall be distributed by Andover on a pro-rata basis to the holders of record of Andover Common Stock existing on the Closing Date; 
 (ii) Series A Preferred Stock received by Andover pursuant to Section 1.4(b)(ii) shall be distributed by Andover on a pro-rata basis to the holders
of record of Andover 6% Series A Convertible Preferred Stock existing on the Closing Date; 
 (iii) Series C Preferred Stock received by
Andover pursuant to Section 1.4(b)(ii) shall be distributed by Andover on a pro-rata basis to the holders of record of Andover 6% Series B Convertible Preferred Stock and 8% Series D Convertible Preferred Stock existing on the Closing Date;

 (iv) notices regarding the Assumed Andover Warrants received by Andover pursuant to Section 1.5(b) shall be distributed to the
holders of record thereof; and 
 (v) notices regarding the Assumed Andover Options received by Andover pursuant to Section 1.6(b)
shall be distributed to the holders of record thereof. 
 (c) Issuance of MSMT Securities. In connection with the distribution of the
MSMT Securities by each Target Company as contemplated in Sections 1.8(a) and 1.8(b), within five (5) Business Days after the Closing each Target Company shall deliver to MSMT a notice certifying the names of the stockholders of record to whom
each Target Company will distribute the MSMT Securities. Each notice shall contain the name and address of each such stockholder of record and the number and class of shares of MSMT Securities to which each such stockholder is entitled. Upon receipt
of each such notice, MSMT will cause its transfer agent to issue stock certificates in the names and denominations set forth therein and to deliver the same to each Target Company within thirty (30) days after the Closing. MSMT shall cause its
transfer agent to issue stock certificates which are, assuming the continued effectiveness of the Registration Statement, free of any restrictions or restrictive legends (other than with respect to certificates to be issued to the Persons listed on
Schedule 1.8(c) hereto who have been identified by MSMT as Persons who will be Affiliates of MSMT immediately following the Closing). 
 1.9. No Fractional Shares. No fraction of a share of MSMT Common Stock will be issued to Andover or CDIP (or subsequently distributed by Andover or CDIP to their respective shareholders). In lieu thereof, MSMT, CDIP and Andover shall
round down any fractional 

  

 -9- 

 
shares to the nearest whole number of shares of MSMT Common Stock. Any shares of MSMT Common Stock remaining after a Target Company’s distribution to
its shareholders in accordance with Section 1.8 hereof shall be forwarded to MSMT for retirement. 
 1.10. Adjustment to Pricing
Ratios. The CDIP Pricing Ratio and the Andover Pricing Ratio, as applicable, shall be equitably adjusted to reflect fully the effect of (a) any stock split, reverse split, stock combination, stock dividend (including any dividend or
distribution of securities convertible into CDIP Common Stock, Andover Common Stock or MSMT Common Stock), reorganization, reclassification, recapitalization or other like change with respect to CDIP Common Stock, Andover Common Stock or MSMT Common
Stock occurring after the Effective Date and prior to the Closing Date; and (b) any adjustment required as a result of any breach of the representations and warranties contained in Sections 2.1(f), 2.2(f) or 2.3(f), as contemplated by
Section 4.12. In addition, the Constituent Companies acknowledge that the CDIP Pricing Ratio and the Andover Pricing Ratio reflect the issuance of securities contemplated by the New MSMT Financing and New Andover Financing. In the event that
either the New MSMT Financing or New Andover Financing have not been consummated prior to Closing, the CDIP Pricing Ratio and Andover Pricing Ratio will adjusted accordingly. At the Closing, the Constituent Companies will execute a certificate
containing the definitive CDIP Pricing Ratio and Andover Pricing Ratio. 
 1.11. Closing. The closing contemplated by this Agreement
(the “Closing” and such date the Closing occurs on, the “Closing Date”) shall be held at the offices of Bush Ross, P.A., 1801 N. Highland Avenue, Tampa, Florida 33602, on a date determined by mutual
agreement among the Constituent Companies which date shall be as soon as practicable after the satisfaction or waiver (subject to applicable law) of the latest to occur of the conditions set forth in Article V hereof (other than those conditions
that relate to action to be taken at the Closing, but subject to satisfaction of such conditions at Closing), unless this Agreement has been theretofore terminated pursuant to its terms or unless extended by mutual written agreement of the
Constituent Companies. At the Closing, the following deliveries shall be made to the applicable parties: 
 (a) a bill of sale for the CDIP
Purchased Assets in the form of Exhibit 1.11(a) (the “CDIP Bill of Sale”) executed by CDIP in favor of MSMT; 
 (b) a bill of sale for the Andover Purchased Assets in the form of Exhibit 1.11(b) (the “Andover Bill of Sale”) executed by Andover in favor of MSMT; 
 (c) an assignment of the CDIP Purchased Assets that are intangible personal property of CDIP in the form of Exhibit 1.11(c), which
assignment shall also contain MSMT’s undertaking and assumption of the CDIP Assumed Liabilities (the “CDIP Assignment, Release and Assumption Agreement”), executed by CDIP and MSMT; 
 (d) an assignment of the Andover Purchased Assets that are intangible personal property of Andover in the form of Exhibit 1.11(d), which
assignment shall also contain MSMT’s undertaking and assumption of the Andover Assumed Liabilities (the “Andover Assignment, Release and Assumption Agreement”), executed by Andover and MSMT; 
  

 -10- 

 (e) an assignment of the CDIP Intellectual Property Rights in the form of Exhibit 1.11(e)
executed by CDIP and MSMT; 
 (f) intentionally omitted; 
 (g) certificates representing all of the outstanding shares of each CDIP Subsidiary, duly endorsed (or accompanied by duly executed stock powers in form and substance reasonably satisfactory to MSMT and Andover) and,
signed by CDIP, for transfer to MSMT; 
 (h) certificates representing all of the outstanding shares of each Andover Subsidiary, duly
endorsed (or accompanied by duly executed stock powers in form and substance reasonably satisfactory to MSMT and CDIP) and, signed by Andover, for transfer to MSMT; 
 (i) the Escrow Agreement executed by CDIP, Andover and MSMT; 
 (j) a list, certified as true, correct and
complete by an officer of CDIP of all of the stockholders of CDIP as of the Closing Date and the number and class of securities owned by each such stockholder on the Closing Date; 
 (k) a list, certified as true, correct and complete by an officer of Andover of all of the stockholders of Andover as of the Closing Date and the number
and class of securities owned by each such stockholder on the Closing Date; 
 (l) a list, certified as true, correct and complete by an
officer of MSMT of all of the stockholders of MSMT as of the Closing Date and the number and class of securities owned by each such stockholder on the Closing Date; 
 (m) a certificate of the secretary of CDIP, certifying (i) that the resolutions attached to such certificate authorizing and approving the execution and delivery of this Agreement and the Transaction Documents to
which CDIP is a party and the consummation of the transactions contemplated hereby and thereby were duly adopted by CDIP, (ii) that such resolutions have not been amended and remain in full force and effect, (iii) as to the incumbency of
each signatory to this Agreement and each Transaction Document to which CDIP is a party and (iv) attaching certificates, dated not more than five (5) days prior to the Closing Date, of the relevant Governmental Authority or other
appropriate official in each state in which CDIP and each CDIP Subsidiary are organized as to each of the aforementioned entities’ legal existence and good standing in such state; 
 (n) a certificate of the secretary of Andover, certifying (i) that the resolutions attached to such certificate authorizing and approving the
execution and delivery of this Agreement and the Transaction Documents to which Andover is a party and the consummation of the transactions contemplated hereby and thereby were duly adopted by Andover, (ii) that such resolutions have not been
amended and remain in full force and effect, (iii) as to the incumbency of each signatory to this Agreement and each Transaction Document to which Andover is a party and (iv) attaching certificates, dated not more than five (5) days
prior to the Closing Date, of the relevant Governmental Authority or other appropriate official in each state in which Andover and each Andover Subsidiary are organized as to each of the aforementioned entities’ legal existence and good
standing in such state; 
  

 -11- 

 (o) a certificate of the secretary of MSMT, certifying (i) that the resolutions attached to such
certificate authorizing and approving the execution and delivery of this Agreement and the Transaction Documents to which MSMT is a party and the consummation of the transactions contemplated hereby and thereby were duly adopted by MSMT,
(ii) that such resolutions have not been amended and remain in full force and effect, (iii) as to the incumbency of each signatory to this Agreement and each Transaction Document to which MSMT is a party and (iv) attaching
certificates, dated not more than five (5) days prior to the Closing Date, of the relevant Governmental Authority or other appropriate official in each state in which MSMT and each MSMT Subsidiary are organized as to each of the aforementioned
entities’ legal existence and good standing in such state; 
 (p) a certificate executed by CDIP’s Chief Executive Officer or Chief
Financial Officer stating that, with respect to CDIP, the conditions set forth in Sections 5.1(a) and 5.1(b), as they relate to CDIP, have been satisfied; the condition set forth in Section 5.1(e) as it relates to the stockholders of CDIP has
been satisfied; and the conditions set forth in Sections 5.2(b)(i), 5.2(c)(i), 5.2(d)(i), 5.3(b)(ii), 5.3(c)(ii) and 5.3(d)(ii) have been satisfied; 
 (q) a certificate executed by Andover’s Chief Executive Officer or Chief Financial Officer stating that with respect to Andover, the conditions set forth in Sections 5.1(a) and 5.1(b), as they relate to Andover,
have been satisfied; the condition set forth in Section 5.1(e) as it relates to the stockholders of Andover has been satisfied; and the conditions set forth in Sections 5.2(b)(ii), 5.2(c)(ii), 5.2(d)(ii), 5.4(b)(ii), 5.4(c)(ii) and 5.4(d)(ii)
have been satisfied; 
 (r) a certificate executed by MSMT’s Vice President-Controller stating that with respect to MSMT, the conditions
set forth in Sections 5.1(a) and 5.1(b), as they relate to MSMT, have been satisfied; the conditions set forth in 5.1(c) and 5.1(d) have been satisfied; the condition set forth in Section 5.1(e) as it relates to the stockholders of MSMT has
been satisfied; and the conditions set forth in Sections 5.3(b)(i), 5.3(c)(i), 5.3(d)(i), 5.4(b)(i), 5.4(c)(i) and 5.4(d)(i) have been satisfied; 
 (s) certificates representing the shares of MSMT Common Stock to be issued to CDIP, duly endorsed (or accompanied by duly executed stock powers in form and substance reasonably satisfactory to CDIP) and, signed by MSMT; 
 (t) certificates representing the shares of MSMT Common Stock to be issued to Andover, duly endorsed (or accompanied by duly executed stock powers in
form and substance reasonably satisfactory to Andover) and, signed by MSMT; 
 (u) certificates representing the shares of Series B Preferred
Stock and Series C Preferred Stock to be issued to CDIP, duly endorsed (or accompanied by duly executed stock powers in form and substance reasonably satisfactory to CDIP) and, signed by MSMT; 
 (v) certificates representing the shares of Series A Preferred Stock and Series C Preferred Stock to be issued to Andover, duly endorsed (or accompanied
by duly executed stock powers in form and substance reasonably satisfactory to Andover) and, signed by MSMT; 
 (w) a certified copy of the
MSMT Charter Amendment as filed with the Secretary of State of the State of Nevada; 
  

 -12- 

 (x) notices relating to the Assumed CDIP Options and the Assumed CDIP Warrants; and 
 (y) notices relating to the Assumed Andover Options and the Assumed Andover Warrants. 
 1.12. Post-Reorganization Capitalization Table. Attached hereto as Exhibit 1.12 is a post-Reorganization capitalization table of
MSMT after giving effect to the transactions contemplated by this Agreement and the New MSMT Financing and New Andover Financing. (such post-Closing capitalization table shall be prepared on both a pre-split and post-split basis). 
 ARTICLE II 
 REPRESENTATIONS AND
WARRANTIES OF THE CONSTITUENT COMPANIES 
 2.1. Representations and Warranties of Andover. Except as set forth under the
corresponding section of the disclosure schedules delivered to each of CDIP and MSMT concurrently herewith (the “Andover Disclosure Schedules”) or as otherwise disclosed in the Andover SEC Reports (as defined below) filed by
Andover, which Andover Disclosure Schedules and Andover SEC Reports shall be deemed a part hereof and to qualify any representation or warranty otherwise made herein to the extent of such disclosure, Andover hereby makes the representations and
warranties set forth below to CDIP and MSMT: 
 (a) Subsidiaries. All of the direct and indirect subsidiaries of Andover are set forth
on Schedule 1.1(b)(i). Except as set forth on Schedule 1.1(b)(i), Andover owns, directly or indirectly, all of the capital stock or other equity interests of each Andover Subsidiary free and clear of any Liens, and all the issued and
outstanding shares of capital stock of each Andover Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. 
 (b) Organization and Qualification. Andover and each Andover Subsidiary is duly incorporated or otherwise organized, validly existing and in good
standing under the laws of the jurisdiction of incorporation or organization (as applicable), with the requisite corporate power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither
Andover nor any Andover Subsidiary is in violation or default of any of the provisions of its certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of Andover and each Andover Subsidiary is duly
qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to
be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to
revoke, limit or curtail such power and authority or qualification. 
 (c) Authorization; Enforcement. Andover has the requisite
corporate power and authority to enter into and to consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The 

  

 -13- 

 
execution and delivery of each of the Transaction Documents by Andover and the consummation by it of the transactions contemplated hereby have been duly
authorized by all necessary corporate action on the part of Andover and no further action is required by Andover, its Board of Directors or its stockholders in connection therewith other than in connection with the Andover Required Approvals (as
defined in Section 2.1(e) hereof). Each Transaction Document has been (or upon delivery will have been) duly executed by Andover and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding
obligation of Andover enforceable against Andover in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law. 
 (d) No Conflicts. The execution, delivery and performance of the Transaction Documents
by Andover and the consummation by Andover of the other transactions contemplated hereby and thereby do not and will not: (i) conflict with or violate any provision of Andover’s or any Andover Subsidiary’s certificate or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) subject to the Andover Required Approvals, conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under,
result in the creation of any Lien upon any of the properties or assets of Andover or any Andover Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of,
any agreement, credit facility, debt or other instrument or other understanding to which Andover or any Andover Subsidiary is a party or by which any property or asset of Andover or any Andover Subsidiary is bound or affected, or (iii) subject
to the Andover Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or Governmental Authority to which Andover or an Andover Subsidiary is
subject (including federal and state securities laws and regulations), or by which any property or asset of Andover or an Andover Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or
reasonably be expected to result in a Material Adverse Effect. 
 (e) Filings, Consents and Approvals. Neither Andover nor any Andover
Subsidiary is required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other Governmental Authority or other Person in connection with
the execution, delivery and performance by Andover of the Transaction Documents, other than the delivery of the notices and the receipt of the approvals set forth on Schedule 2.1(e) (collectively, the “Andover Required
Approvals”). 
 (f) Capitalization. The capitalization of Andover is as set forth on Schedule 2.1(f). Except as
set forth on Schedule 2.1(f), Andover has not issued any capital stock since its most recently filed periodic report under the Exchange Act. Except as set forth on Schedule 2.1(f), no Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth on Schedule 2.1(f), there are no outstanding options, warrants, script rights to subscribe
to, calls or commitments of any character whatsoever relating to, or securities, rights or 

  

 -14- 

 
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Andover Common
Stock, or contracts, commitments, understandings or arrangements by which Andover or any Andover Subsidiary is or may become bound to issue additional shares of Andover Common Stock or Common Stock Equivalents. All of the outstanding shares of
capital stock of Andover are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. Except as set forth on Schedule 2.1(f), there are no stockholders agreements, voting agreements or other similar agreements with respect to Andover’s capital stock to which Andover is a
party or, to the knowledge of Andover, between or among any of Andover’s stockholders. 
 (g) SEC Reports; Financial Statements.
Except as set forth on Schedule 2.1(g), Andover has filed all reports, schedules, forms, statements and other documents required to be filed by it under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or
15(d) thereof, since August 31, 2006 (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “Andover SEC Reports”) on a
timely basis or has received a valid extension of such time of filing and has filed any such Andover SEC Reports prior to the expiration of any such extension. As of their respective dates, each Andover SEC Report (i) was prepared in accordance
and complied in all material respects with the requirements of the Securities Act, or the Exchange Act, as the case may be, and the rules and regulations of the SEC thereunder applicable to such Andover SEC Reports, and (ii) did not at the time
they were filed (or if amended or superseded by a filing prior to the date of this Agreement then on the date of such filing) contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. None of the Andover Subsidiaries are required to file any forms, reports or other documents with the SEC. The consolidated
financial statements of Andover and the Andover Subsidiaries included in the Andover SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at
the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis during the periods involved, except as may be
otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the consolidated financial position of
Andover and the Andover Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

 (h) Material Changes. Since the date of the latest audited annual consolidated financial statements included within the Andover SEC
Reports, except as specifically disclosed in any subsequent Andover SEC Report: (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect; (ii) none of
Andover or the Andover Subsidiaries has incurred any material liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice, and
(B) liabilities not required to be reflected in Andover’s consolidated financial statements pursuant to GAAP or disclosed in filings made with 

  

 -15- 

 
the SEC; (iii) Andover has not materially altered its method of accounting; (iv) Andover has not declared or made any dividend or distribution of
cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) Andover has not issued any equity securities to any officer, director or Affiliate of Andover
or any Andover Subsidiary. Andover does not have pending before the SEC any request for confidential treatment of information. Except as set forth on Schedule 2.1(h), no event, liability or development has occurred or exists with respect to
Andover or any Andover Subsidiary or their respective business, properties, operations or financial condition, that is required to be disclosed by Andover by the Exchange Act. 
 (i) Litigation. Except as set forth on Schedule 2.1(i), there is no action, suit, inquiry, notice of violation, proceeding or investigation
(collectively, an “Action”) pending or, to the knowledge of Andover, threatened against or affecting Andover, any Andover Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or
administrative agency or regulatory authority (federal, state, county, local or foreign) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or (ii) could, if there were an
unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither Andover nor any Andover Subsidiary, nor, to the knowledge of Andover, any director or officer thereof, is or has been the subject of any Action
involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of Andover, there is not pending or contemplated, any investigation by the SEC
involving Andover or any current or, to the knowledge of Andover, former director or officer of Andover. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by Andover under the
Securities Act. 
 (j) Labor Relations. Except as set forth on Schedule 2.1(j), no material labor dispute exists or, to the
knowledge of Andover, is imminent with respect to any of the employees of Andover or any Andover Subsidiary which could be reasonably expected to result in a Material Adverse Effect. None of Andover’s or Andover Subsidiaries’ employees is
a member of a union that relates to such employee’s relationship with Andover or any Andover Subsidiary, as the case may be, and neither Andover nor any Andover Subsidiary is a party to a collective bargaining agreement, and Andover believes
that its and the Andover Subsidiaries’ relationships with their respective employees are good. No employee of Andover or any Andover Subsidiary, including their respective executive officers, to the knowledge of Andover, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant, and, to the knowledge
of Andover, the continued employment of each such executive officer does not subject Andover or any Andover Subsidiary to any liability with respect to any of the foregoing matters. To the knowledge of Andover, Andover and the Andover Subsidiaries
are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not,
individually or in the aggregate, have a Material Adverse Effect. 
 (k) Compliance. Except as set forth on Schedule 2.1(k),
neither Andover nor any Andover Subsidiary (i) is in material default under or in violation of (and no event has 

  

 -16- 

 
occurred that has not been waived that, with notice or lapse of time or both, would result in a default by Andover or any subsidiary under), nor has Andover
or any Andover Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its
properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body, or (iii) to the knowledge of Andover, is or has been in violation of any
statute, rule or regulation of any Governmental Authority, including without limitation all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except in each case as could not be expected
to result in a Material Adverse Effect. 
 (l) Regulatory Permits. Andover and each Andover Subsidiary possess all Material Permits,
except where the failure to possess such permits could not be expected to result in a Material Adverse Effect, and neither Andover nor any Andover Subsidiary has received any notice of proceedings relating to the revocation or modification of any
Material Permit. 
 (m) Title to Assets. Andover and each Andover Subsidiary have good and marketable title in fee simple to all real
property owned by them that is material to the business of Andover and each Andover Subsidiary and good and marketable title to all personal property owned by them that is material to the business of Andover and the Andover Subsidiaries, in each
case free and clear of all Liens, except for Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties and Liens set forth on Schedule 2.1(m). Any real property and facilities
held under lease by Andover and the Andover Subsidiaries are held by them under valid, subsisting and enforceable leases with which Andover and the Andover Subsidiaries are in compliance. 
 (n) Patents and Trademarks. Andover and each Andover Subsidiary have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or material for use in connection with their respective businesses as described
in the Andover SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the “Andover Intellectual Property Rights”). Neither Andover nor any Andover Subsidiary has received a notice
(written or otherwise) that the Andover Intellectual Property Rights used by Andover or any Andover Subsidiary violates or infringes upon the rights of any Person unless such notice has been resolved without a Material Adverse Effect. To the
knowledge of Andover, all such Andover Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Andover Intellectual Property Rights. Andover and each Andover Subsidiary have taken all
security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expect to have a Material Adverse Effect.

 (o) Insurance. Andover and each Andover Subsidiary are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which Andover and each Andover Subsidiary are engaged. Neither Andover nor any Andover Subsidiary have any reason to believe that it will not be able to renew its
existing insurance coverage as and when such coverage expires or to 

  

 -17- 

 
obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. 
 (p) Transactions With Affiliates and Employees. Except as set forth in Schedule 2.1(p), none of the officers, directors or other Affiliates
of Andover or any Andover Subsidiary, and, to the knowledge of Andover, none of the employees of Andover or any Andover Subsidiary is presently a party to any transaction with Andover or any Andover Subsidiary (other than for services as employees,
officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of Andover, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $60,000 other than
(i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of Andover and (iii) for other employee benefits, including stock option agreements under any stock option plan of
Andover or any Andover Subsidiary. 
 (q) Sarbanes-Oxley; Internal Accounting Controls. Andover is in material compliance with all
provisions of the Sarbanes-Oxley Act of 2002. Andover and each Andover Subsidiary have established and maintain a system of internal control over financial reporting required by Rule 13a-15(f) or 15d-15(f) of the Exchange Act regarding the
reliability of financial reporting and the preparation of its consolidated financial statements in accordance with GAAP. Andover’s certifying officers evaluated the effectiveness of Andover’s internal controls as of the end of its most
recent fiscal year as required by Item 308 or Item 308T of Regulation S-K and presented the report of such evaluation in its Annual Report on Form 10-K filed with the SEC. Andover presented in its most recently filed periodic report under
the Exchange Act the conclusions of its certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the end of the period covered by the report (the “Andover Evaluation
Date”) as required by Item 307 of Regulation S-K. Since the Andover Evaluation Date, there have been no changes in Andover’s internal control over financial reporting (as such term is defined in the Exchange Act) that has
materially affected, or is reasonably likely to materially affect, Andover’s internal control over financial reporting. 
 (r)
Certain Fees. Except as set forth on Schedule 2.1(r), no brokerage or finder’s fees or commissions are or will be payable by Andover or any Andover Subsidiary to any broker, financial advisor or consultant, finder, placement
agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. Neither CDIP nor MSMT shall have any obligation with respect to any fees or with respect to any claims made by or on behalf of
other Persons for fees of a type contemplated in this Section 2.1(r) that may be due in connection with the transactions contemplated by the Transaction Documents. 
 (s) Registration Rights. Except as set forth on Schedule 2.1(s), no Person has any right to cause Andover or any Andover Subsidiary to effect the registration under the Securities Act of any securities
of Andover or any Andover Subsidiary. 
  

 -18- 

 (t) Listing and Maintenance Requirements. Andover is obligated to file periodic reports under the
Exchange Act pursuant to Section 13(a) or 15(d) of the Exchange Act, and Andover has not taken any action designed to, or which to its knowledge is likely to have the effect of, terminating such reporting obligation under the Exchange Act nor
has Andover received any notification that the SEC is contemplating terminating such reporting obligation. Except as set forth on Schedule 2.1(t), Andover has not, in the twenty four (24) months preceding the Effective Date, received
notice from any Trading Market on which the Andover Common Stock is or has been listed or quoted to the effect that Andover is not in compliance with the listing or maintenance requirements of such Trading Market. Andover is, and has no reason to
believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. 
 (u)
Tax Status. Andover has timely filed all Tax Returns and/or extensions required by law to be filed with or supplied to any taxing authority with respect to the Taxes owed by Andover and the Andover Subsidiaries. All such Tax Returns are true,
correct and complete in all material respects. Except as set forth on Schedule 2.1(u), all Taxes due and payable by Andover and all Andover Subsidiaries on or before the Closing Date have been paid or will be paid prior to the time they
become delinquent. All Taxes that Andover or any Andover Subsidiary is or was required by law to withhold or collect have been duly withheld or collected and, to the extent required, have been paid to the proper governmental entity. Andover has not
been advised (i) that any of the Tax Returns have been or are being examined or audited as of the Effective Date, (ii) that any such examination or audit is currently threatened or contemplated, or (iii) of any deficiency in
assessment or proposed judgment with to its or the Andover Subsidiaries’ Taxes. Andover has no knowledge of any liability for any Taxes to be imposed upon its or the Andover Subsidiaries’ respective properties or assets as of the date of
this Agreement that are not adequately provided for in the consolidated financial statements included in the Andover SEC Reports. Andover has delivered or made available to CDIP and MSMT true and complete copies of all federal and state income Tax
Returns, examination reports, and statements of deficiencies filed by, assessed against or agreed to by Andover or any of the Andover Subsidiaries in the past three years. Andover has never been a member of a consolidated or affiliated group of
corporations filing a consolidated or combined income Tax Return, nor does Andover or any Andover Subsidiary have any liability for Taxes of any other Person or entity. Neither Andover nor any Andover Subsidiary is a party to any tax allocation or
sharing arrangement or tax indemnity agreement. 
 (v) Foreign Corrupt Practices. Neither Andover, nor to the knowledge of Andover,
any agent or other Person acting on behalf of Andover or any Andover Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political
activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by
Andover or any Andover Subsidiary (or made by any Person acting on its behalf of which Andover is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as
amended. 
 (w) Auditors. Andover’s auditors for the fiscal years ended December 31, 2006 and 2007 and ending
December 31, 2008 are set forth on Schedule 2.1(w). To the 

  

 -19- 

 
knowledge of Andover, each auditor on Schedule 2.1(w) is a registered public accounting firm as required by the Exchange Act and the rules and
regulations of the SEC. 
 (x) Disclosure. All disclosure furnished by or on behalf of Andover to MSMT and CDIP regarding Andover,
each Andover Subsidiary, their respective business and the transactions contemplated hereby, including the Andover Disclosure Schedules, with respect to the representations and warranties made herein are and will be true and correct with respect to
such representations and warranties as of the Effective Date and as of the Closing Date and do not and will not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which they were made, not misleading. 
 (y) Material Contracts. Schedule 2.1(y)
sets forth a true and complete list of all agreements, understandings, instruments, and contracts, proposed transactions (including a description of those currently being negotiated), judgments, orders, writs, or decrees to which Andover or any
Andover Subsidiary is a party or, to its knowledge, by which it is bound that may involve: (i) the sale of Andover’s or any Andover Subsidiary’s products or services to any customer, vendor, or provider (other than such contracts
entered into in the ordinary course of business); (ii) obligations (contingent or otherwise) of, or payments to, Andover or any Andover Subsidiary in excess of $50,000; (iii) the license of any proprietary rights to or from Andover or any
Andover Subsidiary (other than licenses arising from the purchase of “off the shelf” or other standard products); (iv) the development, administration, or distribution of Andover’s and any Andover Subsidiary’s products or
services, including without limitation, any that involve any brokers or dealers; (v) provisions restricting or affecting the development, manufacture, or distribution of Andover’s or any Andover Subsidiary’s products or services or
Andover’s or any Andover Subsidiary’s freedom to compete in any line of business; (vi) any joint venture or similar arrangement; (vii) any restriction or limitation on the ability of Andover or any Andover Subsidiary to pay
dividends or make any other distributions or to repurchase, redeem, or otherwise acquire any of its equity securities; or (viii) indemnification by Andover or any Andover Subsidiary of any other person or entity (except as may be provided in
the Transaction Documents) (each, an “Andover Material Contract”). Andover has delivered or made available to CDIP and MSMT true and complete copies of each Andover Material Contract. Each Andover Material Contract is in full
force and effect and is binding and enforceable against the parties thereto in accordance with its terms, and Andover and each Andover Subsidiary, as the case may be, has performed in all material respects all obligations required to be performed by
it under each Andover Material Contract, and no condition exists or events have occurred that, with or without the passage of time or giving of notice, would constitute a default by Andover or any Andover Subsidiary, as the case may be, under any
Andover Material Contract. 
 (z) Disclosure Documents; Andover Information. The information relating to Andover and each Andover
Subsidiary provided to MSMT for use in the Registration Statement will not, on the date the Registration Statement is filed with the SEC, at any time it is amended or supplemented, or at the time it becomes effective under the Securities Act,
contain any untrue statement of any material fact, or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not false or misleading at the time and in light of the circumstances under
which such statement is made. The information relating to Andover and each Andover Subsidiary provided to MSMT for use in the Information Statement will not, 

  

 -20- 

 
on the date the Information Statement is first mailed to MSMT’s stockholders or at the time of the MSMT Stockholders’ Meeting, contain any untrue
statement of any material fact, or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not false or misleading at the time and in light of the circumstances under which such statement is
made. Notwithstanding the foregoing, no representation is made by Andover with respect to the information that has been or will be supplied by CDIP or MSMT or their respective subsidiaries or their representatives for inclusion in the Registration
Statement or the Information Statement. 
 2.2. Representations and Warranties of CDIP. Except as set forth under the corresponding
section of the disclosure schedules delivered to each of Andover and MSMT concurrently herewith (the “CDIP Disclosure Schedules”) which CDIP Disclosure Schedules shall be deemed a part hereof and to qualify any representation
or warranty otherwise made herein to the extent of such disclosure, CDIP, hereby makes the representations and warranties set forth below to Andover and MSMT: 
 (a) Subsidiaries. All of the direct and indirect subsidiaries of CDIP are set forth on Schedule 1.1(a)(i). Except as set forth on Schedule 1.1(a)(i), CDIP owns, directly or indirectly, all of the
capital stock or other equity interests of each CDIP Subsidiary free and clear of any Liens, and all the issued and outstanding shares of capital stock of each CDIP Subsidiary are validly issued and are fully paid, non-assessable and free of
preemptive and similar rights to subscribe for or purchase securities. 
 (b) Organization and Qualification. Except as set forth on
Schedule 2.2(b), CDIP and each CDIP Subsidiary is duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the requisite
corporate power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither CDIP nor any CDIP Subsidiary is in violation or default of any of the provisions of its certificate or articles of
incorporation, bylaws or other organizational or charter documents. Each of CDIP and each CDIP Subsidiary is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature
of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse
Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. 
 (c) Authorization; Enforcement. CDIP has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by each of the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of the Transaction Documents by CDIP and the consummation by it of the transactions contemplated hereby have
been duly authorized by all necessary corporate action on the part of CDIP and no further action is required by CDIP, its Board of Directors or its stockholders in connection therewith other than in connection with the CDIP Required Approvals (as
defined in Section 2.2(e) hereof). Each Transaction Document has been (or upon delivery will have been) duly executed by CDIP and, when delivered in accordance with the 

  

 -21- 

 
terms hereof and thereof, will constitute the valid and binding obligation of CDIP enforceable against CDIP in accordance with its terms except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 
 (d) No Conflicts. The execution, delivery and performance of the Transaction Documents by CDIP and the consummation by CDIP of the other
transactions contemplated hereby and thereby do not and will not: (i) conflict with or violate any provision of CDIP’s or any CDIP Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter
documents or (ii) subject to the CDIP Required Approvals, conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of CDIP or any CDIP Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument or other
understanding to which CDIP or any CDIP Subsidiary is a party or by which any property or asset of CDIP or any CDIP Subsidiary is bound or affected, or (iii) subject to the CDIP Required Approvals, conflict with or result in a violation of any
law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or Governmental Authority to which CDIP or a CDIP Subsidiary is subject (including federal and state securities laws and regulations), or by which any
property or asset of CDIP or a CDIP Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect. 
 (e) Filings, Consents and Approvals. Neither CDIP nor any CDIP Subsidiary is required to obtain any consent, waiver, authorization or order of,
give any notice to, or make any filing or registration with, any court or other federal, state, local or other Governmental Authority or other Person in connection with the execution, delivery and performance by CDIP of the Transaction Documents,
other than the delivery of the notices and the receipt of the approvals set forth on Schedule 2.2(e) (collectively, the “CDIP Required Approvals”). 
 (f) Capitalization. The capitalization of CDIP is as set forth on Schedule 2.2(f). Except as set forth on Schedule 2.2(f), no Person
has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth on Schedule 2.2(f), there are no outstanding
options, warrants, script rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for
or acquire, any shares of CDIP Common Stock, or contracts, commitments, understandings or arrangements by which CDIP or any CDIP Subsidiary is or may become bound to issue additional shares of CDIP Common Stock or Common Stock Equivalents. All of
the outstanding shares of capital stock of CDIP are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase securities. Except as set forth on Schedule 2.2(f), there are no stockholders agreements, voting agreements or other similar agreements with 

  

 -22- 

 
respect to CDIP’s capital stock to which CDIP is a party or, to the knowledge of CDIP, between or among any of CDIP’s stockholders. 
 (g) Financial Statements. CDIP has delivered to Andover and MSMT: (a) an audited balance sheet of CDIP as at October 31, 2007 (the
“CDIP Balance Sheet”), and the related audited statements of income, changes in stockholders’ equity and cash flows for the two fiscal years then ended, including in each case the notes thereto, together with the report
thereon of KBL, LLP, CPA, independent certified public accountants for CDIP for the fiscal year ended October 31, 2007; (b) an audited balance sheet of CDIP as at October 31, 2006, and the related audited statements of income, changes
in stockholders’ equity and cash flows for the two fiscal years then ended, including in each case the notes thereto, together with the report thereon of Wheeler Herman Hopkins & Lagor, CPA, independent certified public accountants for
CDIP for the fiscal year ended October 31, 2007; (c) an audited balance sheet of Diabetic Plus, Inc. as at October 31, 2007, and the related audited statements of income, changes in stockholders’ equity and cash flows for the two
fiscal years then ended, including in each case the notes thereto, together with the report thereon of KBL, LLP, CPA, independent certified public accountants for Diabetic Plus, Inc. for the fiscal year ended October 31, 2007; and (d) an
unaudited balance sheet of CDIP as at April 30, 2008 (the “CDIP Interim Balance Sheet”) and the related unaudited statements of income, changes in stockholders’ equity and cash flows for the six months then ended
including in each case the notes thereto. Such financial statements fairly present the financial condition and the results of operations, changes in stockholders’ equity and cash flows of CDIP as at the respective dates of and for the periods
referred to in such financial statements, all in accordance with GAAP. The financial statements referred to in this Section 2.2(g) reflect and will reflect the consistent application of such accounting principles throughout the periods
involved, except as disclosed in the notes to such financial statements. Except as set forth on Schedule 2.2(g), CDIP has no Liability except for Liabilities reflected or reserved against in the CDIP Balance Sheet or the CDIP Interim Balance
Sheet and current liabilities incurred in the ordinary course of business of CDIP since the date of the CDIP Interim Balance Sheet. 
 (h)
Material Changes. Since the date of the CDIP Interim Balance Sheet, except as specifically disclosed on Schedule 2.2(h): (i) there has been no event, occurrence or development that has had or that could reasonably be expected to
result in a Material Adverse Effect; (ii) none of CDIP or the CDIP Subsidiaries has incurred any material liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business
consistent with past practice and (B) liabilities not required to be reflected in CDIP’s consolidated financial statements pursuant to GAAP; (iii) CDIP has not materially altered its method of accounting, (iv) CDIP has not
declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) CDIP has not issued any equity securities to
any officer, director or Affiliate of CDIP or any CDIP Subsidiary. 
 (i) Litigation. Except as set forth on Schedule 2.2(i),
there is no Action pending or, to the knowledge of CDIP, threatened against or affecting CDIP, any CDIP Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory
authority (federal, state, county, local or foreign) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or (ii) could, if there were an unfavorable decision, have or
reasonably be expected 

  

 -23- 

 
to result in a Material Adverse Effect. Neither CDIP nor any CDIP Subsidiary, nor, to the knowledge of CDIP, any director or officer thereof, is or has been
the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. 
 (j) Labor Relations. No material labor dispute exists or, to the knowledge of CDIP, is imminent with respect to any of the employees of CDIP or any CDIP Subsidiary which could be reasonably be expected to
result in a Material Adverse Effect. None of CDIP or CDIP Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with CDIP or any CDIP Subsidiary, as the case may be, and neither CDIP nor any CDIP
Subsidiary is a party to a collective bargaining agreement, and CDIP believes that its and each CDIP Subsidiaries’ relationships with their respective employees are good. No employee of CDIP or any CDIP Subsidiary, including their respective
executive officers, to the knowledge of CDIP, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other
contract or agreement or any restrictive covenant, and, to the knowledge of CDIP, the continued employment of each such executive officer does not subject CDIP or any CDIP Subsidiary to any liability with respect to any of the foregoing matters. To
the knowledge of CDIP, CDIP and CDIP Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except
where the failure to be in compliance could not, individually or in the aggregate, have a Material Adverse Effect. 
 (k) Compliance.
Neither CDIP nor any CDIP Subsidiary (i) is in material default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by CDIP or any subsidiary under),
nor has CDIP or any CDIP Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of
its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body, or (iii) to the knowledge of CDIP, is or has been in violation of any
statute, rule or regulation of any Governmental Authority, including without limitation all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except in each case as could not to result
in a Material Adverse Effect. 
 (l) Regulatory Permits. CDIP and each CDIP Subsidiary possess all Material Permits, except where the
failure to possess such permits could not have or reasonably be expected to result in a Material Adverse Effect, and neither CDIP nor any CDIP Subsidiary has received any notice of proceedings relating to the revocation or modification of any
Material Permit. 
 (m) Title to Assets. CDIP and each CDIP Subsidiary have good and marketable title in fee simple to all real
property owned by them that is material to the business of CDIP and each CDIP Subsidiary and good and marketable title to all personal property owned by them that is material to the business of CDIP and the CDIP Subsidiaries, in each case free and
clear of all Liens, except for Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties and Liens set forth on Schedule 2.2(m). Any 

  

 -24- 

 
real property and facilities held under lease by CDIP and the CDIP Subsidiaries are held by them under valid, subsisting and enforceable leases with which
CDIP and each CDIP Subsidiary are in compliance. 
 (n) Patents and Trademarks. CDIP and each CDIP Subsidiary have, or have rights to
use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or material for use in
connection with their respective businesses and which the failure to so have could have a Material Adverse Effect (collectively, the “CDIP Intellectual Property Rights”). Neither CDIP nor any CDIP Subsidiary has received a
notice (written or otherwise) that the CDIP Intellectual Property Rights used by CDIP or any CDIP Subsidiary violates or infringes upon the rights of any Person unless such notice has been resolved without a Material Adverse Effect. To the knowledge
of CDIP, all such CDIP Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the CDIP Intellectual Property Rights. CDIP and each CDIP Subsidiary have taken all security measures to protect
the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 (o) Insurance. CDIP and each CDIP Subsidiary are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which CDIP and each CDIP Subsidiary are engaged. Neither CDIP nor any CDIP Subsidiary have any reason to believe that it will not be able to renew its existing insurance coverage as and
when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. 
 (p) Transactions With Affiliates and Employees. Except as set forth in Schedule 2.2(p), none of the officers, directors or other Affiliates of CDIP or any CDIP Subsidiary, and, to the knowledge of CDIP,
none of the employees of CDIP or any CDIP Subsidiary is presently a party to any transaction with CDIP or any CDIP Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of CDIP, any entity in which any
officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $60,000 other than (i) for payment of salary or consulting fees for services rendered,
(ii) reimbursement for expenses incurred on behalf of CDIP and (iii) for other employee benefits, including stock option or stock grant agreements under any stock option plan of CDIP or any CDIP Subsidiary. 
 (q) Internal Controls. CDIP maintains books and records reflecting its assets and Liabilities and maintains internal accounting controls that CDIP
reasonably believes provide reasonable assurance that (i) transactions are executed with management’s authorization; (ii) transactions are recorded as necessary to permit preparation of the consolidated financial statements of CDIP in
accordance with GAAP and to maintain accountability for CDIP’s consolidated assets; (iii) access to CDIP’s assets is permitted only in accordance with 

  

 -25- 

 
management’s authorization; (iv) the identification of CDIP’s assets is compared with existing assets as necessary to permit preparation of
the consolidated financial statements of CDIP in accordance with GAAP and to maintain accountability for CDIP’s consolidated assets; (v) accounts, notes and other receivables and inventory are recorded accurately, and adequate procedures
are implemented to effect the collection thereof on a timely basis; and (vi) there are adequate procedures in place regarding prevention or timely detection of unauthorized acquisition, use or disposition of CDIP’s assets. As of the date
of this Agreement, to CDIP’s knowledge, (x) there are no significant deficiencies in the design or operation of CDIP’s internal controls over financial reporting that could reasonably be expected to adversely affect in any material
respect CDIP’s ability to record, process, summarize and report financial data or material weaknesses in internal controls over financial reporting and (y) there has been no fraud, whether or not material, that involved management or other
employees of CDIP who have a significant role in CDIP’s internal controls over financial reporting. 
 (r) Certain Fees. Except
as set forth on Schedule 2.2(r), no brokerage or finder’s fees or commissions are or will be payable by CDIP or any CDIP Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other
Person with respect to the transactions contemplated by the Transaction Documents. Neither Andover nor MSMT shall have any obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type
contemplated in this Section 2.2(r) that may be due in connection with the transactions contemplated by the Transaction Documents. 
 (s) Registration Rights. Except as set forth on Schedule 2.2(s), no Person has any right to cause CDIP or any CDIP Subsidiary to effect the registration under the Securities Act of any securities of CDIP or any CDIP
Subsidiary. 
 (t) Intentionally Omitted. 
 (u) Tax Status. CDIP has timely filed all Tax Returns required by law to be filed with or supplied to any taxing authority with respect to the Taxes owed by CDIP and the CDIP Subsidiaries. All such Tax Returns
are true, correct and complete in all material respects. All Taxes due and payable by CDIP and all CDIP Subsidiaries on or before the Closing Date have been paid or will be paid prior to the time they become delinquent. All Taxes that CDIP or and
CDIP Subsidiary is or was required by law to withhold or collect have been duly withheld or collected and, to the extent required, have been paid to the proper governmental entity. CDIP has not been advised (i) that any of the Tax Returns have
been or are being examined or audited as of the Effective Date, (ii) that any such examination or audit is currently threatened or contemplated, or (iii) of any deficiency in assessment or proposed judgment with respect to its or the CDIP
Subsidiaries’ Taxes. CDIP has no knowledge of any liability for any Taxes to be imposed upon its or the CDIP Subsidiaries’ respective properties or assets as of the date of this Agreement that are not adequately provided for on the CDIP
Balance Sheet. CDIP has delivered or made available to Andover and MSMT true and complete copies of all federal and state income Tax Returns, examination reports, and statements of deficiencies filed by, assessed against or agreed to by CDIP or any
of the CDIP Subsidiaries in the past three years. Except as set forth on Schedule 2.2(u), CDIP has never been a member of a consolidated or affiliated group of corporations filing a consolidated or combined income Tax Return, nor does CDIP or
any 

  

 -26- 

 
CDIP Subsidiary have any liability for Taxes of any other Person or entity. Neither CDIP nor any CDIP Subsidiary is a party to any tax allocation or sharing
arrangement or tax indemnity agreement. 
 (v) Foreign Corrupt Practices. Neither CDIP, nor to the knowledge of CDIP, any agent or
other person acting on behalf of CDIP or any CDIP Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by CDIP or any
CDIP Subsidiary (or made by any person acting on its behalf of which CDIP is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 
 (w) Auditors. CDIP’s auditors for its two most recent fiscal years and present fiscal year are set forth on Schedule 2.2(w). Each
auditor on Schedule 2.2(w) is a registered public accounting firm as required by the Exchange Act and the rules and regulations of the SEC. 
 (x) Disclosure. All disclosure furnished by or on behalf of CDIP to Andover and MSMT regarding CDIP, each CDIP Subsidiary, their respective businesses and the transactions contemplated hereby, including the CDIP Disclosure Schedules,
with respect to the representations and warranties made herein are and will be true and correct with respect to such representations and warranties as of the Effective Date and as of the Closing Date and do not and will not contain any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. 
 (y) Material Contracts. Schedule 2.2(y) sets forth a true and complete list of all agreements, understandings, instruments, and contracts,
proposed transactions (including a description of those currently being negotiated), judgments, orders, writs, or decrees to which CDIP or any CDIP Subsidiary is a party or, to its knowledge, by which it is bound that may involve: (i) the sale
of CDIP’s or any CDIP Subsidiary’s products or services to any customer, vendor, or provider (other than such contracts entered into in the ordinary course of business); (ii) obligations (contingent or otherwise) of, or payments to,
CDIP or any CDIP Subsidiary in excess of $50,000; (iii) the license of any proprietary rights to or from CDIP or any CDIP Subsidiary (other than licenses arising from the purchase of “off the shelf” or other standard products);
(iv) the development, administration, or distribution of CDIP’s and any CDIP Subsidiary’s products or services, including without limitation, any that involve any brokers or dealers; (v) provisions restricting or affecting the
development, manufacture, or distribution of CDIP’s or any CDIP Subsidiary’s products or services or CDIP’s or any CDIP Subsidiary’s freedom to compete in any line of business; (vi) any joint venture or similar arrangement;
(vii) any restriction or limitation on the ability of CDIP or any CDIP Subsidiary to pay dividends or make any other distributions or to repurchase, redeem, or otherwise acquire any of its equity securities; or (viii) indemnification by
CDIP or any CDIP Subsidiary of any other person or entity (except as may be provided in the Transaction Documents) (each, a “CDIP Material Contract”). CDIP has delivered or made available to Andover and MSMT true and complete

  

 -27- 

 
copies of each Material Contract. Each Material Contract is in full force and effect and is binding and enforceable against the parties thereto in accordance
with its terms, and CDIP and each CDIP Subsidiary, as the case may be, has performed in all material respects all obligations required to be performed by it under each Material Contract, and no condition exists or events have occurred that, with or
without the passage of time or giving of notice, would constitute a default by CDIP or any CDIP Subsidiary, as the case may be, under any CDIP Material Contract. 
 (z) Disclosure Documents; CDIP Information. The information relating to CDIP and each CDIP Subsidiary to be contained in the Registration Statement will not, on the date the Registration Statement is filed with
the SEC, at any time it is amended or supplemented, or at the time it becomes effective under the Securities Act, contain any untrue statement of any material fact, or omit to state any material fact required to be stated therein or necessary in
order to make the statements therein not false or misleading at the time and in light of the circumstances under which such statement is made. The information relating to CDIP and each CDIP Subsidiary to be contained in the Information Statement
will not, on the date the Information Statement is first mailed to MSMT’s stockholders or at the time of the MSMT’s Stockholders’ Meeting, contain any untrue statement of any material fact, or omit to state any material fact required
to be stated therein or necessary in order to make the statements therein not false or misleading at the time and in light of the circumstances under which such statement is made. The Information Statement will comply in all material respects as to
form with the requirements of the Exchange Act and the rules and regulations thereunder. Notwithstanding the foregoing, no representation is made by CDIP with respect to the information that has been or will be supplied by Andover or MSMT or their
respective subsidiaries or their representatives for inclusion in the Registration Statement or the Information Statement. 
 2.3.
Representations and Warranties of MSMT. Except as set forth under the corresponding section of the disclosure schedules delivered to each of Andover and CDIP concurrently herewith (the “MSMT Disclosure Schedules”) or
as otherwise disclosed in the MSMT SEC Reports filed by MSMT which MSMT Disclosure Schedules and MSMT SEC Reports shall be deemed a part hereof and to qualify any representation or warranty otherwise made herein to the extent of such disclosure,
MSMT, hereby makes the representations and warranties set forth below to Andover and CDIP: 
 (a) Subsidiaries. All of the direct and
indirect subsidiaries of MSMT are set forth on Schedule 2.3(a) (each, an “MSMT Subsidiary” and collectively, the “MSMT Subsidiaries”). Except as set forth on Schedule 2.3(a), MSMT owns,
directly or indirectly, all of the capital stock or other equity interests of each MSMT Subsidiary free and clear of any Liens, and all the issued and outstanding shares of capital stock of each MSMT Subsidiary are validly issued and are fully paid,
non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. 
 (b) Organization and
Qualification. Except as set forth on Schedule 2.3(b), MSMT and each MSMT Subsidiary is duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of incorporation or organization
(as applicable), with the requisite corporate power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither MSMT nor any MSMT Subsidiary is in violation or default of any of the provisions
of its certificate or articles of 

  

 -28- 

 
incorporation, bylaws or other organizational or charter documents. Each of MSMT and each MSMT Subsidiary is duly qualified to conduct business and is in
good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and
authority or qualification. 
 (c) Authorization; Enforcement. Except as set forth on Schedule 2.3(c), MSMT has the requisite
corporate power and authority to enter into and to consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of the
Transaction Documents by MSMT and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of MSMT and no further action is required by MSMT, its Board of Directors or its
stockholders in connection therewith other than in connection with the MSMT Required Approvals (as defined in Section 2.3(e) hereof). Each Transaction Document has been (or upon delivery will have been) duly executed by MSMT and, when delivered
in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of MSMT enforceable against MSMT in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other
equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 
 (d) No
Conflicts. Except as set forth on Schedule 2.3(d), The execution, delivery and performance of the Transaction Documents by MSMT and the consummation by MSMT of the other transactions contemplated hereby and thereby do not and will not:
(i) conflict with or violate any provision of MSMT’s or any MSMT Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents or (ii) subject to the MSMT Required Approvals, conflict
with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of MSMT or any MSMT Subsidiary, or give to others any rights
of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument or other understanding to which MSMT or any MSMT Subsidiary is a party or by which
any property or asset of MSMT or any MSMT Subsidiary is bound or affected, or (iii) subject to the MSMT Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other
restriction of any court or Governmental Authority to which MSMT or a MSMT Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of MSMT or a MSMT Subsidiary is bound or affected;
except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect. 
 (e) Filings, Consents and Approvals. Neither MSMT nor any MSMT Subsidiary is not required to obtain any consent, waiver, authorization or order of, give any 

  

 -29- 

 
notice to, or make any filing or registration with, any court or other federal, state, local or other Governmental Authority or other Person in connection
with the execution, delivery and performance by MSMT of the Transaction Documents, other than (i) the filing with the SEC of the Registration Statement and the Information Statement, (ii) any filings as are required to be made under
applicable state securities laws; and (iii) than the delivery of the notices and the receipt of the approvals set forth on Schedule 2.3(e) (collectively, the “MSMT Required Approvals”). 
 (f) Capitalization. The capitalization of MSMT is as set forth on Schedule 2.3(f). Except as set forth on Schedule 2.3(f), MSMT has
not issued any capital stock since its most recently filed periodic report under the Exchange Act. Except as set forth on Schedule 2.3(f), no Person has any right of first refusal, preemptive right, right of participation, or any similar
right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the issuance of the MSMT Securities as contemplated by this Agreement or as set forth on Schedule 2.3(f), there are no outstanding
options, warrants, script rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for
or acquire, any shares of MSMT Common Stock, or contracts, commitments, understandings or arrangements by which MSMT or any MSMT Subsidiary is or may become bound to issue additional shares of MSMT Common Stock or Common Stock Equivalents. All of
the outstanding shares of capital stock of MSMT are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase securities. Upon the filing and effectiveness of the MSMT Charter Amendment, the MSMT Common Stock (inclusive of the Escrow Shares) and MSMT Preferred Stock, when issued in compliance
with the provisions of this Agreement, and the MSMT Common Stock, when issued in compliance with the provisions of the MSMT Preferred Stock, Assumed Options or Assumed Warrants, will have been in all such cases duly authorized and validly issued,
will be fully paid and nonassessable, will have been issued in compliance with all applicable laws concerning the issuance of securities, and will be free and clear of any encumbrances (except any restrictions on transfer under applicable securities
laws). At the Closing, the MSMT Common Stock issuable upon conversion of the MSMT Preferred Stock and upon exercise of the Assumed Options and Assumed Warrants will be duly and validly reserved for issuance. Except as set forth on Schedule
2.3(f), there are no stockholders agreements, voting agreements or other similar agreements with respect to MSMT’s capital stock to which MSMT is a party or, to the knowledge of MSMT, between or among any of MSMT’s stockholders.

 (g) SEC Reports; Financial Statements. Except as set forth on Schedule 2.3(g), MSMT has filed all reports, schedules, forms,
statements and other documents required to be filed by it under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for two years preceding the Effective Date (the foregoing materials, including the
exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “MSMT SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any
such MSMT SEC Reports prior to the expiration of any such extension. As of their respective dates, each MSMT SEC Report (i) was prepared in accordance and complied in all material respects with the requirements of the Securities Act or the
Exchange 

  

 -30- 

 
Act, as the case may be, and the rules and regulations of the SEC thereunder applicable to such MSMT SEC Reports, and (ii) did not at the time they were
filed (or if amended or superseded by a filing prior the date of this Agreement then on the date of such filing) contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading. None of the MSMT Subsidiaries are required to file any forms, reports or other documents with the SEC. The consolidated financial statements
of MSMT and the MSMT Subsidiaries included in the MSMT SEC Reports complied in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. Such
financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP,
and fairly present in all material respects the consolidated financial position of MSMT and the MSMT Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of
unaudited statements, to normal, immaterial, year-end audit adjustments. 
 (h) Material Changes. Since the date of the latest audited
annual consolidated financial statements included within the MSMT SEC Reports, except as specifically disclosed in any subsequent MSMT SEC Report: (i) there has been no event, occurrence or development that has had or that could reasonably be
expected to result in a Material Adverse Effect; (ii) none of MSMT or the MSMT Subsidiaries has incurred any material liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course
of business consistent with past practice and (B) liabilities not required to be reflected in MSMT’s consolidated financial statements pursuant to GAAP or disclosed in filings made with the SEC; (iii) MSMT has not materially altered
its method of accounting; (iv) MSMT has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and
(v) MSMT has not issued any equity securities to any officer, director or Affiliate of MSMT or any MSMT Subsidiary. MSMT does not have pending before the SEC and has not been granted by the SEC any request for confidential treatment of
information, other than as set forth on Schedule 2.3(h). Except as set forth on Schedule 2.3(h), no event, liability or development has occurred or exists with respect to MSMT or any MSMT Subsidiary or their respective business,
properties, operations or financial condition, that is required to be disclosed by MSMT under the Exchange Act. 
 (i) Litigation.
Except as set forth on Schedule 2.3(i), there is no Action pending or, to the knowledge of MSMT, threatened against or affecting MSMT, any MSMT Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or (ii) could, if there were
an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither MSMT nor any MSMT Subsidiary, nor, to the knowledge of MSMT, any director or officer thereof, is or has been the subject of any Action involving
a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of MSMT, there is not pending or contemplated, any investigation by the SEC involving MSMT
or any current or, to 

  

 -31- 

 
the knowledge of MSMT, former director or officer of MSMT. The SEC has not issued any stop order or other order suspending the effectiveness of any
registration statement filed by MSMT under the Securities Act. 
 (j) Labor Relations. Except as set forth on Schedule 2.3(j),
no material labor dispute exists or, to the knowledge of MSMT, is imminent with respect to any of the employees of MSMT or any MSMT Subsidiary which could be reasonably expected to result in a Material Adverse Effect. None of MSMT’s or the MSMT
Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with MSMT or any MSMT Subsidiary, as the case may be, and neither MSMT or any MSMT Subsidiary is a party to a collective bargaining agreement, and
MSMT believes that its and the MSMT Subsidiaries’ relationships with their respective employees are good. No employee of MSMT or any MSMT Subsidiary, including their respective executive officers, to the knowledge of MSMT, is, or is now
expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant, and, to the
knowledge of MSMT, the continued employment of each such executive officer does not subject MSMT or any MSMT Subsidiary to any liability with respect to any of the foregoing matters. To the knowledge of MSMT, MSMT and the MSMT Subsidiaries are in
compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not,
individually or in the aggregate, have a Material Adverse Effect. 
 (k) Compliance. Except as set forth on Schedule 2.3(k),
neither MSMT nor any MSMT Subsidiary (i) is in material default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by MSMT or any MSMT Subsidiary
under), nor has MSMT or any MSMT Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or
any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body, or (iii) to the knowledge of MSMT, is or has been in violation of
any statute, rule or regulation of any Governmental Authority, including without limitation all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except in each case as could not have or
reasonably be expected to result in a Material Adverse Effect. 
 (l) Regulatory Permits. Except as set forth on Schedule
2.3(l), MSMT and each MSMT Subsidiary possess all Material Permits, except where the failure to possess such permits could not have or reasonably be expected to result in a Material Adverse Effect, and neither MSMT nor any MSMT Subsidiary has
received any notice of proceedings relating to the revocation or modification of any Material Permit. 
 (m) Title to Assets. MSMT and
each MSMT Subsidiary have good and marketable title in fee simple to all real property owned by them that is material to the business of MSMT and each MSMT Subsidiary and good and marketable title in all personal property owned by them that is
material to the business of MSMT and the MSMT Subsidiaries, in each case free and clear of all Liens, except for Liens for the payment of federal, state or other taxes, 

  

 -32- 

 
the payment of which is neither delinquent nor subject to penalties and Liens set forth on Schedule 2.3(m). Any real property and facilities held
under lease by MSMT and the MSMT Subsidiaries are held by them under valid, subsisting and enforceable leases with which MSMT and the MSMT Subsidiaries are in compliance. 
 (n) Patents and Trademarks. Except as set forth on Schedule 2.3(n), MSMT and each MSMT Subsidiary have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or material for use in connection with their respective businesses as described in the MSMT SEC Reports
and which the failure to so have could have a Material Adverse Effect (collectively, the “MSMT Intellectual Property Rights”). Neither MSMT nor any MSMT Subsidiary has received a notice (written or otherwise) that the MSMT
Intellectual Property Rights used by MSMT or any MSMT Subsidiary violates or infringes upon the rights of any Person unless such notice has been resolved without a Material Adverse Effect. To the knowledge of MSMT, all such MSMT Intellectual
Property Rights are enforceable and there is no existing infringement by another Person of any of the MSMT Intellectual Property Rights. MSMT and each MSMT Subsidiary have taken all security measures to protect the secrecy, confidentiality and value
of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 (o) Insurance. Except as set forth on Schedule 2.3(o), MSMT and each MSMT Subsidiary are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which MSMT and each MSMT Subsidiary are engaged. Neither MSMT nor any MSMT Subsidiary have any reason to believe that it will not be
able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. 
 (p) Transactions With Affiliates and Employees. Except as set forth in Schedule 2.3(p), none of the officers, directors or other Affiliates
of MSMT or any MSMT Subsidiary, and, to the knowledge of MSMT, none of the employees of MSMT or any MSMT Subsidiary is presently a party to any transaction with MSMT or any MSMT Subsidiary (other than for services as employees, officers and
directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or
such employee or, to the knowledge of MSMT, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $60,000 other than (i) for payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of MSMT and (iii) for other employee benefits, including stock option agreements under any stock option plan of MSMT or any MSMT
Subsidiary. 
 (q) Sarbanes-Oxley; Internal Accounting Controls. MSMT is in material compliance with all provisions of the
Sarbanes-Oxley Act of 2002. Except as set forth in MSMT’s most recent periodic report filed with the SEC, MSMT and each MSMT Subsidiary have established and maintain a system of internal control over financial reporting required by 

  

 -33- 

 
Rule 13a-15(f) or 15d-15(f) of the Exchange Act regarding the reliability of financial reporting and the preparation of its consolidated financial statements
in accordance with GAAP. MSMT’s certifying officers evaluated the effectiveness of MSMT’s internal controls as of the end of its most recent fiscal year as required by Item 308 or Item 308T of Regulation S-K and presented the
report of such evaluation in its Annual Report on Form 10-KSB filed with the SEC. MSMT presented in its most recently filed periodic report under the Exchange Act the conclusions of its certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the end of the period covered by the report (the “MSMT Evaluation Date”) as required by Item 307 of Regulation S-K. Except as set forth on Schedule 2.3(q),
since the MSMT Evaluation Date, there have been no changes in MSMT’s internal control over financial reporting (as such term is defined in the Exchange Act) that has materially affected, or is reasonably likely to materially affect, MSMT’s
internal control over financial reporting. 
 (r) Certain Fees. Except as set forth on Schedule 2.3(r), no brokerage or
finder’s fees or commissions are or will be payable by MSMT or any MSMT Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by
the Transaction Documents. Neither Andover nor CDIP shall have any obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this section that may be due in connection
with the transactions contemplated by the Transaction Documents. 
 (s) Registration Rights. Except as set forth on Schedule
2.3(s), no Person has any right to cause MSMT or any MSMT Subsidiary to effect the registration under the Securities Act of any securities of MSMT or any MSMT Subsidiary. 
 (t) Listing and Maintenance Requirements. MSMT is obligated to file periodic reports under the Exchange Act pursuant to Section 13(a)
or 15(d) of the Exchange Act. The MSMT Common Stock is registered pursuant to Section 12(g) of the Exchange Act, and MSMT has not taken any action designed to, or which to its knowledge is likely to have the effect of, terminating such
reporting obligation under the Exchange Act, nor has MSMT received any notification that the SEC is contemplating terminating such reporting obligation. Except as set forth on Schedule 2.3(t), MSMT has not, in the twenty-four (24) months
preceding the Effective Date, received notice from any Trading Market on which the MSMT Common Stock is or has been listed or quoted to the effect that MSMT is not in compliance with the listing or maintenance requirements of such Trading Market.
MSMT is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. 
 (u) Tax Status. Except as set forth on Schedule 2.3(u), MSMT has timely filed all Tax Returns required by law to be filed with or supplied to any taxing authority with respect to the Taxes owed by MSMT
and the MSMT Subsidiaries. All such Tax Returns are true, correct and complete in all material respects. All Taxes due and payable by MSMT and all MSMT Subsidiaries on or before the Closing Date have been paid or will be paid prior to the time they
become delinquent. All Taxes that MSMT or any MSMT Subsidiary is or was required by law to withhold or collect have been duly withheld or collected and, to the extent required, have been paid to the proper governmental entity. MSMT has not been
advised (i) that any of the Tax Returns have been or are being examined or audited as of the date hereof, (ii) that 

  

 -34- 

 
any such examination or audit is currently threatened or contemplated, or (iii) of any deficiency in assessment or proposed judgment with respect to its
or the MSMT Subsidiaries’ Taxes. MSMT has no knowledge of any liability for any Taxes to be imposed upon its or the MSMT Subsidiaries’ respective properties or assets as of the date of this Agreement that are not adequately provided for in
the consolidated financial statements included in the MSMT SEC Reports. MSMT has delivered or made available to CDIP and Andover true and complete copies of all federal and state income Tax Returns, examination reports, and statements of
deficiencies filed by, assessed against or agreed to by MSMT or any MSMT Subsidiary in the past three years. MSMT has never been a member of a consolidated or affiliated group of corporations filing a consolidated or combined income Tax Return, nor
does MSMT or any MSMT Subsidiary have any liability for Taxes of any other person or entity. Neither MSMT nor any MSMT Subsidiary is a party to any tax allocation or sharing arrangement or tax indemnity agreement. 
 (v) Foreign Corrupt Practices. Except as set forth on Schedule 2.3(v), Neither MSMT, nor to the knowledge of MSMT, any agent or other
person acting on behalf of MSMT or any MSMT Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made
any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by MSMT or any MSMT Subsidiary
(or made by any person acting on its behalf of which MSMT is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 
 (w) Auditors. MSMT’s auditors for the fiscal years ended December 31, 2006 and 2007 and ending December 31, 2008 are set forth on
Schedule 2.3(w). To the knowledge of MSMT, each auditor on Schedule 2.3(w) is a registered public accounting firm as required by the Exchange Act and the rules and regulations of the SEC. 
 (x) Disclosure. Except as set forth on Schedule 2.3(x), All disclosure furnished by or on behalf of MSMT to Andover and CDIP regarding
MSMT, each MSMT Subsidiary, their respective businesses and the transactions contemplated hereby, including the MSMT Disclosure Schedules, with respect to the representations and warranties made herein are and will be true and correct with respect
to such representations and warranties as of the Effective Date and will be true and correct as of the Closing Date and do not and will not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make
the statements made therein, in light of the circumstances under which they were made, not misleading. 
 (y) Material Contracts.
Schedule 2.3(y) sets forth a true and complete list of all agreements, understandings, instruments, and contracts, proposed transactions (including a description of those currently being negotiated), judgments, orders, writs, or decrees to
which MSMT or any MSMT Subsidiary is a party or, to its knowledge, by which it is bound that may involve: (i) the sale of MSMT’s or any MSMT Subsidiary’s products or services to any customer, vendor, or provider (other than such
contracts entered into in the ordinary course of business); (ii) obligations (contingent or otherwise) of, or payments to, MSMT or any MSMT 

  

 -35- 

 
Subsidiary in excess of $50,000; (iii) the license of any proprietary rights to or from MSMT or any MSMT Subsidiary (other than licenses arising from
the purchase of “off the shelf” or other standard products); (iv) the development, administration, or distribution of MSMT’s and any MSMT Subsidiary’s products or services, including without limitation, any that involve any
brokers or dealers; (v) provisions restricting or affecting the development, manufacture, or distribution of MSMT’s or any MSMT Subsidiary’s products or services or MSMT’s or any MSMT Subsidiary’s freedom to compete in any
line of business; (vi) any joint venture or similar arrangement; (vii) any restriction or limitation on the ability of MSMT or any MSMT Subsidiary to pay dividends or make any other distributions or to repurchase, redeem, or otherwise
acquire any of its equity securities; or (viii) indemnification by MSMT or any MSMT Subsidiary of any other person or entity (except as may be provided in the Transaction Documents) (each, an “MSMT Material Contract”).
Andover has delivered or made available to CDIP and Andover true and complete copies of each MSMT Material Contract. Each MSMT Material Contract is in full force and effect and is binding and enforceable against the parties thereto in accordance
with its terms, and MSMT and each MSMT Subsidiary, as the case may be, has performed in all material respects all obligations required to be performed by it under each MSMT Material Contract, and no condition exists or events have occurred that,
with or without the passage of time or giving of notice, would constitute a default by MSMT or any MSMT Subsidiary, as the case may be, under any MSMT Material Contract. 
 (z) Disclosure Documents; MSMT Information. Except as set forth on Schedule 2.3(z), the Registration Statement will not, on the date the Registration Statement is filed with the SEC, at any time it is
amended or supplemented, or at the time it becomes effective under the Securities Act, contain any untrue statement of any material fact, or omit to state any material fact required to be stated therein or necessary in order to make the statements
therein not false or misleading at the time and in light of the circumstances under which such statement is made. The Information Statement will not, on the date the Information Statement is first mailed to MSMT’s stockholders or at the time of
the MSMT Stockholders’ Meeting, contain any untrue statement of any material fact, or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not false or misleading at the time and in
light of the circumstances under which such statement is made. The Information Statement will comply in all material respects as to form with the requirements of the Exchange Act and the rules and regulations thereunder. Notwithstanding the
foregoing, no representation is made by MSMT with respect to the information that has been or will be supplied by Andover or CDIP or their respective subsidiaries or their representatives for inclusion in the Registration Statement or the
Information Statement. 
 ARTICLE III 
 COVENANTS RELATING TO CONDUCT OF BUSINESS 
 3.1. Conduct of the Constituent Companies’
Businesses Pending the Closing Date. During the period commencing on the Effective Date and ending at the Closing Date or such earlier date as this Agreement may be terminated in accordance with its terms (the “Pre-Closing
Period”), each Constituent Company agrees (unless required to take such action pursuant to this Agreement or unless the other parties hereto have given their prior written consent) to, and to cause each of its respective subsidiaries
to, carry on its business in the usual, regular and 

  

 -36- 

 
ordinary course consistent with past practice, including with respect to working capital management, pay its Liabilities and Taxes consistent with its
respective past practices (and in any event when due) unless being contested in good faith by appropriate proceedings, pay or perform other material obligations when due consistent with its respective past practice (other than Liabilities, Taxes and
other obligations, if any, contested in good faith through appropriate proceedings), and use commercially reasonable efforts to (x) preserve its present business organization, (y) keep available the services of its present officers and
employees and (z) preserve its relationships with customers, suppliers, distributors, licensors, licensees, independent contractors and other persons having business dealings with it, all with the express purpose and intent of preserving
unimpaired its goodwill and ongoing business. Without limiting the generality of the foregoing, during the Pre-Closing Period, each Constituent Company shall not do, cause or permit, and shall cause its subsidiaries not to do, cause or permit, any
of the following actions, without the prior written consent of the other parties, except as expressly provided or permitted in or as contemplated by this Agreement: 
 (a) (i) declare, set aside or pay any dividends on, or make any other distributions (whether in cash, securities or other property) in respect of, any of its capital stock, (ii) split, combine or reclassify any
of its capital stock or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or any of its other securities, or (iii) purchase, redeem or otherwise acquire any
shares of its capital stock or any securities or obligations convertible into or exchangeable for any shares of its capital stock or any other of its securities or any rights, warrants or options to acquire any such shares or other securities other
than, in the case of clauses (i) through (iii) above, as required by law or the terms of such Constituent Company’s outstanding securities; 
 (b) (i) authorize for issuance, issue, deliver or sell or agree or commit to issue or sell (whether through the issuance or granting of options, warrants, commitments, subscriptions, rights to purchase or otherwise)
or accelerate the vesting of any stock of any class or any other securities or equity equivalents other than pursuant to pre-existing terms (including, without limitation, stock appreciation rights) of such Constituent Company (other than issuances
upon conversion or exercise of currently outstanding securities), or (ii) enter into any contract with respect to the foregoing, or (iii) permit any grants of restricted stock or issuance of similar stock-based employee rights; 

(c) cause, make or permit any change or amendment to the organizational documents of such Constituent Company or any of its subsidiaries, or change
the authorized capital stock or equity interests of such Constituent Company or any of its subsidiaries; 
 (d) (i) other than with respect
to capitalized leases, incur any Indebtedness or guarantee any Indebtedness of another Person, (ii) issue, sell or amend any debt securities or warrants or other rights to acquire any debt securities of such Constituent Company or any of its
subsidiaries, guarantee any debt securities of another Person, or enter into any arrangement having the economic effect of any of the foregoing, (iii) make any loans, advances or capital contributions to, or investment in, any other Person,
other than a direct or indirect wholly-owned subsidiary of such Constituent Company, other than in the ordinary course of business consistent with past practice, or (iv) mortgage, pledge or otherwise encumber any material assets, or create or
suffer any material encumbrance thereupon, except, in each case, in the ordinary course of 

  

 -37- 

 
business consistent with past practice pursuant to credit facilities in existence on the date hereof (or any extensions or renewals thereof); 
 (e) (i) prepay any loans (if any) from its stockholders, officers or directors or any Person affiliated with any of the foregoing, (ii) amend its
borrowing arrangements or (iii) waive, release or assign any material rights or claims, in each case, other than in the ordinary course of business consistent with past practice; 
 (f) materially reduce the amount of any insurance coverage provided by its existing insurance policies; 
 (g) materially change or implement accounting policies, methods or procedures, except as required by GAAP or applicable law; 
 (h) (i) increase the annual or discretionary amounts of base salary, bonus compensation or any other form of compensation payable or to become
payable to any officer, employee, agent or consultant of such Constituent Company or any of its subsidiaries, except in the ordinary course of business consistent with past practice, or (ii) grant or agree to grant or accelerate any right to
any severance or termination pay or enter into any contract to make or grant any severance or termination pay or pay or agree to pay any bonus or other incentive compensation to any officer or employee, except in the ordinary course of business
consistent with past practice; 
 (i) enter into, establish, adopt or amend (except, in each case, (i) as may be required by applicable
laws, or (ii) to satisfy contractual obligations existing as of the Effective Date, or (iii) in the ordinary course of business consistent with past practice), any pension, retirement, stock purchase, savings, profit sharing, deferred
compensation, consulting, bonus, group insurance or other employee benefit, incentive or welfare contract, plan or arrangement, or any trust agreement (or similar arrangement) related thereto, or communicate any intention to take such foregoing
actions, in respect of any director, officer or employee of such Constituent Company or any of its subsidiaries; 
 (j) hire any employee or
consultant with an annual salary in excess of $75,000 except in the ordinary course of business consistent with past practice; 
 (k) make
any material acquisition or capital expenditure in excess of $100,000 in the aggregate for such Constituent Company and its subsidiaries, taken as a whole, other than in the ordinary course of business consistent with past practice; 
 (l) sell, lease, license, pledge or otherwise dispose of, distribute or encumber any properties or assets of such Constituent Company or any of its
subsidiaries other than in the ordinary course of business consistent with past practice; 
 (m) acquire or agree to acquire by merging or
consolidating with, or by purchasing a substantial portion of the assets of, or by any other manner, any business or any corporation, partnership, association or other business organization or division thereof; 
  

 -38- 

 (n) other than in the ordinary course of business consistent with past practice, enter into, modify,
amend, violate or terminate any Material Contract (as such term is defined herein or under Item 601(b)(10) of Regulation S-K of the Exchange Act) or agreement to which such Constituent Company or any of its subsidiaries is party, or knowingly
waive, release or assign any rights or claims (other than any write-off or other compromise of any accounts receivable of such Constituent Company or any of its subsidiaries in accordance with GAAP); 
 (o) materially modify or terminate any Lease, except as set forth in Schedule 3.1(o); 
 (p) acquire or dispose of any real property, except as set forth in Schedule 3.1(p); 
 (q) settle or compromise any pending or threatened Action (whether or not commenced prior to the date of this Agreement) for an amount in excess of
$100,000; or 
 (r) agree, commit to or enter into any contract or arrangement to take any of the actions referred to in Section 3.1(a)
through Section 3.1(q) above, or intentionally take any other action that would prevent such Constituent Company from performing, or cause such Constituent Company not to perform, any of its covenants and agreements hereunder. 
 ARTICLE IV 
 ADDITIONAL AGREEMENTS

 4.1. Disclosure Documents. 
 (a) As promptly as practicable after the date of this Agreement, MSMT shall prepare and file or cause to be filed with the SEC (i) an information statement pursuant to Section 14 of the Exchange Act (the “Information
Statement”), relating to the vote of the requisite MSMT stockholders to consider the adoption and approval of this Agreement and the amendment and restatement of MSMT’s articles of incorporation to increase the number of authorized
shares of MSMT Common Stock and to create the MSMT Preferred Stock (herein, the “MSMT Charter Amendment,” the form of which is attached hereto as Exhibit 4.1), and (ii) a registration statement on Form S-4
(or other appropriate form) (the “Registration Statement”) registering the MSMT Common Stock and the MSMT Common Stock underlying the MSMT Preferred Stock and the Assumed Warrants to be issued to the Target Companies pursuant
to this Agreement. MSMT shall use reasonable best efforts to cause the Registration Statement and Information Statement, as the case may be, to comply in all material respects in form and substance with the rules and regulations promulgated by the
SEC and to respond promptly to any comments of the SEC or its staff with respect to the Registration Statement and Information Statement, as the case may be. The Target Companies shall furnish all information concerning themselves and their
subsidiaries, as applicable, as MSMT may reasonably request in connection with the preparation of the Information Statement and Registration Statement or which may be required under applicable law. MSMT shall promptly notify the other parties upon
the receipt of any comments from the SEC or its staff or any request from the SEC or its staff for amendments or supplements to the Registration Statement or Information Statement, as 

  

 -39- 

 
the case may be, shall consult with the other parties prior to responding to any such comments or requests or filing any amendment or supplement to the
Registration Statement or Information Statement, as the case may be, and shall provide the other parties with copies of all correspondence between such party and its representatives on the one hand and the SEC and its staff on the other hand. MSMT
shall use reasonable best efforts (A) to cause the Registration Statement to be declared effective by the SEC as promptly as reasonably practicable after the filing thereof; (B) to allow MSMT to file a definitive Information Statement with
the SEC; (C) to obtain any necessary state securities law or “Blue Sky” permits and approvals required to carry out the transactions contemplated by this Agreement; and (D) to cause the Information Statement to be mailed to the
MSMT’s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. Each Constituent Company will promptly inform MSMT of any material change in the information previously provided to
MSMT pursuant to Section 4.1. 
 (b) Notwithstanding anything to the contrary stated above, prior to filing and mailing, as applicable,
the Registration Statement or Information Statement (or any amendment or supplement thereto) or responding to any comments of the SEC with respect thereto, MSMT shall provide the Target Companies a reasonable opportunity to review and comment on
such document or response and shall discuss with the Target Companies and include in such document or response, comments reasonably and promptly proposed by either Target Company. 
 (c) MSMT will advise the Target Companies, promptly after MSMT receives written notice thereof, of the time when the Registration Statement has become
effective or any supplement or amendment has been filed, of the issuance of any stop order or the suspension of the qualification of MSMT Common Stock for offering or sale in any jurisdiction, of the initiation or threat of any proceeding for any
such purpose, or of any request by the SEC for the amendment or supplement of the Registration Statement or for additional information. 
 4.2. Constituent Companies’ Stockholder Meetings; Board Recommendation. 
 (a) Andover Stockholders’ Meeting;
Board Recommendation. 
 (i) Promptly after the Registration Statement is declared effective under the Securities Act, Andover will take
all action necessary in accordance with Delaware law and its certificate of incorporation and bylaws to call, hold and convene a meeting of its stockholders to consider the adoption and approval of this Agreement and the transactions contemplated
hereby (the “Andover Stockholders’ Meeting”) to be held as promptly as reasonably practicable, and in any event (to the extent permissible under applicable law) within thirty (30) days after the mailing of the proxy
statement relating thereto (the “Andover Proxy Statement”) to Andover’s stockholders. Subject to Section 4.3(d), Andover will use reasonable best efforts to solicit from its stockholders proxies in favor of the
adoption and approval of this Agreement and the transactions contemplated hereby, and will take all other action reasonably necessary or advisable to secure the vote or consent of its stockholders required by Delaware law to obtain such approvals.
Notwithstanding anything to the contrary contained in this Agreement, Andover may adjourn or postpone the Andover Stockholders’ Meeting to the extent necessary to ensure that any necessary supplement or amendment to the Andover Proxy Statement
is provided to its stockholders in advance of a vote on this Agreement or, if as of the time for which the 

  

 -40- 

 
Andover Stockholders’ Meeting is scheduled (as set forth in the Andover Proxy Statement) there are insufficient shares of Andover Common Stock
represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Andover Stockholders’ Meeting. Andover shall ensure that the Andover Stockholders’ Meeting is called, noticed, convened, held and
conducted, and that all proxies solicited by it in connection with the Andover Stockholders’ Meeting are solicited in compliance with Delaware law, its certificate of incorporation and bylaws and all other applicable legal requirements.

 (ii) Except to the extent expressly permitted by Section 4.3(d): (A) the Board of Directors of Andover shall recommend that
Andover’s stockholders vote at the Andover Stockholders’ Meeting in favor of the adoption and approval of this Agreement and the transactions contemplated hereby; and (B) the Andover Proxy Statement shall include a statement to the
effect that the Board of Directors of Andover has recommended that Andover’s stockholders vote at the Andover Stockholders’ Meeting in favor of the adoption and approval of this Agreement and the transactions contemplated hereby.

 (b) CDIP Stockholders’ Meeting; Board Recommendation. 
 (i) Promptly after the Registration Statement is declared effective under the Securities Act, CDIP will take all action necessary in accordance with
Delaware law and its certificate of incorporation and bylaws to call, hold and convene a meeting of its stockholders to consider the adoption and approval of this Agreement and the transactions contemplated hereby (the “CDIP
Stockholders’ Meeting”) to be held as promptly as reasonably practicable, and in any event (to the extent permissible under applicable law) within thirty (30) days after the mailing of the proxy statement relating thereto (the
“CDIP Proxy Statement”) to CDIP’s stockholders. Subject to Section 4.3(d), CDIP will use reasonable efforts to solicit from its stockholders proxies in favor of the adoption and approval of this Agreement and the
transactions contemplated hereby, and will take all other action reasonably necessary or advisable to secure the vote or consent of its stockholders required by Delaware law to obtain such approvals. Notwithstanding anything to the contrary
contained in this Agreement, CDIP may adjourn or postpone the CDIP Stockholders’ Meeting to the extent necessary to ensure that any necessary supplement or amendment to the CDIP Proxy Statement is provided to its stockholders in advance of a
vote on the adoption and approval of this Agreement and the transactions contemplated hereby or, if as of the time for which the CDIP Stockholders’ Meeting is scheduled (as set forth in the CDIP Proxy Statement) there are insufficient shares of
CDIP Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the CDIP Stockholders’ Meeting. CDIP shall ensure that the CDIP Stockholders’ Meeting is called, noticed, convened,
held and conducted, and that all proxies solicited by it in connection with the CDIP Stockholders’ Meeting are solicited in compliance with Delaware law, its certificate of incorporation and bylaws and all other applicable legal requirements.

 (ii) Except to the extent expressly permitted by Section 4.3(d): (A) the Board of Directors of CDIP shall recommend that
CDIP’s stockholders vote at the CDIP Stockholders’ Meeting in favor of the adoption and approval of this Agreement and the transactions contemplated hereby; and (B) the CDIP Proxy Statement shall include a statement to the effect that
the Board of Directors of CDIP has recommended that CDIP’s stockholders vote at 

  

 -41- 

 
the CDIP Stockholders’ Meeting in favor of the adoption and approval of this Agreement and the transactions contemplated hereby. 
 (c) MSMT Stockholders’ Meeting; Board Recommendation. 
 (i) Promptly after the Registration Statement is declared effective under the Securities Act, MSMT will take all action necessary in accordance with Nevada law and its articles of incorporation and bylaws to call,
hold and convene a meeting of its stockholders to consider the adoption and approval of this Agreement and the transactions contemplated hereby (the “MSMT Stockholders’ Meeting,” collectively with the Andover
Stockholders’ Meeting and the CDIP Stockholders’ Meeting, the “Stockholders’ Meetings”) to be held as promptly as reasonably practicable, and in any event (to the extent permissible under applicable law) within
thirty (30) days after the mailing of the Information Statement to MSMT’s stockholders. Subject to Section 4.3(d), MSMT will take all other action reasonably necessary or advisable to secure the vote or consent of its stockholders
required by Nevada law to obtain such approvals. Notwithstanding anything to the contrary contained in this Agreement, MSMT may adjourn or postpone the MSMT Stockholders’ Meeting to the extent necessary to ensure that any necessary supplement
or amendment to the Information Statement is provided to its stockholders in advance of a vote on the adoption and approval this Agreement and the transactions contemplated hereby or, if as of the time for which the MSMT Stockholders’ Meeting
is scheduled (as set forth in the Information Statement) there are insufficient shares of MSMT Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the MSMT Stockholders’ Meeting.
MSMT shall ensure that the MSMT Stockholders’ Meeting is called, noticed, convened, held and conducted, and that all proxies solicited by it in connection with the Stockholders’ Meeting are solicited in compliance with Nevada law, its
articles of incorporation and bylaws and all other applicable legal requirements. 
 (ii) Except to the extent expressly permitted by
Section 4.3(d): (A) the Board of Directors of MSMT shall recommend that MSMT’s stockholders vote at the MSMT Stockholders’ Meeting in favor of the adoption and approval of this Agreement and the transactions contemplated hereby;
and (B) the Information Statement shall include a statement to the effect that the Board of Directors of MSMT has recommended that MSMT’s stockholders vote at the MSMT Stockholders’ Meeting in favor of the adoption and approval of
this Agreement and the transactions contemplated hereby. 
 (d) Consent of Stockholders in Lieu of Meeting. Notwithstanding Sections
4.2(a)(i), 4.2(b)(i) or 4.2(c)(i) and unless otherwise prohibited by a Constituent Company’s charter documents, bylaws, or applicable law, nothing contained herein shall preclude the stockholders of any Constituent Company from adopting and
approving this Agreement and the transactions contemplated hereby without a meeting, without prior notice and without a vote, at such time as is deemed appropriate by such Constituent Company, if a consent or consents in writing shall be signed by
holders of the outstanding capital stock of such Constituent Company having no less than the minimum number of votes that would be necessary to authorize or take such action at the applicable stockholders’ meetings at which the requisite number
of shares of capital stock of such Constituent Company entitled to vote thereat were present and voted. 
 4.3. Acquisition Proposals.

  

 -42- 

 (a) No Solicitation. Each Constituent Company agrees that none of it, any of its respective
subsidiaries, or any of its or its respective subsidiaries’ officers or directors, shall, and that it shall use all reasonable efforts to cause its and its Affiliates, subsidiaries, agents and representatives (including any of its or its
subsidiaries’ investment bankers, financial advisors, attorneys, accountants or other representatives) not to (and shall not authorize or permit any of them to), directly or indirectly: (i) solicit, initiate or knowingly induce any inquiry
concerning any Acquisition Proposal; (ii) participate or engage in any discussions or negotiations regarding, or furnish to any Person other than its representatives (including any of its or its subsidiaries’ investment bankers, financial
advisors, attorneys, accountants or other representatives) any nonpublic information with respect to, or take any other action to encourage any inquiries concerning the making of any proposal that constitutes or would reasonably be expected to lead
to, any Acquisition Proposal; (iii) approve, endorse, recommend or make or authorize any public statement, recommendation or solicitation in support of any Acquisition Proposal; or (iv) execute or enter into, or agree to execute or enter
into, any letter of intent or similar document or any contract, agreement or commitment contemplating or otherwise relating to any Acquisition Proposal or transaction contemplated thereby, except in the case of clauses (ii), (iii) or
(iv) to the extent specifically permitted pursuant to Sections 4.3(c) or 4.3(d). Each Constituent Company and its respective subsidiaries will immediately cease and cause to be terminated any and all existing activities, discussions or
negotiations (including, without limitation, any such activities, discussions or negotiations conducted by its Affiliates, directors, officers, employees, agents and representatives (including any of its or its subsidiaries’ investment bankers,
financial advisors, attorneys, accountants or other representatives) of such Constituent Company or any of its subsidiaries) with any third Persons conducted prior to the Effective Date with respect to the consideration of any Acquisition Proposal.
Each Constituent Company will exercise any rights under any confidentiality or non-disclosure agreements with any such third parties in connection with the consideration of any Acquisition Proposal to require the return or destruction of non-public
information provided prior to the Effective Date by such Constituent Company, its subsidiaries or their agents and representatives, to any such third Persons. 
 (b) Notification of Unsolicited Acquisition Proposals. As promptly as practicable (and in any event no later than two (2) Business Days) after receipt of any Acquisition Proposal, any request for nonpublic
information or inquiry that would reasonably be expected to lead to an Acquisition Proposal, or any other communication from any Person seeking to have discussions or negotiations with a Constituent Company relating to a possible Acquisition
Proposal (the Constituent Company receiving an unsolicited Acquisition Proposal, request or inquiry or other communication is hereinafter referred to as the “Receiving Constituent Company”), the Receiving Constituent Company
shall provide the other Constituent Companies with notice of such Acquisition Proposal, request or inquiry or other communication, including: (i) the material terms and conditions of such Acquisition Proposal, request or inquiry or other
communication; and (ii) the identity of the Person or group making any such Acquisition Proposal, request or inquiry or other communication. The Receiving Constituent Company shall provide the other Constituent Companies with two
(2) Business Days prior notice (or such lesser prior notice as is provided to the members of its Board of Directors) of any meeting of its Board of Directors at which its Board of Directors is expected to consider any Acquisition Proposal or
any such request or inquiry or other communication to consider providing nonpublic information to any such Person. The Receiving Constituent Company shall notify the other Constituent Companies, in writing, of any decision of its Board of Directors
as to 

  

 -43- 

 
whether to consider such Acquisition Proposal, request or inquiry or other communication or to enter into discussions or negotiations concerning any
Acquisition Proposal or to provide nonpublic information or data to any Person, which written notice shall be given as promptly as practicable after such meeting. 
 (c) Superior Offers. Notwithstanding anything to the contrary contained in Sections 4.2(a), 4.2(b) or 4.2(c), in the event that any Receiving Constituent Company receives, prior to the adoption and approval of
this Agreement and the transactions contemplated hereby by the stockholders of such Receiving Constituent Company in accordance with applicable law, an unsolicited, bona fide written Acquisition Proposal from a third Person with respect to which
such Receiving Constituent Company’s Board of Directors has in good faith concluded, after consultation with its outside legal counsel and its financial advisor, if any, that such Acquisition Proposal is, or is reasonably likely to result in, a
Superior Offer, such Receiving Constituent Company may then (i) furnish nonpublic information to the third Person making such Acquisition Proposal, and (ii) engage in negotiations with the third Person with respect to such Acquisition
Proposal; provided that: 
 (A) prior to furnishing any nonpublic information or entering into any negotiations or discussions with such
third Person, such Receiving Constituent Company receives from such third Person an executed confidentiality agreement containing customary limitations on the use and disclosure of all nonpublic written and oral information furnished to such third
Person on such Receiving Constituent Company’s behalf; and 
 (B) the Board of Directors of such Receiving Constituent Company
reasonably determines in good faith, after consultation with outside legal counsel, that the failure to provide such information or enter into such discussion or negotiations would reasonably be expected to result in a breach of the Board of
Directors’ fiduciary duties to the stockholders of such Receiving Constituent Company under applicable law. 
 (d) Change of
Recommendation. Notwithstanding anything to the contrary contained in Sections 4.2(a), 4.2(b) or 4.2(c), in response to the receipt of a Superior Offer, (i) the Board of Directors of the Receiving Constituent Company may withhold, withdraw,
amend or modify its recommendation in favor of the adoption and approval of this Agreement and the transactions contemplated hereby, and, may recommend in favor of a Superior Offer, and in the case of a Superior Offer that is a tender or exchange
offer made directly to the stockholders of such Receiving Constituent Company, may recommend that the stockholders of such Receiving Constituent Company accept the tender or exchange offer (any of the foregoing actions, whether by the Board of
Directors of such Receiving Constituent Company or a committee thereof, a “Change of Recommendation”), (ii) such Receiving Constituent Company or its subsidiaries (including each of their respective directors, officers,
employees, agents or other representatives) may approve, endorse, or recommend a Superior Offer, or (iii) such Receiving Constituent Company or any of its subsidiaries may execute or enter into or propose to execute or enter into any letter of
intent or similar document or any contract, agreement or commitment (which may be conditioned on the termination of this Agreement) contemplating or otherwise relating to any Superior Offer or transaction contemplated thereby, if all of the
following conditions in clauses (A) through (E) are met: 
  

 -44- 

 (A) the Board of Directors of such Receiving Constituent Company determines in good faith, after
consultation with such Receiving Constituent Company’s financial advisor, if any, and outside legal counsel, that a Superior Offer has been made and not withdrawn; 
 (B) the stockholders of such Receiving Constituent Company have not previously adopted and approved this Agreement and the transactions contemplated hereby in accordance with applicable law; 
 (C) such Receiving Constituent Company shall have delivered to the other Constituent Companies written notice (a “Change of Recommendation
Notice”) at least four (4) Business Days prior to publicly effecting such Change of Recommendation which shall state expressly (w) that such Receiving Constituent Company has received a Superior Offer; (x) the most recent
terms and conditions of the Superior Offer and the identity of the Person or group making the Superior Offer (and in the event such Receiving Constituent Company exercises its right to terminate this Agreement pursuant to Section 6.1(c), such
Receiving Constituent Company shall provide to the other Constituent Companies a copy of the final agreement to be entered into in connection with the Superior Offer); (y) that such Receiving Constituent Company intends to effect a Change of
Recommendation; and (z) that such Receiving Constituent Company agrees to reimburse the expenses of the other Constituent Companies as contemplated under Section 6.2; 
 (D) after delivering the Change of Recommendation Notice, such Receiving Constituent Company shall provide the other Constituent Companies with a
reasonable opportunity to make such adjustments in the terms and conditions of this Agreement during such four (4) Business Day period, and negotiate in good faith with respect thereto during such four (4) Business Day period, as would
enable such Receiving Constituent Company to proceed with its recommendation to its stockholders in favor of the adoption and approval of this Agreement and the transactions contemplated hereby without making a Change of Recommendation; and

 (E) the Board of Directors of such Receiving Constituent Company shall have determined (x) after consultation with its financial
advisor, if any, that the terms of the Superior Offer are more favorable to the stockholders of such Receiving Constituent Company than the terms of this Agreement (as it may be adjusted pursuant to subsection (D) above), and (y) after
consultation with outside legal counsel, the failure to effect a Change of Recommendation would reasonably be expected to result in a breach of the Board of Directors’ fiduciary duties to the stockholders of such Receiving Constituent Company
under applicable law. 
 (e) Compliance with Disclosure Obligations. Nothing contained in this Agreement shall prohibit each
Constituent Company or its respective Board of Directors from complying with the Securities Act and the Exchange Act and the rules and regulations promulgated thereunder. 
 (f) Obligation to Call, Hold and Convene Stockholders’ Meetings. Notwithstanding anything to the contrary contained in this Agreement, the obligation of any 

  

 -45- 

 
Constituent Company to call, give notice of, convene and hold the Stockholders’ Meetings shall be terminated upon the commencement, disclosure,
announcement or submission of any Change of Recommendation. 
 (g) Specific Performance. The parties hereto agree that irreparable
damage would occur in the event that the provisions of this Section 4.3 were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed by the parties hereto that each of the Constituent Companies
shall be entitled to an immediate injunction or injunctions, without the necessity of proving the inadequacy of money damages as a remedy and without the necessity of posting any bond or other security, to prevent breaches of the provisions of this
Section 4.3 by any other Constituent Company and to enforce specifically the terms and provisions hereof in any court of the United States or any state having competent jurisdiction, this being in addition to any other remedy to which any
Constituent Company may be entitled at law or in equity. Without limiting the foregoing, it is understood that any violation of the restrictions set forth above by any officer, director, agent, representative or Affiliate of a Constituent Company
shall be deemed to be a breach of this Agreement by such Constituent Company. 
 4.4. Board of Directors of MSMT. Immediately
following the Closing, the Board of Directors of MSMT shall in accordance with provisions contained in MSMT’s articles of incorporation and bylaws, take such action as necessary to (a) increase the size of the Board of Directors of MSMT to
nine (9) directors and (b) elect Lowell M. Fisher, Jr. (Chairman of the Board), Shad Stastney, Christopher D. Phillips, Edwin A. Reilly, one designee of Frank Magliochetti, two (2) designees of Vicis Capital Master Fund and two
(2) additional members who qualify as “independent directors” as that term is defined by a Senior Trading Market and who otherwise shall be reasonably acceptable to a majority of the other above-named nominees, to serve as members of
its Board of Directors until December 31, 2009 or until their successors are duly qualified, seated and elected, or until their earlier resignation or removal. Prior to Closing, MSMT shall prepare the information statement required by Rule
14f-1 promulgated under the Exchange Act (“14f-1 Information Statement”), and MSMT shall file the 14f-1 Information Statement with the SEC and mail the same to each of MSMT’s stockholders of record. MSMT will use its
reasonable best efforts to ensure that MSMT’s current directors will remain as directors of MSMT until the expiration of the ten (10) day period beginning on the date of the mailing of the 14f-1 Information Statement. 
 4.5. Officers of MSMT. Immediately following the Closing, the Board of Directors of MSMT shall appoint and elect the individuals set forth on
Schedule 4.5 to the corporate offices set forth opposite each persons name to serve in those capacities until their successors are duly elected, qualified and seated. 
 4.6. Third Party Consents and Regulatory Approvals. 
 (a) Subject to the terms hereof and applicable law, each Constituent Company shall use their reasonable best efforts to: 
 (i) take, or cause to be taken, all actions, and do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper, or 

  

 -46- 

 
advisable to consummate and make effective the transactions contemplated hereby as promptly as practicable; 
 (ii) as promptly as practicable, obtain from any Governmental Authority or any other third party any consents, licenses, permits, waivers, approvals,
authorizations, or orders required to be obtained or made by such Constituent Companies or any of their respective subsidiaries in connection with the authorization, execution, and delivery of this Agreement and the consummation of the transactions
contemplated hereby; 
 (iii) as promptly as practicable, make all necessary filings for such Constituent Company, and thereafter make any
other required submissions for such Constituent Company, with respect to this Agreement required under (A) the Securities Act, the Exchange Act and any other applicable federal or state securities laws, and (B) any other applicable law;
and 
 (iv) execute or deliver any additional instruments necessary to consummate the transactions contemplated by, and to fully carry out
the purposes of, this Agreement. 
 (b) The Constituent Companies shall cooperate with each other in connection with the making of all such
filings, including providing copies of all such documents to the non-filing parties and their advisors prior to filing and, if requested, accepting reasonable additions, deletions or changes suggested in connection therewith. The Constituent
Companies shall use their respective reasonable best efforts to furnish to each other all information required for any application or other filing to be made pursuant to the rules and regulations of any applicable law (including all information
required to be included in the Registration Statement and Information Statement) in connection with the transactions contemplated by this Agreement. 
 (c) Each Constituent Company shall use its reasonable best efforts to obtain the respective authorizations, consents, orders and approvals and to make filings from or with any Governmental Authority or other third
party necessary for its respective execution and delivery of, and the performance of its respective obligations pursuant to, this Agreement. The parties hereto will not take any action that will have the effect of delaying, impairing or impeding the
receipt of any required approvals and shall promptly respond to any requests for additional information from any Governmental Authority. 
 4.7. Access and Investigation. Between the Effective Date and the Closing Date, and upon reasonable advance written notice, each Constituent Company shall (a) afford the other Constituent Companies access, during regular
business hours, to such Constituent Company’s personnel, properties, books and records and other documents and data, such rights of access to be exercised in a manner that does not unreasonably interfere with the operations of such Constituent
Company; (b) furnish the requesting Constituent Company with copies of all such books and records and other existing documents and data as the requesting Constituent Company may reasonably request; (c) furnish the requesting Constituent
Company with such additional financial, operating and other relevant data and information as the requesting Constituent Company may reasonably request; and (d) otherwise cooperate and assist, to the extent 

  

 -47- 

 
reasonably requested, with the requesting Constituent Company’s investigation of the properties, assets and financial condition related to such
Constituent Company. 
 4.8. Application for listing on Senior Trading Market; Reverse Stock Split. At or before the Closing, MSMT
shall prepare and submit a listing application to the New York Stock Exchange, the American Stock Exchange, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market (a “Senior Trading Market”)
covering the shares of MSMT Common Stock and shall use commercially reasonable best efforts to obtain approval for the listing of such shares of MSMT Common Stock on a Senior Trading Market; provided, however, that in no event shall the
status of such application delay the Closing. In furtherance of the same, to the extent necessary as determined by the MSMT Board of Directors, MSMT will effect a reverse stock split in order to satisfy certain pricing requirements of the Senior
Trading Market. 
 4.9. Proxy Agreement. Andover shall use its best efforts to obtain from the holders of a percentage of the Andover
Common Stock acceptable to MSMT and CDIP a written proxy in favor of Vicis Capital Master Fund, the form of which is attached hereto as Exhibit 4.7 (the “Form of Proxy”). 
 4.10. Publicity. So long as this Agreement is in effect, each Constituent Company shall not, nor shall any Constituent Company permit any of its
respective subsidiaries to, issue or cause the publication of any press release or other public announcement with respect to, or otherwise make any public statement or filing concerning, the transactions contemplated by this Agreement without the
prior written consent of all other parties, which consent shall not be unreasonably withheld or delayed, except as may be required by applicable law or the applicable rules of any stock exchange, in which case the party required to make the release,
announcement, statement or filing shall use its reasonable best efforts to allow the other parties reasonable time to comment on such release, announcement, statement or filing in advance of such issuance. Upon the execution of this Agreement and at
the Closing, the Constituent Companies shall issue a mutually agreed upon press release announcing the transactions contemplated hereby. 
 4.11. Notification of Certain Events. Each Constituent Company will give prompt written notice to the other Constituent Companies of (a) any notice or other communication from any Person alleging that the consent of such Person
is or may be required in connection with the Reorganization or any of the other transactions contemplated by this Agreement, (b) any notice or other communication from any Governmental Authority in connection with the Reorganization or any of
the other transactions contemplated by this Agreement, or (c) any litigation relating to, involving or otherwise affecting the Constituent Companies or any of their respective subsidiaries that relates to the Reorganization or any of the other
transactions contemplated by this Agreement. 
 4.12. Breach of Representation and Warranty Concerning Capitalization. In the event of
a breach at any time of the representation and warranty concerning the capitalization of any Constituent Company contained in Sections 2.1(f), 2.2(f) or 2.3(f), as applicable, the number of MSMT Securities issuable by MSMT pursuant to the terms of
this Agreement shall be adjusted, without the exchange of any additional consideration by the non-breaching Constituent Company, to that amount of MSMT Securities that should have been issued had such 

  

 -48- 

 
representation and warranty been true and correct at the time made so that the Constituent Company’s percentage interest in MSMT is not less than that
which it was intended to be based upon the incorrect representation and warranty. 
 4.13. Takeover Statutes. If any anti-takeover,
control share acquisition, fair price, moratorium or other similar statute is or may become applicable to the Reorganization or the other transactions contemplated by this Agreement, each Constituent Company and their respective Boards of Directors
shall grant such approvals and take such lawful actions as are necessary to ensure that such transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise take such lawful actions to eliminate
or minimize the effects of such statute and any regulations promulgated thereunder on such transactions. 
 4.14. Tax Treatment. The
Constituent Companies hereto acknowledge and agree that the transactions contemplated hereby are intended to qualify and to be treated as tax-free reorganizations under Sections 368(a)(1)(C) of the Code, and that this Agreement shall constitute a
“plan of reorganization” within the meaning of Section 368 of the Code and the associated Treasury Regulations. In furtherance of the same, each Constituent Company hereby makes the following representations, warranties and covenants,
severally and not jointly, as applicable: 
 (a) Each Target Company will retain only its corporate charter and those assets, if any,
necessary to satisfy state minimum law capital requirements to maintain corporate existence (minimum capital). 
 (b) MSMT will acquire at
least ninety percent (90%) of the fair market value of the net assets and at least seventy percent (70%) of the fair market value of the gross assets held by each Target Company immediately prior to the Closing Date. For purposes of this
calculation, the following shall be included as an asset of each Target Company held immediately prior to the Closing Date: (i) the corporate charter and minimum capital retained by each Target Company; (ii) amounts paid by each Target
Company to any dissenting stockholder (if the Reorganization triggers dissenters’ rights); (iii) amounts used by each Target Company to pay its expenses associated with the Reorganization; (iv) amounts paid by each Target Company to
its stockholders who receive cash or other property; and (v) all redemptions and distributions (except for regular, normal dividends) made by each Target Company immediately preceding the Closing Date. 
 (c) The primary purpose for having each Target Company maintain its corporate existence under state law is to isolate each Target Company’s charter
for resale to an Unrelated Purchaser. As used herein, the term “Unrelated Purchaser” shall mean a purchaser that did not own, actually or constructively pursuant to Section 318(a) of the Code (as modified by
Section 304(c)(3)), any stock of the Target Company prior to the Reorganization or does not own, any stock, actually or constructively pursuant to Section 318(a) of the Code (as modified by Section 304(c)(3)), of MSMT subsequent to
the Reorganization. 
 (d) Each Target Company will use its best efforts to be sold to an Unrelated Purchaser or dissolved under state law
within twelve (12) months following the Closing Date. 
  

 -49- 

 (e) The fair market value of MSMT Securities received by each Target Company (and ultimately distributed
to each Target Company’s stockholders) will be approximately equal to the fair market value of the Target Company securities surrendered in the exchange. 
 (f) There is no plan or intention by the stockholders of the Target Companies who own five percent (5%) or more of the capital stock of each Target Company, and to the best of the knowledge of each Target
Company, there is no plan or intention on the part of the remaining stockholders of each Target Company to sell, exchange or otherwise dispose of MSMT Securities received in the Reorganization that would reduce the Target Company’s (and
ultimately the Target Company’s stockholders, after effecting the distribution described in Section 1.8 hereof) ownership of MSMT Securities to a number of shares of capital stock that have a value, as of the Closing Date, of less than
fifty percent (50%) of the value of all of the formerly outstanding stock of each Target Company as of the Closing Date. For purposes of this calculation, (i) shares of each Target Company exchanged for cash or other property,
(ii) surrender to the Target Companies by any dissenting stockholder (if the Reorganization triggers dissenters’ rights), or (iii) exchanged for cash in lieu of fractional shares of MSMT Securities shall be included as outstanding
Target Company capital stock on the Closing Date. Moreover, shares of Target Company stock and shares of MSMT Securities held by Target Company stockholders and otherwise sold, redeemed or disposed of prior or subsequent to the Reorganization shall
be considered in making this calculation. 
 (g) MSMT has no plan or intention to reacquire any of the MSMT Securities issued in the
Reorganization. 
 (h) MSMT has no plan or intention to sell or otherwise dispose of any of the CDIP Purchased Assets or the Andover
Purchased Assets acquired in the Reorganization, except for dispositions made in the ordinary course of business or transfers described in Section 368(a)(2)(C) of the Code. Each Target Company will distribute the MSMT Securities (and any other
property it receives in the Reorganization), and its other properties, in pursuance of the Reorganization. The CDIP Assumed Liabilities and Andover Assumed Liabilities assumed by MSMT (and any liabilities to which the CDIP Purchased Assets or
Andover Purchased Assets are subject) pursuant to Section 1.3 hereof, were incurred by each of CDIP and Andover, as applicable, in the ordinary course of business. 
 (i) Following the Reorganization, MSMT will continue the historic business of the Target Companies or use a significant portion of the CDIP Purchased Assets and Andover Purchased Assets in its business. 
 (j) There is no intercorporate Indebtedness existing between any of the Constituent Companies that was issued, acquired or will be settled at a discount.
None of the Constituent Companies is an investment company, as defined in Section 368(a)(2)(F)(iii) and (iv) of the Code. 
 (k)
The fair market value of the CDIP Purchased Assets and Andover Purchased Assets transferred to MSMT will equal or exceed the sum of the CDIP Assumed Liabilities and the Andover Assumed Liabilities (such CDIP Assumed Liabilities and Andover 

  

 -50- 

 
Assumed Liabilities inclusive of the amount of any liabilities to which the CDIP Purchased Assets and Andover Purchased Assets are subject). 
 (l) None of the Constituent Companies is under the jurisdiction of a court in a Title 11 or similar case within the meaning of Section 368(a)(3)(A)
of the Code. 
 4.15. Other Actions by the Parties. Each Constituent Company, at the request of the other parties, shall execute and
deliver such other instruments and do and perform such other acts and things as may be reasonably necessary or desirable for effecting completely the consummation of this Agreement and the transactions contemplated hereby (including all action
reasonably necessary to seek and obtain any and all approvals of any Governmental Authority or other Person required in connection with the Reorganization). 
 ARTICLE V 
 CONDITIONS PRECEDENT TO CLOSING 
 5.1. Conditions Precedent to Each Constituent Company’s Obligation to Close. The respective obligations of each Constituent Company to
consummate the transactions contemplated by this Agreement shall be subject to the conditions that at and as of the Closing Date: (a) there shall be no legal requirement, and no injunction or judgment shall have been entered by any Governmental
Authority and not vacated, nor any Action or litigation instituted or threatened, to enjoin, restrain, prohibit or obtain damages in respect of, or that is related to, or arising out of, this Agreement, the consummation of the transactions
contemplated hereby, the assets of any of the Constituent Companies or that is otherwise material to any Constituent Company’s business, and no Governmental Authority shall have enacted or enforced any statute, rule, regulation, executive
order, decree or other order (whether temporary, preliminary or permanent) which is in effect and has the effect of making the transactions contemplated hereby illegal or otherwise prohibiting consummation of the transactions contemplated hereby or
that is otherwise material to the business or assets of any of the Constituent Companies; (b) no written notice shall have been received from any Governmental Authority indicating an intent to restrain, prevent, materially delay or restructure
the transactions contemplated by this Agreement; (c) the Registration Statement shall have been declared effective and no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings for that
purpose shall have been initiated or threatened by the SEC or any other Governmental Authority and no similar proceeding in respect of the Information Statement shall have been initiated or threatened by the SEC or any Governmental Authority;
(d) there shall have been filed with and accepted by the Secretary of State of the State of Nevada the MSMT Charter Amendment; (e) this Agreement and the transactions contemplated hereby shall have been adopted and approved by the
stockholders of each Constituent Company at the Stockholders’ Meetings (or by written consent) in accordance with each Constituent Company’s charter documents, bylaws and applicable law; (f) all consents, authorizations, orders and
approvals of (or filings or registrations with) any Governmental Authority required to be obtained by the Constituent Companies in connection with the execution, delivery and performance of this Agreement shall have been obtained or made;
(g) all consents required from third Persons that are listed on Schedules 2.1(e), 2.2(e) and 2.3(e), respectively, shall have been obtained, and each Constituent Company shall have provided the other Constituent Companies with reasonable
evidence of such consent; (h) 

  

 -51- 

 
this Agreement shall have been adopted and approved by the requisite affirmative vote of the holders of shares of Andover Series A Preferred Stock, Series B
Preferred Stock and Series D Preferred Stock, and CDIP Series C Preferred Stock and Series D Preferred Stock, in each case present and voting at duly call meeting or by written consent in accordance with applicable law and the respective
certificates of incorporation and bylaws of Andover and CDIP, as applicable; (i) the MSMT Common Stock shall continue to be quoted on the OTC Bulletin Board maintained by the Financial Industry Regulatory Authority; and (j) the
registration rights agreements set forth on Schedule 5.1(j) shall have been terminated. 
 5.2. Conditions Precedent to MSMT’s
Obligation to Close. In addition to the satisfaction of the conditions set forth in Section 5.1, the obligations of MSMT to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment at or prior to the
Closing of each of the following conditions: 
 (a) Intentionally Omitted. 
 (b) Representations and Warranties of Target Companies. 
 (i) The representations and warranties of CDIP set forth in this Agreement and the certificates and other documents to be delivered by it as contemplated hereunder shall have been true and correct as of the date of
this Agreement and shall be true and correct as of the Closing Date as though made on and as of the Closing Date (except that those representations and warranties which address matters only as of a particular date shall have been true and correct
only as of such date); and 
 (ii) The representations and warranties of Andover set forth in this Agreement and the certificates and other
documents to be delivered by it as contemplated hereunder shall have been true and correct as of the date of this Agreement and shall be true and correct as of the Closing Date as though made on and as of the Closing Date (except that those
representations and warranties which address matters only as of a particular date shall have been true and correct only as of such date). 
 (c) Covenants of Target Companies. 
 (i) CDIP shall have performed in all material respects all covenants and agreements
required to be performed by it under this Agreement on or prior to the Closing Date; and 
 (ii) Andover shall have performed in all
material respects all covenants and agreements required to be performed by it under this Agreement on or prior to the Closing Date. 
 (d)
No Material Adverse Effect. 
 (i) Since the Effective Date, no event or events have occurred which individually or in the aggregate
have had or would reasonably be expected to have a Material Adverse Effect on CDIP; and 
  

 -52- 

 (ii) Since the Effective Date, no event or events have occurred which individually or in the aggregate
have had or would reasonably be expected to have a Material Adverse Effect on Andover. 
 (e) Financial Statements. 
 (i) CDIP Financial Statements. No later than seven (7) Business Days prior to the Closing, MSMT shall have received an unaudited balance
sheet of CDIP as at the end of the month no more than forty-five (45) days prior to the Closing Date (the “CDIP Closing Balance Sheet”) and the related unaudited statements of income, changes in the stockholders’
equity and cash flows for the period from November 1, 2007 to the date of the CDIP Closing Balance Sheet, including in each case the notes thereto. 
 (ii) Andover Financial Statements. No later than seven (7) Business Days prior to the Closing, MSMT shall have received an unaudited balance sheet of Andover as at the end of the month no more than
forty-five (45) days prior to the Closing Date (the “Andover Closing Balance Sheet”) and the related unaudited statements of income, changes in the stockholders’ equity and cash flows for the period from
January 1, 2008 to the date of the Andover Closing Balance Sheet, including in each case the notes thereto. 
 5.3. Conditions
Precedent to Andover’s Obligation to Close. In addition to the satisfaction of the conditions set forth in Section 5.1, the obligations of Andover to consummate the transactions contemplated by this Agreement shall be subject to the
fulfillment at or prior to the Closing of each of the following conditions: 
 (a) Intentionally Omitted. 
 (b) Representations and Warranties of CDIP and MSMT. 
 (i) The representations and warranties of MSMT set forth in this Agreement and the certificates and other documents to be delivered by it as contemplated hereunder shall have been true and correct as of the date of
this Agreement and shall be true and correct as of the Closing Date as though made on and as of the Closing Date (except that those representations and warranties which address matters only as of a particular date shall have been true and correct
only as of such date); and 
 (ii) The representations and warranties of CDIP set forth in this Agreement and the certificates and other
documents to be delivered by it as contemplated hereunder shall have been true and correct as of the date of this Agreement and shall be true and correct as of the Closing Date as though made on and as of the Closing Date (except that those
representations and warranties which address matters only as of a particular date shall have been true and correct only as of such date). 
 (c) Covenants of MSMT and CDIP. 
 (i) MSMT shall have performed in all material respects all covenants and agreements
required to be performed by it under this Agreement on or prior to the Closing Date; and 
  

 -53- 

 (ii) CDIP shall have performed in all material respects all covenants and agreements required to be
performed by it under this Agreement on or prior to the Closing Date. 
 (d) No Material Adverse Effect. 
 (i) Since the Effective Date, no event or events have occurred which individually or in the aggregate have had or would reasonably be expected to have a
Material Adverse Effect on MSMT; and 
 (ii) Since the Effective Date, no event or events have occurred which individually or in the
aggregate have had or would reasonably be expected to have a Material Adverse Effect on CDIP. 
 (e) Financial Statements. 

(i) CDIP Financial Statements. No later than seven (7) Business Days prior to the Closing, Andover shall have received the CDIP Closing
Balance Sheet and the related unaudited statements of income, changes in the stockholders’ equity and cash flows for the period from November 1, 2007 to the date of the CDIP Closing Balance Sheet, including in each case the notes thereto.

 (ii) MSMT Financial Statements. No later than seven (7) Business Days prior to the Closing, Andover shall have received an
unaudited balance sheet of MSMT as at the end of the month no more than forty-five (45) days prior to the Closing Date (the “MSMT Closing Balance Sheet”) and the related unaudited statements of income, changes in the
stockholders’ equity and cash flows for the period from January 1, 2008 to the date of the MSMT Closing Balance Sheet, including in each case the notes thereto. 
 5.4. Conditions Precedent to CDIP’s Obligation to Close. In addition to the satisfaction of the conditions set forth in Section 5.1, the obligations of CDIP to consummate the transactions contemplated
by this Agreement shall be subject to the fulfillment at or prior to the Closing of each of the following conditions: 
 (a) Intentionally
Omitted. 
 (b) Representations and Warranties of MSMT and Andover. 
 (i) The representations and warranties of MSMT set forth in this Agreement and the certificates and other documents to be delivered by it as contemplated
hereunder shall have been true and correct as of the date of this Agreement and shall be true and correct as of the Closing Date as though made on and as of the Closing Date (except that those representations and warranties which address matters
only as of a particular date shall have been true and correct only as of such date); and 
 (ii) The representations and warranties of
Andover set forth in this Agreement and the certificates and other documents to be delivered by it as contemplated hereunder shall have been true and correct as of the date of this Agreement and shall be true and 

  

 -54- 

 
correct as of the Closing Date as though made on and as of the Closing Date (except that those representations and warranties which address matters only as
of a particular date shall have been true and correct only as of such date). 
 (c) Covenants of MSMT and Andover. 
 (i) MSMT shall have performed in all material respects all covenants and agreements required to be performed by it under this Agreement on or prior to
the Closing Date; and 
 (ii) Andover shall have performed in all material respects all covenants and agreements required to be performed by
it under this Agreement on or prior to the Closing Date. 
 (d) No Material Adverse Effect. 
 (i) Since the Effective Date, no event or events have occurred which individually or in the aggregate have had or would reasonably be expected to have a
Material Adverse Effect on MSMT; and 
 (ii) Since the Effective Date, no event or events have occurred which individually or in the
aggregate have had or would reasonably be expected to have a Material Adverse Effect on Andover. 
 (e) Financial Statements.

 (i) Andover Financial Statements. No later than seven (7) Business Days prior to the Closing, CDIP shall have received the
Andover Closing Balance Sheet and the related unaudited statements of income, changes in the stockholders’ equity and cash flows for the period from January 1, 2008 to the date of the Andover Closing Balance Sheet, including in each case
the notes thereto. 
 (ii) MSMT Financial Statements. No later than seven (7) Business Days prior to the Closing, CDIP shall
have received the MSMT Closing Balance Sheet and the related unaudited statements of income, changes in the stockholders’ equity and cash flows for the period from January 1, 2008 to the date of the MSMT Closing Balance Sheet, including in
each case the notes thereto. 
 ARTICLE VI 
 TERMINATION 
 6.1. Events of Termination. Anything herein or elsewhere to the contrary
notwithstanding, this Agreement may be terminated by written notice of termination at any time before the Closing Date only as follows: 
 (a)
by mutual written consent of each of the Constituent Companies. 
  

 -55- 

 (b) by any of the Constituent Companies at any time prior to the Closing Date: (i) if the
Reorganization shall not have been consummated by December 31, 2008, not on account of any act or omission of such Constituent Company, (ii) if any order enjoining, restraining or otherwise prohibiting the Reorganization exists; or
(iii) approval of any Constituent Company’s stockholders shall not have been obtained at any applicable Stockholders’ Meeting or any adjournment or postponement of any applicable Stockholders’ Meeting taken in accordance with
this Agreement. 
 (c) by any of the Constituent Companies if: (i) the Board of Directors of a Constituent Company or any committee
thereof shall for any reason have withdrawn or shall have amended or modified in a manner adverse to the other Constituent Companies its recommendation in favor of the approval and adoption of the Agreement and the transactions contemplated hereby
by its stockholders; (ii) the Board of Directors of any Constituent Company or any committee thereof fails to reject or shall have approved or recommended any Superior Offer; (iii) any Constituent Company shall have entered into any letter
of intent or similar document or any agreement, contract or commitment accepting any Superior Offer; or (iv) a tender or exchange offer relating to a Constituent Company’s securities shall have been commenced by a Person unaffiliated with
the other Constituent Companies. 
 (d) by any Constituent Company if any other Constituent Company shall have breached or failed to perform
in any material respect any of its representations, warranties, covenants or other agreements contained in this Agreement, which breach or failure to perform is not capable of cure, or remains uncured thirty (30) days after the allegedly
breaching Constituent Company’s receipt of written notice of any alleged breach, which notice shall specify in reasonable detail the circumstances claimed to provide the basis for such termination. 
 (e) by any Constituent Company if any event or events have occurred which individually or in the aggregate have had or would reasonably be expected to
have a Material Adverse Effect on either or both of the other Constituent Companies. 
 6.2. Reimbursement of Expenses. If this
Agreement is terminated by any Constituent Company pursuant to Section 6.1(c), the Constituent Company that has taken (or caused to be taken or by failing to act has caused such action to occur) any of the actions set forth in clauses
(i) through (iv) of Section 6.1(c) resulting in the termination of this Agreement shall be liable for and shall reimburse the other non-terminating Constituent Company’s for any and all expenses incurred through the effective
date of termination relating to the Reorganization, including, without limitation, attorneys’, accountants’ and investment bankers’ fees. 
 6.3. Amendment. Subject to compliance with applicable law, this Agreement may be amended by the parties hereto, by action taken by their respective Boards of Directors, at any time before or after the adoption
and approval of this Agreement and the transactions contemplated hereby by the Constituent Companies’ respective requisite stockholders; provided, however, that after any adoption and approval of this Agreement and the
transactions contemplated hereby by the stockholders of any Constituent Company, no amendment of this Agreement shall be made that by law or in accordance with the rules of any stock exchange requires further adoption and approval by the
stockholders of any Constituent Company without 

  

 -56- 

 
obtaining such adoption and approval. Subject to the foregoing, this Agreement may not be amended except by an instrument in writing signed on behalf of each
of the parties hereto. 
 6.4. Extension; Waiver. At any time prior to the Closing Date, the parties hereto may, to the extent legally
allowed, (a) extend the time for the performance of any of the obligations or other acts of the other parties hereto, (b) waive any inaccuracies in the representations and warranties contained herein or in any document delivered pursuant
hereto, and (c) waive compliance with any of the agreements or conditions contained herein; provided, however, that after the adoption and approval of this Agreement and the transactions contemplated hereby by the stockholders of
any Constituent Company, no extension or waiver of this Agreement or any portion thereof shall be made that by law requires further adoption and approval by the stockholders of any Constituent Company without obtaining such adoption and approval.
Any agreement on the part of a party hereto to any such extension or waiver shall be valid only if set forth in a written instrument signed on behalf of such party, but such extension or waiver or failure to insist on strict compliance with an
obligation, covenant, agreement, or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. 
 ARTICLE VII 
 MISCELLANEOUS 
 7.1. Survival. The representations and warranties of each of Andover, CDIP and MSMT contained in this Agreement shall survive the Closing and the consummation of the transactions contemplated hereby until the
date which is eighteen (18) months after the Closing Date except that representations and warranties respecting tax matters or claims shall survive for the period of the applicable statute of limitations in respect of such matters or claims.

 7.2. Expenses. Except as otherwise provided in Section 6.2, or as otherwise agreed to in writing by the parties, all legal and
other costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses. 
 7.3. Notices. All notices or other communications hereunder shall be in writing and shall be deemed given if delivered personally, sent by nationally recognized overnight courier (providing proof of delivery),
mailed by prepaid registered or certified mail (return receipt requested), or by facsimile transmission (providing confirmation of transmission) addressed as follows: 
  

	 	(a)	If to Andover, to: 

 Andover Medical, Inc.

 510 Turnpike Street, Suite 204, 
 N. Andover, Massachusetts 01845 
 Attn: Edwin A. Reilly, Chief Executive Officer 
 Email: ereilly@andovermedical.com

 with a copy to: 
 Elliot H. Lutzker 
  

 -57- 

 Phillips Nizer LLP 
 666 Fifth Avenue, Suite 2800 
 New York, NY 10103 
 Email: elutzker@phillipsnizer.com 
  

	 	(b)	If to CDIP, to: 

 Certified Diabetic
Services, Inc. 
 3030 Horseshoe Drive South, Suite 200 
 Naples, Florida 34104 
 Attn: Lowell M. Fisher, Jr., Chief Executive Officer 
 Email: lowellf@cdiabetic.com 
 with a copy to: 
 John N. Giordano, Esq. 
 Bush Ross, P.A. 
 1801 N. Highland Avenue 
 Tampa, Florida 33602 
 Email: jgiordano@bushross.com 
  

	 	(c)	If to MSMT, to: 

 Medical Solutions
Management, Inc. 
 237 Cedar Hill Street, 
 Marlboro, Massachusetts 01752 
 Attn: Lowell M. Fisher, Jr., Interim Chief Executive Officer 
 Email: lowellf@cdiabetic.com

 with a copy to: 
 Andrew B. White, Esq. 
 Bingham McCutchen LLP 
 150 Federal Street 
 Boston, MA 02110 
 Email: andrew.white@bingham.com 
 or such other address as shall be furnished in writing by any party, and any such notice or communication shall be deemed to have been given as of the date so delivered (if delivered personally) or on the date of
confirmation of receipt; provided that any notice received at the addressee’s location on any Business Day after 5:00 p.m. (addressee’s local time) shall be deemed to have been received at 9:00 a.m. (addressee’s local time) on
the next Business Day. 
 7.4. Interpretation. When a reference is made in this Agreement to sections, Exhibits, Andover Disclosure
Schedules, CDIP Disclosure Schedules or MSMT Disclosure Schedules, such reference shall be to a section of, or Exhibit or Schedule to this Agreement unless otherwise indicated. No provision of this Agreement shall be construed to require any
Constituent 

  

 -58- 

 
Company or any of their respective subsidiaries or Affiliates to take any action that would violate applicable law, rule, or regulation. 
 7.5. Rules of Construction. The parties hereto agree that they have been represented by counsel during the negotiation and execution of this
Agreement and, therefore, waive the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or document. 

7.6. Counterparts. This Agreement may be executed in counterparts, all of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all parties need not sign the same counterpart. 
 7.7. Entire Agreement. This Agreement, together with the Exhibits and Schedules hereto, and any documents delivered by the parties in connection
herewith constitutes the entire agreement and supersede all prior agreements and understandings, both written and oral, among the parties hereto, or any of them, with respect to the subject matter hereof. 
 7.8. Governing Law; Jurisdiction and Venue. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware
without regard to its rules of conflict of laws. Each Constituent Company hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of Delaware and of the United States of America located in
the State of Delaware (the “Delaware Courts”) for any litigation arising out of or relating to this Agreement and the transactions contemplated hereby (and agrees not to commence any litigation relating thereto except in such
courts), waives any objection to the laying of venue of any such litigation in the Delaware Courts, and agrees not to plead or claim in any Delaware Court that such litigation brought therein has been brought in any inconvenient forum. Each of the
parties hereto agrees, (a) to the extent such party is not otherwise subject to service of process in the State of Delaware, to appoint and maintain an agent in the State of Delaware as such party’s agent for acceptance of legal process,
and (b) that service of process may also be made on such party by prepaid certified mail with a proof of mailing receipt validated by United States Postal Service constituting evidence of valid service. Service made pursuant to (a) or
(b) above shall have the same legal force and effect as if served upon such party personally with the State of Delaware. 
 7.9.
Severability. In the event that any one or more provisions of this Agreement shall for any reason be held invalid, illegal, or unenforceable in any respect by any court of competent jurisdiction, such invalidity, illegality, or
unenforceability shall not affect any other provisions of this Agreement and the parties shall use their reasonable best efforts to substitute a valid, legal, and enforceable provision which, insofar as practicable, implements the original purposes
and intents of this Agreement. 
 7.10. Assignment; Reliance of Other Parties. Neither this Agreement nor any of the rights,
interests, or obligations hereunder shall be assigned by any of the parties hereto in whole or in part (whether by operation of law or otherwise) without the prior written consent of the other parties and any attempt to make any such assignment
without such consent shall be null 

  

 -59- 

 
and void. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by the parties and their
respective successors and assigns. This Agreement (including the documents and instruments referred to herein) is not intended to confer upon any Person other than the parties hereto any rights or remedies under or by reason of this Agreement.

 7.11. Specific Performance. The parties hereto agree that irreparable damage would occur in the event that the provisions contained
in this Agreement were not performed in accordance with its specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to seek an injunction or injunctions, without the posting of any bond, to prevent
breaches of this Agreement and to enforce specifically the terms and provisions thereof in the Delaware Courts, this being in addition to any other remedy to which they are entitled at law or in equity. 
 7.12. Definitions. Except as otherwise provided herein or as otherwise clearly required by the context, the following terms shall have the
respective meanings indicated when used in this Agreement: 
 (a) “14f-1 Information Statement” shall have the meaning set
forth in Section 4.4. 
 (b) “Action” shall have the meaning set forth in Section 2.1(i). 
 (c) “Acquisition Proposal” shall mean any offer or proposal relating to any transaction or series of related transactions involving:
(i) any purchase from such party or acquisition by any Person or “group” (as defined under Section 13(d) of the Exchange Act and the rules and regulations thereunder) of more than a twenty percent (20%) interest in the total
outstanding voting securities of any Constituent Company or any of its subsidiaries or any tender offer or exchange offer that if consummated would result in any Person or group beneficially owning twenty percent (20%) or more of the total
outstanding voting securities of any Constituent Company or any of its subsidiaries, (ii) any merger, consolidation, business combination or similar transaction involving any Constituent Company or any of its subsidiaries, (iii) any sale,
lease (other than in the ordinary course of business consistent with past practice), exchange, transfer, license (other than in the ordinary course of business consistent with past practice), acquisition or disposition of more than twenty percent
(20%) of the assets of any Constituent Company (including its subsidiaries taken as a whole) or (iv) any liquidation or dissolution of any Constituent Company (provided, however, that the transactions between the other Constituent
Companies and any such first Constituent Company contemplated by this Agreement shall not be deemed an Acquisition Proposal). 
 (d)
“Affiliate” shall mean any Person that, directly or indirectly through one (1) or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule
144 under the Securities Act. 
 (e) “Agreement” shall mean this Asset Purchase Agreement and Plan of Reorganization.

  

 -60- 

 (f) “Andover” shall have the meaning set forth in the preamble to this Agreement.

 (g) “Andover Assignment, Release and Assumption Agreement” shall have the meaning set forth in Section 1.11(d).

 (h) “Andover Assumed Liabilities” shall have the meaning set forth in Section 1.3(b). 
 (i) “Andover Bill of Sale” shall have the meaning set forth in Section 1.11(b). 
 (j) “Andover Closing Balance Sheet” shall have the meaning set forth in Section 5.2(e)(ii). 
 (k) “Andover Common Stock” shall have the meaning set forth in Section 1.4(b)(i). 
 (l) “Andover Disclosure Schedules” shall have the meaning set forth in Section 2.1. 
 (m) “Andover Evaluation Date” shall have the meaning set forth in Section 2.1(q). 
 (n) “Andover Excluded Assets” shall have the meaning set forth in Section 1.2(b). 
 (o) “Andover Governmental Permits” shall have the meaning set forth in Section 1.1(b)(viii). 
 (p) “Andover Intellectual Property Rights” shall have the meaning set forth in Section 2.1(n). 
 (q) “Andover Material Contract” shall have the meaning set forth in Section 2.1(y). 
 (r) “Andover Options” shall have the meaning set forth in Section 1.6(b). 
 (s) “Andover Pricing Ratio” shall mean 4.2800711 as may be adjusted pursuant to Section 1.10. 
 (t) “Andover Proxy Statement” shall have the meaning set forth in Section 4.2(a)(i). 
 (u) “Andover Purchased Assets” shall have the meaning set forth in Section 1.1(b). 
 (v) “Andover Required Approvals” shall have the meaning set forth in Section 2.1(e). 
  

 -61- 

 (w) “Andover SEC Reports” shall have the meaning set forth in Section 2.1(g).

 (x) “Andover Stockholders’ Meeting” shall have the meaning set forth in Section 4.2(a)(i). 
 (y) “Andover Subsidiary” and “Andover Subsidiaries” shall have the meaning set forth in Section 1.1(b)(i).

 (z) “Andover Warrants” shall have the meaning set forth in Section 1.5(b). 
 (aa) “Assumed Andover Options” shall have the meaning set forth in Section 1.6(b). 
 (bb) “Assumed Andover Warrants” shall have the meaning set forth in Section 1.5(b). 
 (cc) “Assumed CDIP Options” shall have the meaning set forth in Section 1.6(a). 
 (dd) “Assumed CDIP Warrants” shall have the meaning set forth in Section 1.5(a). 
 (ee) “Assumed Options” shall have the meaning set forth in Section 1.6(b). 
 (ff) “Assumed Warrants” shall have the meaning set forth in Section 1.5(b). 
 (gg) “Business Day” shall mean any day except Saturday, Sunday, or any day which shall be a federal legal holiday in the United States.

 (hh) “CDIP” shall have the meaning set forth in the preamble to this Agreement. 
 (ii) “CDIP Assignment, Release and Assumption Agreement” shall have the meaning set forth in Section 1.11(c). 
 (jj) “CDIP Assumed Liabilities” shall have the meaning set forth in Section 1.3(a). 
 (kk) “CDIP Balance Sheet” shall have the meaning set forth in Section 2.2(g). 
 (ll) “CDIP Bill of Sale” shall have the meaning set forth in Section 1.11(a). 
 (mm) “CDIP Closing Balance Sheet” shall have the meaning set forth in Section 5.2(e)(i). 
 (nn) “CDIP Common Stock” shall have the meaning set forth in Section 1.4(a)(i). 
  

 -62- 

 (oo) “CDIP Disclosure Schedules” shall have the meaning set forth in Section 2.2.

 (pp) “CDIP Excluded Assets” shall have the meaning set forth in Section 1.2(a). 
 (qq) “CDIP Governmental Permits” shall have the meaning set forth in Section 1.1(a)(viii). 
 (rr) “CDIP Interim Balance Sheet” shall have the meaning set forth in Section 2.2(g). 
 (ss) “CDIP Intellectual Property Rights” shall have the meaning set forth in Section 2.2(n). 
 (tt) “CDIP Material Contract” shall have the meaning set forth in Section 2.2(y). 
 (uu) “CDIP Options” shall have the meaning set forth in Section 1.6(a). 
 (vv) “CDIP Pricing Ratio” shall mean 1.98296239 as may be adjusted pursuant to Section 1.10. 
 (ww) “CDIP Proxy Statement” shall have the meaning set forth in Section 4.2(b)(i). 
 (xx) “CDIP Purchased Assets” shall have the meaning set forth in Section 1.1(a). 
 (yy) “CDIP Required Approvals” shall have the meaning set forth in Section 2.2(e). 
 (zz) “CDIP Stockholders’ Meeting” shall have the meaning set forth in Section 4.2(b)(i). 
 (aaa) “CDIP Subsidiary” and “CDIP Subsidiaries” shall have the meaning set forth in Section 1.1(a)(i). 

(bbb) “CDIP Warrants” shall have the meaning set forth in Section 1.5(a). 
 (ccc) “Change of Recommendation” shall have the meaning set forth in Section 4.3(d). 
 (ddd) “Change of Recommendation Notice” shall have the meaning set forth in Section 4.3(d)(C). 
 (eee) “Closing” shall have the meaning as set forth in Section 1.11. 
 (fff) “Closing Date” shall have the meaning as set forth in Section 1.11. 
  

 -63- 

 (ggg) “Code” shall mean the Internal Revenue Code of 1986, as amended. 
 (hhh) “Common Stock Equivalents” shall mean any securities of the Constituent Companies or the subsidiaries which would entitle
the holder thereof to acquire at any time MSMT Common Stock or TC Common Stock, as applicable, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or
exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, common stock. 
 (iii) “Constituent
Company” and “Constituent Companies” shall have the meaning set forth in the preamble to this Agreement. 
 (jjj)
“Delaware Courts” shall have the meaning set forth in Section 7.8. 
 (kkk) “Effective Date” shall
have the meaning set forth in the preamble to this Agreement. 
 (lll) “Escrow Agent” shall have the meaning set forth in
the Escrow Agreement attached hereto as Exhibit 1.7. 
 (mmm) “Escrow Agreement” shall have the meaning set forth in
Section 1.7. 
 (nnn) “Escrow Shares” shall have the meaning set forth in Section 1.7. 
 (ooo) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 (ppp) “Excluded Assets” shall mean the CDIP Excluded Assets and Andover Excluded Assets. 
 (qqq) “Form of Proxy” shall have the meaning set forth in Section 4.9. 
 (rrr) “GAAP” shall mean United States generally accepted accounting principles. 
 (sss) “Governmental Authority” shall mean any United States or foreign, federal, state, or local governmental commission, board, body,
bureau, or other regulatory authority, agency, including courts and other judicial bodies, or any self-regulatory body or authority, including any instrumentality or entity designed to act for or on behalf of the foregoing. 
 (ttt) “Indebtedness” shall mean Liabilities (i) for borrowed money, (ii) evidenced by bonds, debentures, notes or similar
instruments, (iii) upon which interest charges are customarily paid (other than obligations accepted in connection with the purchase of products or services in the ordinary course of business), (iv) of others secured by (or which the
holder of such Liabilities has an existing right, contingent or otherwise, to be secured by) any Encumbrance or security interest on property owned or acquired by the Person in question whether or not the obligations secured thereby have been
assumed, (v) under leases required to 

  

 -64- 

 
be accounted for as capital leases under GAAP, or (vi) guarantees relating to any such Liabilities. Notwithstanding the foregoing, for all purposes
hereunder, Indebtedness shall not include any payables between any Constituent Company and its subsidiaries. 
 (uuu) “Information
Statement” shall have the meaning set forth in Section 4.1(a). 
 (vvv) “Liabilities” shall mean all debts,
obligations and other liabilities of any kind or nature (whether known, unknown, accrued, or not accrued, absolute or contingent, liquidated or unliquidated, due or to become due, asserted or unasserted or otherwise). 
 (www) “Liens” shall mean a lien, security interest, encumbrance, mortgage, deed of trust, pledge, attachment, hypothecation or a
financing statement filing under the Uniform Commercial Code or similar statute (except for those of the foregoing which arise by operation of law and do not materially interfere with the ownership or operation of the assets to which they relate)
and with respect to capital stock, “Liens” shall mean, in addition to the foregoing, any charge, preemptive right or right of first refusal. 
 (xxx) “Material Adverse Effect” shall mean (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the
results of operations, assets, business, prospects or condition (financial or otherwise) of any Constituent Company and its subsidiaries, taken as a whole, or (iii) a material adverse effect on any Constituent Company’s ability to perform
in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii)). 
 (yyy)
“Material Permits” shall mean all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authority necessary to conduct business. 
 (zzz) “MSMT” shall have the meaning set forth in the preamble to this Agreement. 
 (aaaa) “MSMT Charter Amendment” shall have the meaning set forth in Section 4.1(a). 
 (bbbb) “MSMT Closing Balance Sheet” shall have the meaning set forth in Section 5.3(e)(ii). 
 (cccc) “MSMT Common Stock” shall have the meaning set forth in the Background Section of this Agreement. 
 (dddd) “MSMT Disclosure Schedules” shall have the meaning set forth in Section 2.3. 
 (eeee) “MSMT Evaluation Date” shall have the meaning set forth in Section 2.3(q). 
  

 -65- 

 (ffff) “MSMT Intellectual Property Rights” shall have the meaning set forth in
Section 2.3(n). 
 (gggg) “MSMT Material Contract” shall have the meaning set forth in Section 2.3(y). 

(hhhh) “MSMT Preferred Stock” shall have the meaning set forth in Section 1.4(b)(ii). 
 (iiii) “MSMT Required Approvals” shall have the meaning set forth in Section 2.3(e). 
 (jjjj) “MSMT SEC Reports” shall have the meaning set forth in Section 2.3(g). 
 (kkkk) “MSMT Securities” shall have the meaning set forth in Section 1.4(b)(ii). 
 (llll) “MSMT Stockholders’ Meeting” shall have the meaning set forth in Section 4.2(c)(i). 
 (mmmm) “MSMT Subsidiary” or “MSMT Subsidiaries” shall have the meaning set forth in Section 2.3(a). 
 (nnnn) “New Andover Financing” shall mean that certain financing transaction between Andover and Vicis Capital Master Fund
(“Vicis”) pursuant to which Vicis is investing the approximate amount of $1,000,000 in exchange for shares of a newly-created series of Andover preferred stock. 
 (oooo) “New MSMT Financing” shall mean that certain financing transaction between MSMT and Vicis pursuant to which Vicis is investing
the approximate amount of $7,900,000 in exchange for shares of a newly-created series of MSMT preferred stock. 
 (pppp)
“Person” shall mean an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or
other entity of any kind. 
 (qqqq) “Post-Closing Capitalization Table” shall have the meaning set forth in
Section 1.12. 
 (rrrr) “Pre-Closing Period” shall have the meaning set forth in Section 3.1. 
 (ssss) “Receiving Constituent Company” shall have the meaning set forth in Section 4.3(b). 
 (tttt) “Registration Statement” shall have the meaning set forth in Section 4.1(a). 
 (uuuu) “Reorganization” shall have the meaning set forth in the Background Section of this Agreement. 
  

 -66- 

 (vvvv) “SEC” shall mean the Securities and Exchange Commission. 
 (wwww) “Securities Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated hereunder.

 (xxxx) “Senior Trading Market” shall have the meaning set forth in Section 4.8. 
 (yyyy) “Series A Preferred Stock” shall have the meaning set forth in Section 1.4(b)(ii). 
 (zzzz) “Series B Preferred Stock” shall have the meaning set forth in Section 1.4(a)(ii). 
 (aaaaa) “Series C Preferred Stock” shall have the meaning set forth in Section 1.4(a)(ii). 
 (bbbbb) “Stockholders’ Meeting” shall have the meaning set forth in Section 4.2(c)(i). 
 (ccccc) “Superior Offer,” with respect to each Constituent Company, shall mean an unsolicited, bona fide Acquisition Proposal by a third
Person or group on terms that the Board of Directors of such Constituent Company has in good faith concluded, after consultation with its outside legal counsel and financial advisor, if any, taking into account, among other things, all legal,
financial, regulatory and other aspects of the offer and the Person or group making the offer, to be more favorable to such Constituent Company’s stockholders (in their capacities as stockholders) than the terms of this Agreement and is
reasonably capable of being consummated. 
 (ddddd) “Target Company” and “Target Companies” shall have the
meaning set forth in the preamble to this Agreement. 
 (eeeee) “Tax” shall mean any and all taxes, customs, duties,
tariffs, deficiencies, assessments, levies, or other like governmental charges, including, without limitation, income, gross receipts, excise, real or personal property, ad valorem, value added, estimated, alternative minimum, stamp, sales,
withholding, social security, occupation, use, service, service use, license, net worth, payroll, franchise, transfer and recording taxes and charges, imposed by the IRS or any other taxing authority (whether domestic or foreign including, without
limitation, any state, county, local, or foreign government or any subdivision or taxing agency thereof (including a United States possession)), whether computed on a separate, consolidated, unitary, combined, or any other basis; and such term shall
include any interest, fines, penalties, or additional amounts attributable to, or imposed upon, or with respect to, any such amounts. 
 (fffff) “Tax Return” shall mean any report, return, document, declaration, election, schedule or other information or filing required to be supplied to any taxing authority or jurisdiction (foreign or domestic) with respect
to Taxes, including, without limitation, information returns and any documents with respect to or accompanying payments of estimated Taxes or requests for the extension of time in which to file any such report, return, document, declaration, or
other information. 
  

 -67- 

 (ggggg) “TC Common Stock” shall have the meaning set forth in Section 1.4(b)(i).

 (hhhhh) “Trading Market” shall mean the following markets or exchanges on which the Common Stock is listed or quoted for
trading on the date in question: the Nasdaq Capital Market, the American Stock Exchange, the New York Stock Exchange, the Nasdaq National Market, the OTC Bulletin Board, or “Pink Sheets” published by Pink Sheets, LLC (or a similar
organization or agency succeeding to its functions of reporting prices). 
 (iiiii) “Transaction Documents” shall mean this
Agreement, the Escrow Agreement, the Form of Proxy and any other documents or agreements executed in connection with the transactions contemplated hereunder. 
 (jjjjj) “Unrelated Purchaser” shall have the meaning set forth in Section 4.14(c). 
 [SIGNATURE PAGE TO FOLLOW] 
  

 -68- 

 Dated: July 25, 2008 
  

							
	MEDICAL SOLUTIONS MANAGEMENT, INC.	  	CERTIFIED DIABETIC SERVICES, INC.
				
	By:	 	 /s/ Marshall Sterman
	  	By:	 	 /s/ Lowell M. Fisher, Jr.

		 	Marshall Sterman,	  		 	Lowell M. Fisher, Jr.,
		 	Chairman of the Board of Directors	  		 	Chief Executive Officer
			
		 		  	ANDOVER MEDICAL, INC.
				
		 		  	By:	 	 /s/ Edwin A. Reilly

		 		  		 	Edwin A. Reilly,
		 		  		 	Chief Executive Officer

 [ASSET PURCHASE AGREEMENT AND PLAN OF REORGANIZATION] 
  

 -69- 

 EXHIBIT LIST 
  

			
	Exhibit 1.7	 	Form of Escrow Agreement
		
	Exhibit 1.11(a)	 	Form of CDIP Bill of Sale
		
	Exhibit 1.11(b)	 	Form of Andover Bill of Sale
		
	Exhibit 1.11(c)	 	Form of CDIP Assignment, Release and Assumption Agreement
		
	Exhibit 1.11(d)	 	Form of Andover Assignment, Release and Assumption Agreement
		
	Exhibit 1.11(e)	 	Form of Assignment of Intellectual Property
		
	Exhibit 1.12	 	Post-Closing Capitalization Table
		
	Exhibit 4.1	 	Form of Amended and Restated Articles of Incorporation of Medical Solutions Management Inc.
		
	Exhibit 4.7	 	Form of Proxy

  

 -70- 

 EXHIBIT 1.7 
 FORM OF ESCROW AGREEMENT 
 This ESCROW
AGREEMENT dated             , 2008 (this “Escrow Agreement”), is by and among Certified Diabetic Services, Inc., a Delaware corporation with a mailing address
of 3030 Horseshoe Drive South, Suite 200, Naples, Florida 34104 (“CDIP”); Andover Medical, Inc., a Delaware corporation with a mailing address of 510 Turnpike Street, Suite 204, N. Andover, Massachusetts 01845
(“Andover,” collectively with CDIP, the “Target Companies” and sometimes each individually referred to as a “Target Company”); Medical Solutions Management Inc., a Nevada
corporation with a mailing address of 237 Cedar Hill Street, Marlboro, Massachusetts 01752 (“MSMT”); and Continental Stock Transfer & Trust Company, as escrow agent with a mailing address of 17 Battery Place,
8th Floor, New York, New 10004 (the “Escrow Agent”). MSMT and the Target Companies are each sometimes referred to
individually as a “Constituent Company” and collectively as the “Constituent Companies.” Capitalized terms not otherwise defined herein shall have the meaning set forth in the Plan of Reorganization
(as defined below). 
 BACKGROUND 
 The Constituent Companies have executed that certain Asset Purchase Agreement and Plan of Reorganization dated as of July [*], 2008 (the “Plan of Reorganization”) pursuant to which MSMT will
issue shares of its capital stock to each Target Company in exchange for substantially all of the assets of each Target Company. Pursuant to Section 1.7 of the Plan of Reorganization, MSMT has agreed to issue shares of MSMT Common Stock equal
to eight percent (8%) of the issued and outstanding shares of MSMT Common Stock (calculated immediately following the Closing of the Plan of Reorganization and after giving effect to the conversion or exercise of all outstanding shares of MSMT
Preferred Stock and all convertible debentures of MSMT which are convertible into shares of MSMT Common Stock, but excluding any shares of MSMT Common Stock issuable upon the exercise of warrants or options of MSMT) (collectively, the
“Escrow Shares”) to the Escrow Agent to be distributed to the preferred and common stockholders of record of each Target Company existing on the Closing Date based upon the respective performances of the Target Companies in
achieving revenue and earnings targets during the fiscal year ended December 31, 2008. 
 Contemporaneous with the execution of this
Escrow Agreement, the Escrow Shares, represented by share certificate [            ], along with a stock power in a form sufficient to cause a transfer/distribution of the Escrow
Shares if properly presented to MSMT’s stock transfer agent, have been delivered to and deposited with the Escrow Agent to be held and disbursed in accordance with the terms and conditions set forth in this Escrow Agreement. Each Target Company
has, in turn, delivered to the Escrow Agent a list of the preferred and common stockholders of record of each Target Company as of the close of business on the Closing Date (each, a “Shareholder List,” and collectively, the
“Shareholder Lists,” and the shareholders named on such Shareholder Lists being referred to herein as the “Shareholders”). 
 The Escrow Agent has agreed to serve as escrow agent and to hold the Escrow Shares in accordance with the terms and conditions hereinafter set forth. Now, therefore, in consideration 

  

 -71- 

 
of the foregoing and of the mutual covenants and agreements hereinafter set forth, the parties, intending to be bound legally, agree as follows: 

OPERATIVE PROVISIONS 
 1.
Establishment of Escrow. Simultaneously with the execution and delivery of this Escrow Agreement, MSMT shall deliver the Escrow Shares and each Target Company shall deliver its Shareholder List to the Escrow Agent, which Escrow Shares shall
be held and disbursed by the Escrow Agent as hereinafter set forth. All dividends and other distributions, if any (collectively, the “Earnings”) with respect to the Escrow Shares earned while the Escrow Shares are in escrow
pursuant to this Escrow Agreement shall also be held in escrow pursuant to the terms of this Escrow Agreement and distributed with the Escrow Shares as set forth herein. 
 2. Receipt. The Escrow Agent hereby acknowledges receipt of and accepts the Escrow Shares and the Shareholder Lists in escrow and agrees to hold and keep same in accordance with the terms and conditions hereof.

 3. Earnings, Ownership for Tax Purposes. All Earnings on the Escrow Shares shall be allocated and distributed upon distribution of
the Escrow Shares as provided for under Section 4 hereof. For purposes of U.S. federal and other taxes based on income, the party to whom the Escrow Shares are distributed will be treated as the owner of the Escrow Shares and will report all
Earnings, if any, that are earned on, or derived from, the Escrow Shares as its income, in the taxable year or years in which such income is distributed and properly includible and pay any taxes attributed thereto as may be required by law.

 4. Distribution of the Escrow Shares. The Escrow Shares shall be distributed as follows: 
 (kkkkk) Preparation of Pro-forma Income Statement. Within ten (10) Business Days after MSMT’s receipt from its independent public
accountants (the “Auditor”) of the audited financial statements of MSMT and its subsidiaries for the fiscal year ended December 31, 2008, the Chief Financial Officer or other senior finance officer of MSMT (herein, the
“CFO”) shall prepare and deliver to the representatives of the stockholders of CDIP and Andover designated on Schedule 4(a) (each, a “Representative” and collectively, the
“Representatives”), a pro-forma condensed income statement of MSMT for the fiscal year ended December 31, 2008, which shall be prepared in accordance with GAAP and reflect the consolidated operations of each of the MSMT
Subsidiaries, the CDIP Subsidiaries and the Andover Subsidiaries, as if the Reorganization had occurred effective as of January 1, 2008 (the “Pro-forma Income Statement”). The Pro-forma Income Statement shall be
presented in columnar form showing (i) the condensed income statements of each Constituent Company for the fiscal year ended December 31, 2008; (ii) any pro-forma adjustments; and (iii) the pro-forma results. The Pro-forma Income
Statement shall not include actual or allocated costs for the Constituent Companies relating to expenses directly attributable to the Reorganization. 
 (lllll) Review of Pro-forma Income Statement. The Representatives shall have ten (10) Business Days from the date on which the Pro-forma Income Statement is delivered to them by the CFO (the
“Review Period”) to review such statement. If any Representative 

  

 -72- 

 
disagrees with any item or amount shown or reflected in the Pro-forma Income Statement, the Representative may, on or prior to the last day of the Review
Period, deliver a notice to the CFO (and copies to the other Representatives) setting forth, in reasonable detail, each disputed item or amount and the basis for the Representative’s disagreement therewith, together with supporting calculations
(each, a “Dispute Notice”). If no Dispute Notice is received by the CFO on or prior to the last day of the Review Period, the Pro-forma Income Statement shall be deemed accepted by the Representatives. If, however, the CFO
and the Representatives shall not have resolved all of the issues set forth in the Dispute Notice(s), if any, within ten (10) Business Days after the conclusion of the Review Period, the parties will engage the Auditor to resolve any such
disputed matters in accordance with the terms of this Escrow Agreement. The Auditor shall act as an arbitrator to determine, based solely on presentations by the CFO and each Representative, and not by independent review, only those items still in
dispute (including any dispute regarding the exclusion of costs pursuant to the last sentence of Section 4(a) hereof), which items shall be submitted to the Auditor. The Auditor’s determination shall be made within ten (10) Business
Days after the submission of the items remaining in dispute under the Dispute Notice(s), and shall set forth in a report the Auditor’s determination with respect to each of the disputed items specified in the Dispute Notice(s), and the
revisions, if any, to be made to the Pro-forma Income Statement, together with supporting calculations. The conclusions of the Auditor shall be conclusive and binding on all parties in the absence of manifest error. The Pro-forma Income Statement
approved in accordance with this Section 4(b) shall be referred to as the “Approved Pro-forma Income Statement.” 
 (mmmmm) Allocation of Escrow Shares and Delivery of Final Distribution Instructions to Escrow Agent. Based upon the Approved Pro-forma Income Statement, the Escrow Shares will be distributed as follows: 
 (i) fifty percent (50%) of the Escrow Shares shall be allocated to the shareholders of the Target Companies based on each Target Company’s
respective subsidiaries’ contributions to the consolidated revenues as reflected in the Approved Pro-forma Income Statement; and 
 (ii) fifty percent (50%) of the Escrow Shares shall be allocated to the Target Companies based on each Target Company’s respective subsidiaries’ contributions to the consolidated EBITDA as reflected in and derived from the
Approved Pro-forma Income Statement; provided, however, in the event that only one Target Company’s respective subsidiaries’ contributions to EBITDA is greater than zero ($0.00), then the Shareholders of such Target Company shall be
allocated all Escrow Shares available for allocation pursuant to this Section 4©(ii); and in the event that none of the Target Companies’ respective subsidiaries’ contributions to EBITDA is greater than zero ($0.00), then the
Escrow Shares available for distribution shall be allocated in accordance with Section 4©(i) hereof. For purposes of this Escrow Agreement, the term “EBITDA” shall mean and be calculated as follows: net income, plus
(A) depreciation, amortization, and all other non-cash charges that were deducted in arriving at net income for such period; (B) provisions for taxes based on income that were deducted in arriving at net income for such period,
(C) interest expense; (D) all public company costs such as audit fees, SEC filing fees (including attorney and auditor reviews and printing expenses), directors and officers’ insurance and investor relations expenses; and
(E) actual or allocated costs for the Constituent Companies relating to expenses directly attributable to the Reorganization. 
  

 -73- 

 Schedule 4© contains an example of the distributions contemplated by this Section 4.

 The Representatives and the CFO shall jointly execute and deliver final distribution instructions (the “Final Distribution
Instructions”) to the Escrow Agent within five (5) Business Days after the finalization of the Approved Pro-forma Income Statement. The Final Distribution Instructions will include (i) instructions signed by the two
Representatives and the CFO stating the number of Escrow Shares to be allocated to the Shareholders of each of the two Target Companies, and (ii) with respect to each Target Company whose Shareholders are to be allocated Escrow Shares,
instructions signed by such Target Company’s Representative, stating the number of Escrow Shares to be distributed to each Shareholder appearing on such Target Company’s Shareholder List and instructing the Escrow Agent to return to MSMT
for retirement the balance of the Escrow Shares remaining after such distribution. No fraction of an Escrow Share will be distributed to the Shareholders of the Target Companies. In lieu thereof, the Representatives of the Target Companies shall
round down any fractional shares otherwise distributable to such Shareholders to the nearest whole number of Escrow Shares and instruct the Escrow Agent to return to MSMT for retirement any Escrow Shares remaining after distribution to its
respective Shareholder List. 
 (nnnnn) Distribution of Escrow Shares. Upon receipt by the Escrow Agent of Final Distribution
Instructions, the Escrow Agent shall distribute the Escrow Shares in accordance with the Final Distribution Instructions to the Shareholders of the Target Companies as set forth in the Final Distribution Instructions. 
 5. Rights and Limitations Upon Duty of Escrow Agent: The Escrow Agent: 
 a. shall not be responsible in any manner for the validity, correctness or sufficiency of any document or instrument received by or made available to it,
in its capacity as Escrow Agent hereunder; nor for the status or failure of any investment into which subscription deposits have been placed with the approval of the remaining parties. 
 b. shall be entitled to act upon any written certificate, statement, notice, demand, request, consent, agreement or other instrument whatever, not only
in reliance upon its due execution and the validity and effectiveness of its provisions, but also as to the accuracy and completeness of any information therein contained, which the Escrow Agent shall in good faith believe to be genuine and to have
been signed or presented by any authorized person. 
 c. shall be entitled to request and receive from any party hereto such documents in
addition to those provided for herein as the Escrow Agent may deem necessary to resolve any questions of fact involved in the administration of its duties hereunder. 
 d. may, at the expense of the remaining parties, consult independent counsel of its choice in respect to any question relating to its duties or responsibilities under this Escrow Agreement, and shall not be liable for
any action taken or omitted in good faith on advice of such counsel. 
 e. shall be under no obligation to advance any monetary sum in
connection with the maintenance or administration of this Escrow Agreement, to institute or defend any 

  

 -74- 

 
action, suit or legal proceeding in connection herewith, or to take any other action likely to involve the Escrow Agent in expense, unless first indemnified
by the remaining parties to the Escrow Agent’s satisfaction. 
 f. shall not be bound by any amendment to this Escrow Agreement or by
any other such amendment or agreement unless the same shall have been executed by the Escrow Agent. 
 g. shall have only such duties and
responsibilities as are expressly set forth in this Escrow Agreement, together with a general fiduciary duty of reasonable diligence in the performance of its obligations hereunder. 
 h. may resign and be discharged from its duties hereunder at any time by furnishing notice of such intended resignation to the remaining parties,
specifying a date when such resignation shall take effect (which date shall be no fewer than fifteen (15) days after the date of mailing or other delivery of such notice) and furnishing to the remaining parties, on or prior to such date, a
final accounting of all financial activity within the escrow account from the date of the Escrow Agent’s appointment until the date of such resignation (the “Accounting”). Upon receipt of such notice, the remaining
parties shall appoint a successor escrow agent, such successor to become Escrow Agent hereunder upon the resignation date specified in the subject notice or, if later, upon the Escrow Agent’s presentation of the Accounting. If the remaining
parties are unable to agree upon the identity of a successor escrow agent within fifteen (15) days after the date of such notice, the Escrow Agent shall be entitled to appoint its own successor and shall continue to act in its fiduciary
capacity until its successor accepts the escrow by notice to the parties hereto and takes possession of the Escrow Shares. If the Escrow Agent is unable, despite the use of its best efforts, to obtain the services of a successor, it may petition a
court of competent jurisdiction for an appointment effecting such an appointment or providing another remedy, and, pending entry, may deposit the Escrow Shares then within its possession in the registry of the court, together with the Accounting
(prepared, in such event, through the end of the business day immediately preceding such a deposit). The remaining parties may at any time agree to substitute a new escrow agent by giving notice thereof to the Escrow Agent then acting. 

i. shall be indemnified and held harmless by MSMT against any and all liabilities incurred by it hereunder (including all costs, expenses and fees
incurred in defending any legal action or administrative proceeding or in resisting any claim), except for those resulting from its own willful misconduct or gross negligence. 
 j. may, if it becomes uncertain concerning its rights and responsibilities with respect to the escrow or receives instructions with respect to the Escrow
Shares that it believes to be in conflict with this Escrow Agreement or is advised that a dispute has arisen with respect to the Escrow Shares, without liability refrain from taking any action other than to use its best efforts to safeguard the
Escrow Shares until it is directed otherwise in a writing signed by the remaining parties or by an order of a court of competent jurisdiction. The Escrow Agent is not obligated to institute or defend any legal proceedings, although it may, in its
sole discretion and at the remaining parties’ expense, institute or defend such proceedings (including proceedings 

  

 -75- 

 
seeking a declaratory judgment), join interested parties and deposit the Escrow Shares in the registry of the court. 
 6. Voting of Escrow Shares. Until the termination of this Escrow Agreement, each Shareholder named on a Shareholder List of any Target Company
shall have the right to vote that number of Escrow Shares set forth by such Shareholder’s name on the Shareholders Lists as the record holder of such Escrow Shares. Voting of the Escrow Shares shall be allocated (a) among the Shareholders
of the two Target Companies as though all of the Escrow Shares were distributed upon the Closing Date with CDIP shareholders receiving 56.25% of the Escrow Shares and Andover shareholders receiving 43.75% of the Escrow Shares, and (b) among the
Shareholders of any one Target Company in accordance with the pro rata shareholdings of such Target Company’s common stock (voting on an as-converted basis and after giving effect to the conversion or exercise of all outstanding shares of
preferred stock reflected on the Shareholder Lists). 
 7. Termination. This Escrow Agreement shall terminate upon the completion of
the distribution of the Escrow Shares and the Earnings, if any, in accordance with Section 4 of this Escrow Agreement, or upon mutual written agreement of the parties hereto. 
 8. Miscellaneous. 
 a.
Notices. All notices or other communications hereunder shall be in writing and shall be deemed given if delivered in accordance with Section 7.3 of the Plan of Reorganization. Any notice to the Escrow Agent shall be addressed as follows:
                                        .

 b. Rules of Construction. The parties hereto agree that they have been represented by counsel during the negotiation and execution
of this Escrow Agreement and, therefore, waive the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or
document. 
 c. Counterparts. This Escrow Agreement may be executed in counterparts, all of which shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all parties need not sign the same counterpart. 
 d. Entire Agreement. This Escrow Agreement, together with the Plan of Reorganization, and any documents delivered by the parties in connection
herewith constitutes the entire agreement and supersede all prior agreements and understandings, both written and oral, among the parties hereto, or any of them, with respect to the subject matter hereof. 
 e. Governing Law; Jurisdiction and Venue. This Escrow Agreement shall be governed by and construed in accordance with the laws of the State of
Delaware without regard to its rules of conflict of laws. Each Constituent Company hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of 

  

 -76- 

 
Delaware and of the United States of America located in the State of Delaware (the “Delaware Courts”) for any litigation arising out
of or relating to this Escrow Agreement and the transactions contemplated hereby (and agrees not to commence any litigation relating thereto except in such courts), waives any objection to the laying of venue of any such litigation in the Delaware
Courts, and agrees not to plead or claim in any Delaware Court that such litigation brought therein has been brought in any inconvenient forum. Each of the parties hereto agrees, (a) to the extent such party is not otherwise subject to service
of process in the State of Delaware, to appoint and maintain an agent in the State of Delaware as such party’s agent for acceptance of legal process, and (b) that service of process may also be made on such party by prepaid certified mail
with a proof of mailing receipt validated by United States Postal Service constituting evidence of valid service. Service made pursuant to (a) or (b) above shall have the same legal force and effect as if served upon such party personally
with the State of Delaware. 
 [Signatures on following page] 
  

 -77- 

							
	ANDOVER MEDICAL, INC.	  	CONTINENTAL STOCK TRANSFER & TRUST COMPANY
				
	By:	 	  
	  	By:	 	  

		 	Edwin A. Reilly, Chief Executive Officer	  		 	  

			
	CERTIFIED DIABETIC SERVICES, INC.	  		 	
				
	By:	 	  
	  		 	
		 	Lowell M. Fisher, Jr., Chief Executive Officer	  		 	
			
	MEDICAL SOLUTIONS MANAGEMENT INC.	  		 	
				
	By:	 	  
	  		 	
		 	Marshall Sterman,	  		 	
		 	Chairman of the Board of Directors	  		 	

 [SIGNATURE PAGE TO ESCROW AGREEMENT] 
  

 -78- 

 Schedule 4(a) 
 Representatives 
  

			
	Andover Medical, Inc.	 	Edwin A. Reilly
		
	Certified Diabetic Services, Inc.	 	Lowell M. Fisher, Jr.

  

 -79- 

 Schedule 4(c) 
 Agreement on Distribution of Escrow Shares 
  

	1.	Fifty percent (50%) of the Escrow Shares shall be allocated to the shareholders of the Target Companies based on each Target Company’s respective subsidiaries’
contributions to the consolidated revenues as reflected in the Approved Pro-forma Income Statement; and 

  

	2.	Fifty percent (50%) of the Escrow Shares shall be allocated to the Target Companies based on each Target Company’s respective subsidiaries’ contributions to the
consolidated EBITDA as reflected in and derived from the Approved Pro-forma Income Statement. 

  

	3.	Example: 

  

											
	 	  	Revenues	 	 	% of Revenues	 	 	 	 
	 CDIP
	  	$	14.0	 	 	45.6	%	 		
	 MSMT
	  	$	6.7	 	 	21.8	%	 		
	 Andover
	  	$	10.0	 	 	32.6	%	 		
		  	 	 	 	 	 	 	 		
	 TOTAL
	  	$	30.7	 	 	100	%	 		
				
	 	  	EBITDA	 	 	% of EBITDA	 	 	 	 
	 CDIP
	  	$	1.4	 	 	64	%	 		
	 MSMT
	  	$	0.0	 	 	0.0	%	 		
	 Andover
	  	$	0.80	 	 	36	%	 		
		  	 	 	 	 	 	 	 		
	 TOTAL
	  	$	2.2	 	 	100	%	 		
	
	DISTRIBUTION OF ESCROW SHARES BASED ON ACTUAL PERFORMANCE	 
				
	 	  	Revenues	 	 	% of Revenues	 	 	Escrow Shares
Allocable to Revenue	 
	 CDIP
	  	$	14.0	 	 	58.3	%	 	2.33	%
	 Andover
	  	$	10.0	 	 	41.7	%	 	1.67	%
		  	 	 	 	 	 	 	 	 	 
	 TOTAL
	  	$	24.0	 	 	100	%	 	4.00	%
				
	 	  	EBITDA	 	 	% of EBITDA	 	 	Escrow Shares
Allocable to EBITDA	 
	 CDIP
	  	$	1.40	 	 	64	%	 	2.55	%
	 Andover
	  	$	0.80	 	 	36	%	 	1.45	%
		  	 	 	 	 	 	 	 	 	 
	 TOTAL
	  	$	2.2	 	 	100	%	 	4.00	%
	
	TOTAL DISTRIBUTIONS	 
				
	 	  	Revenues	 	 	EBITDA	 	 	TOTAL	 
	 CDIP
	  	 	2.33	%	 	2.56	%	 	4.89	%
	 MSMT
	  	 	0.00	%	 	0.00	%	 	0.00	%
	 Andover
	  	 	1.67	%	 	1.44	%	 	3.11	%
		  	 	 	 	 	 	 	 	 	 
	 TOTAL
	  	 	4.00	%	 	4.00	%	 	8.00	%

  

 -80- 

 EXHIBIT 1.11(a) 
 FORM OF BILL OF SALE 
 This Bill of Sale (“Bill of Sale”) is entered
into as of             , 2008, between Certified Diabetic Services, Inc., a Delaware corporation (the “Conveyor”) whose address is 3030 Horseshoe Drive South,
Suite 200, Naples, Florida 34104 and Medical Solutions Management Inc., a Nevada corporation (the “Conveyee”), whose address is 237 Cedar Hill Street, Marlboro, Massachusetts 01752, pursuant to the terms of that certain Asset
Purchase Agreement and Plan of Reorganization dated July [*], 2008 among Conveyor, Conveyee and Andover Medical, Inc., a Delaware corporation whose address is 510 Turnpike Street, Suite 204, North Andover, Massachusetts 01845 (the “Plan
of Reorganization”). 
 NOW, THEREFORE, for good and valuable consideration, the receipt, adequacy, and legal sufficiency
of which are hereby acknowledged, and as contemplated by Article I of the Plan of Reorganization, Conveyor and Conveyee agree as follows: 
 1. Conveyance and Transfer of CDIP Purchased Assets. Conveyor hereby sells, transfers, assigns, conveys, grants and delivers to Conveyee and its successors and assigns forever, effective as of the date first set forth above,
all of Conveyor’s right, title and interest in and to all of the CDIP Purchased Assets, including, without limitation those set forth in Exhibit A attached hereto, free and clear of all Liens. 
 2. Excluded Assets. Notwithstanding the foregoing, the CDIP Purchased Assets shall not include, and Conveyor is not selling to Conveyee,
and Conveyee is not purchasing or acquiring from Conveyor, the CDIP Excluded Assets, as set forth in Exhibit B attached hereto. 
 3. Further Actions. Conveyor hereby covenants that it is the lawful owner of the CDIP Purchased Assets described herein, that it has good right and lawful authority to sell same and that the CDIP Purchased Assets are
free from all Liens. Conveyor covenants and agrees to warrant and defend the sale, transfer, assignment, conveyance, grant and delivery of title to the CDIP Purchased Assets hereby made against all persons whomsoever, to take all steps reasonably
necessary to establish the record of Conveyee’s title to the CDIP Purchased Assets and, at the request of Conveyee, to execute and deliver further instruments of transfer and assignment and take such other action as Conveyee may reasonably
request to more effectively transfer and assign to and vest in Conveyee each item of the CDIP Purchased Assets. 
 THE CDIP PURCHASED ASSETS
ARE BEING SOLD ON AN “AS IS, WHERE IS” CONDITION. ACCORDINGLY, EXCEPT AS MAY BE SPECIFICALLY SET FORTH HEREIN OR AS WARRANTED IN THE PLAN OF REORGANIZATION, CONVEYOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR
IMPLIED, AS TO ANY MATTER, INCLUDING, WITHOUT LIMITATION, THE CONDITION OF THE CDIP PURCHASED ASSETS, THEIR MERCHANTABILITY OR THEIR FITNESS FOR ANY PARTICULAR PURPOSE. CONVEYOR SHALL IN NO EVENT BE LIABLE TO CONVEYEE FOR ANY INDIRECT, SPECIAL,
CONSEQUENTIAL, OR PUNITIVE DAMAGES CAUSED, DIRECTLY OR INDIRECTLY, BY THE CDIP PURCHASED ASSETS OR ANY INADEQUACY THEREOF FOR ANY PURPOSE, OR ANY DEFICIENCY OR DEFECT THEREIN, OR THE USE OR MAINTENANCE THEREOF, OR ANY REPAIRS, SERVICING OR
ADJUSTMENTS THERETO. 
  

 -81- 

 4. Power of Attorney. Without limiting Section 2 hereof, Conveyor hereby constitutes
and appoints Conveyee the true and lawful agent and attorney in fact of Conveyor, with full power of substitution and resubstitution, in whole or in part, in the name and stead of Conveyor but on behalf and for the benefit of Conveyee and its
successors and assigns, from time to time: 
  

	 	(a)	to demand, receive and collect any and all of the CDIP Purchased Assets and to give receipts and releases for and with respect to the same, or any part thereof;

  

	 	(b)	to institute and prosecute, in the name of Conveyor or otherwise, any and all proceedings at law, in equity or otherwise, that Conveyee or its successors and assigns may deem proper
in order to collect or reduce to possession any of the CDIP Purchased Assets and in order to collect or enforce any claim or right of any kind hereby assigned or transferred, or intended so to be; and 

  

	 	(c)	to do all things legally permissible, required or reasonably deemed by Conveyee to be required to recover and collect the CDIP Purchased Assets and to use Conveyor’s name in
such manner as Conveyee may reasonably deem necessary for the collection and recovery of same. 

 Conveyor hereby declares that the foregoing
powers are coupled with an interest and are and shall be irrevocable by Conveyor. 
 5. Capitalized Terms. Capitalized terms
used but not defined herein shall have the meanings for such terms that are set forth in the Plan of Reorganization. 
 6. Successors
and Assigns. This Bill of Sale will be binding upon Conveyor’s successors and will inure to the benefit of Conveyee’s successors and assigns. 
 7. Terms of the Plan of Reorganization. The terms of the Plan of Reorganization, including but not limited to Conveyor’s representations, warranties, covenants and agreements relating to the CDIP
Purchased Assets, are incorporated herein by this reference. Conveyor acknowledges and agrees that the representations, warranties, covenants and agreements contained in the Plan of Reorganization shall not be superseded hereby but shall remain in
full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Plan of Reorganization and the terms hereof, the terms of the Plan of Reorganization shall govern. 
 8. Binding Effect; Governing Law. This Bill of Sale shall be binding on and inure to the benefit of and be enforceable by Conveyor and
Conveyee and their respective successors and assigns. This Bill of Sale shall be governed, construed, and enforced in accordance with the laws of the State of Delaware without regard to the choice of law principles thereof. 
 9. Counterparts. This Bill of Sale may be executed in counterparts, each of which shall be deemed an original and all of which, when taken
together, shall constitute one and the same instrument. 
 [Signature Page Follows] 
  

 -82- 

 IN WITNESS WHEREOF, the parties hereto have executed this Bill of Sale as of the date first written
above. 
  

			
	“CONVEYOR”
	
	CERTIFIED DIABETIC SERVICES, INC.
		
	By:	 	  

		 	Lowell M. Fisher, Jr.,
		 	Chief Executive Officer
	
	“CONVEYEE”
	
	MEDICAL SOLUTIONS MANAGEMENT INC.
		
	By:	 	  

		 	Marshall Sterman,
		 	Chairman of the Board of Directors

 [Signature Page to the Bill of Sale] 
  

 -83- 

 Exhibit A 
 CDIP Purchased Assets 
 The CDIP Purchased Assets shall include all of the assets of CDIP including, without
limitation: 
 (i) those shares of capital stock or other equity interests of each CDIP Subsidiary set forth on Schedule 1.1(a)(i) of
the Plan of Reorganization; 
 (ii) title to all of the property used or held for use in CDIP’s business, including without limitation,
all furniture, fixtures, computers, office equipment and miscellaneous assets of every kind and nature owned by CDIP or used in or necessary for the operation of its business; 
 (iii) all right, title and interest of CDIP in and to all contracts (expressly including unfilled contracts for services), agreements, leases,
commitments, arrangements or understandings pertaining to the operation of CDIP’s business; 
 (iv) all right, title and interest in
and to all of the following: patents and patent rights, trademarks and trademark rights (whether registered or not), including any goodwill therein, trade names and trade name rights, domain names, service marks and service mark rights, service
names and service name rights, brand names, inventions, processes, formulae, copyrights and copyright rights (whether registered or not), trade dress, business and product names, logos, slogans, trade secrets, industrial models, processes, designs,
methodologies, computer programs, software (whether in source or object code) and related documentation, technical information, manufacturing, engineering and technical drawings, know-how and all pending applications for and registrations of
patents, trademarks, service marks and copyrights; the foregoing shall include, without limitation, all software under development owned by CDIP and listed on Schedule 1.1(a)(iv) of the Plan of Reorganization (including the software
development schedule included therein) and all licenses, agreements and other arrangements under which CDIP has the right to use any of the intangible or proprietary rights of a third party to the extent used or held for use by CDIP in the conduct
of the business; 
 (v) all lists of present customers and lists of former customers and other customer-related records of CDIP’s
business; 
 (vi) all goodwill associated with CDIP’s business or the CDIP Purchased Assets; 
 (vii) all books, files and records of CDIP (including, without limitation, all surveys, schematics, flow charts, permit filings, mailing lists, customer
lists, equipment maintenance records, warranty information, records of operations, payroll history, standard forms of documents, manuals of operation or business procedures, training manuals and training aids and other proprietary or confidential
information to the extent the same may be necessary or desirable for the operation of CDIP’s business) relating to CDIP’s business (other than minutes of corporate meetings, capital stock ledger and purely corporate records); provided that
any of the foregoing which CDIP reasonably deems necessary to CDIP’s continued operation, proper accounting and record keeping functions following the Closing shall not constitute part of the CDIP Purchased Assets and shall be retained by CDIP;

 (viii) the CDIP Governmental Permits (and to the extent any such permits are not assignable or transferable to MSMT, CDIP will use its
best efforts to cooperate with MSMT as may 

  

 -84- 

 
be reasonably requested to enable MSMT to apply for and obtain the CDIP Governmental Permits or to receive the benefits of the CDIP Governmental Permits);
and 
 (ix) except as specifically provided in Section 1.2(a) of the Plan of Reorganization, all other assets of CDIP that exist on the
Closing Date, whether tangible or intangible, real or personal. 
  

 -85- 

 Exhibit B 
 CDIP Excluded Assets 
 None. 
  

 -86- 

 EXHIBIT 1.11(b) 
 FORM OF BILL OF SALE 
 This Bill of Sale (“Bill of Sale”) is entered
into as of             , 2008, between Andover Medical, Inc., a Delaware corporation (the “Conveyor”) whose address is 510 Turnpike Street, Suite 204, North
Andover, Massachusetts 01845 and Medical Solutions Management Inc., a Nevada corporation (the “Conveyee”), whose address is 237 Cedar Hill Street, Marlboro, Massachusetts 01752, pursuant to the terms of that certain Asset
Purchase Agreement and Plan of Reorganization dated July [*], 2008 among Conveyor, Conveyee and Certified Diabetic Services, Inc. whose address is 3030 Horseshoe Drive South, Suite 200, Naples, Florida 34104 (the “Plan of
Reorganization”). 
 NOW, THEREFORE, for good and valuable consideration, the receipt, adequacy, and legal sufficiency of
which are hereby acknowledged, and as contemplated by Article I of the Plan of Reorganization, Conveyor and Conveyee agree as follows: 
 1. Conveyance and Transfer of Andover Purchased Assets. Conveyor hereby sells, transfers, assigns, conveys, grants and delivers to Conveyee and its successors and assigns forever, effective as of the date first set forth
above, all of Conveyor’s right, title and interest in and to all of the Andover Purchased Assets, including, without limitation those set forth in Exhibit A attached hereto, free and clear of all Liens. 
 2. Excluded Assets. Notwithstanding the foregoing, the Andover Purchased Assets shall not include, and Conveyor is not selling to Conveyee,
and Conveyee is not purchasing or acquiring from Conveyor, the Andover Excluded Assets, as set forth in Exhibit B attached hereto. 
 3. Further Actions. Conveyor hereby covenants that it is the lawful owner of the Andover Purchased Assets described herein, that it has good right and lawful authority to sell same and that the Andover Purchased Assets
are free from all Liens. Conveyor covenants and agrees to warrant and defend the sale, transfer, assignment, conveyance, grant and delivery of title to the Andover Purchased Assets hereby made against all persons whomsoever, to take all steps
reasonably necessary to establish the record of Conveyee’s title to the Andover Purchased Assets and, at the request of Conveyee, to execute and deliver further instruments of transfer and assignment and take such other action as Conveyee may
reasonably request to more effectively transfer and assign to and vest in Conveyee each item of the Andover Purchased Assets. 
 THE ANDOVER
PURCHASED ASSETS ARE BEING SOLD ON AN “AS IS, WHERE IS” CONDITION. ACCORDINGLY, EXCEPT AS MAY BE SPECIFICALLY SET FORTH HEREIN OR AS WARRANTED IN THE PLAN OF REORGANIZATION, CONVEYOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND OR
NATURE, EXPRESS OR IMPLIED, AS TO ANY MATTER, INCLUDING, WITHOUT LIMITATION, THE CONDITION OF THE ANDOVER PURCHASED ASSETS, THEIR MERCHANTABILITY OR THEIR FITNESS FOR ANY PARTICULAR PURPOSE. CONVEYOR SHALL IN NO EVENT BE LIABLE TO CONVEYEE FOR ANY
INDIRECT, SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES CAUSED, DIRECTLY OR INDIRECTLY, BY THE ANDOVER PURCHASED ASSETS OR ANY INADEQUACY THEREOF FOR ANY PURPOSE, OR ANY DEFICIENCY OR DEFECT THEREIN, OR THE USE OR MAINTENANCE THEREOF, OR ANY REPAIRS,
SERVICING OR ADJUSTMENTS THERETO. 
  

 -87- 

 4. Power of Attorney. Without limiting Section 2 hereof, Conveyor hereby constitutes
and appoints Conveyee the true and lawful agent and attorney in fact of Conveyor, with full power of substitution and resubstitution, in whole or in part, in the name and stead of Conveyor but on behalf and for the benefit of Conveyee and its
successors and assigns, from time to time: 
  

	 	(a)	to demand, receive and collect any and all of the Andover Purchased Assets and to give receipts and releases for and with respect to the same, or any part thereof;

  

	 	(b)	to institute and prosecute, in the name of Conveyor or otherwise, any and all proceedings at law, in equity or otherwise, that Conveyee or its successors and assigns may deem proper
in order to collect or reduce to possession any of the Andover Purchased Assets and in order to collect or enforce any claim or right of any kind hereby assigned or transferred, or intended so to be; and 

  

	 	(c)	to do all things legally permissible, required or reasonably deemed by Conveyee to be required to recover and collect the Andover Purchased Assets and to use Conveyor’s name in
such manner as Conveyee may reasonably deem necessary for the collection and recovery of same. 

 Conveyor hereby declares that the foregoing
powers are coupled with an interest and are and shall be irrevocable by Conveyor. 
 5. Capitalized Terms. Capitalized terms
used but not defined herein shall have the meanings for such terms that are set forth in the Plan of Reorganization. 
 6. Successors
and Assigns. This Bill of Sale will be binding upon Conveyor’s successors and will inure to the benefit of Conveyee’s successors and assigns. 
 7. Terms of the Plan of Reorganization. The terms of the Plan of Reorganization, including but not limited to Conveyor’s representations, warranties, covenants and agreements relating to the Andover
Purchased Assets, are incorporated herein by this reference. Conveyor acknowledges and agrees that the representations, warranties, covenants and agreements contained in the Plan of Reorganization shall not be superseded hereby but shall remain in
full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Plan of Reorganization and the terms hereof, the terms of the Plan of Reorganization shall govern. 
 8. Binding Effect; Governing Law. This Bill of Sale shall be binding on and inure to the benefit of and be enforceable by Conveyor and
Conveyee and their respective successors and assigns. This Bill of Sale shall be governed, construed, and enforced in accordance with the laws of the State of Delaware without regard to the choice of law principles thereof. 
 9. Counterparts. This Bill of Sale may be executed in counterparts, each of which shall be deemed an original and all of which, when taken
together, shall constitute one and the same instrument. 
 [Signature Page Follows] 
  

 -88- 

 IN WITNESS WHEREOF, the parties hereto have executed this Bill of Sale as of the date first written
above. 
  

			
	“CONVEYOR”
	
	ANDOVER MEDICAL, INC.
		
	By:	 	  

		 	Edwin A. Reilly,
		 	Chief Executive Officer
	
	“CONVEYEE”
	
	MEDICAL SOLUTIONS MANAGEMENT INC.
		
	By:	 	  

		 	Marshall Sterman,
		 	Chairman of the Board of Directors

 [Signature Page to the Bill of Sale] 
  

 -89- 

 Exhibit A 
 Andover Purchased Assets 
 The Andover Purchased Assets shall include all of the assets of Andover including, without
limitation: 
 (x) those shares of capital stock of each Andover Subsidiary; 
 (xi) title to all of the property used or held for use in Andover’s business, including without limitation, all furniture, fixtures, computers,
office equipment and miscellaneous assets of every kind and nature owned by Andover or used in or necessary for the operation of its business; 
 (xii) all right, title and interest of Andover in and to all contracts (expressly including unfilled contracts for services), agreements, leases, commitments, arrangements or understandings pertaining to the operation of Andover’s
business; 
 (xiii) all right, title and interest in and to all of the following: patents and patent rights, trademarks and trademark rights
(whether registered or not), including any goodwill therein, trade names and trade name rights, domain names, service marks and service mark rights, service names and service name rights, brand names, inventions, processes, formulae, copyrights and
copyright rights (whether registered or not), trade dress, business and product names, logos, slogans, trade secrets, industrial models, processes, designs, methodologies, computer programs, software (whether in source or object code) and related
documentation, technical information, manufacturing, engineering and technical drawings, know-how and all pending applications for and registrations of patents, trademarks, service marks and copyrights; the foregoing shall include, without
limitation, all software under development owned by Andover and listed on Schedule 1.1(b)(iv) of the Plan of Reorganization and all licenses, agreements and other arrangements under which Andover has the right to use any of the intangible or
proprietary rights of a third party to the extent used or held for use by Andover in the conduct of the business; 
 (xiv) all lists of
present customers and lists of former customers and other customer-related records of Andover’s business; 
 (xv) all goodwill
associated with Andover’s business or the Andover Purchased Assets; 
 (xvi) all books, files and records of Andover (including,
without limitation, all surveys, schematics, flow charts, permit filings, mailing lists, customer lists, equipment maintenance records, warranty information, records of operations, payroll history, standard forms of documents, manuals of operation
or business procedures, training manuals and training aids and other proprietary or confidential information to the extent the same may be necessary or desirable for the operation of Andover’s business) relating to Andover’s business
(other than minutes of corporate meetings, capital stock ledger and purely corporate records); provided that any of the foregoing which Andover reasonably deems necessary to Andover’s continued operation, proper accounting and record keeping
functions following the Closing shall not constitute part of the Andover Purchased Assets and shall be retained by Andover; 
 (xvii) the
Andover Governmental Permits (and to the extent any such permits are not assignable or transferable to MSMT, Andover will use its best efforts to cooperate with MSMT as 

  

 -90- 

 
may be reasonably requested to enable MSMT to apply for and obtain the Andover Governmental Permits or to receive the benefits of the Andover Governmental
Permits); and 
 (xviii) except as specifically provided in Section 1.2(b) of the Plan of Reorganization, all other assets of Andover
that exist on the Closing Date, whether tangible or intangible, real or personal. 
  

 -91- 

 Exhibit B 
 Andover Excluded Assets 
  

	 	1.	Cash in the amount of $75,000 

  

	 	2.	The Microsoft Dynamics Software is not an Excluded Andover Asset, however, Andover retains the right to use the Microsoft Dynamics Software after the Closing.

  

	 	3.	Historic records associated with Andover Medical, Inc. including SEC and tax filing and general bookkeeping records. 

 The certificate of incorporation, bylaws and corporate existence of Andover Medical, Inc. is not an asset of Andover 
  

 -92- 

 EXHIBIT 1.11(c ) 
 FORM OF ASSIGNMENT, RELEASE AND ASSUMPTION AGREEMENT 
 This Assignment, Release and Assumption
Agreement (the “Assumption Agreement”) is made and entered into as of the      day of             , 2008, by and between Certified
Diabetic Services, Inc. a Delaware corporation (the “Assignor”) and Medical Solutions Management Inc., a Nevada corporation (the “Assignee”). 
 RECITALS 
 WHEREAS, Assignor, Assignee and Andover Medical, Inc., a
Delaware corporation entered into that certain Asset Purchase Agreement and Plan of Reorganization dated July     , 2008 (the “Plan of Reorganization”), pursuant to which Assignee has purchased
substantially all of the assets of Assignor; and 
 WHEREAS, pursuant to the Plan of Reorganization, Assignor has agreed to assign
certain rights and agreements to Assignee, and Assignee has agreed to assume certain CDIP liabilities of Assignor, as set forth herein; 
 NOW, THEREFORE, for and in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged, the
parties do hereby agree as follows: 
 1. Capitalized Terms. Capitalized terms used but not defined herein shall have the
meanings for such terms that are set forth in the Plan of Reorganization. 
 2. Assignment and Assumption. Effective as of the
first date set forth above, Assignor hereby assigns, sells, transfers and sets over (collectively, the “Assignment”) to Assignee all right, title and interest of Assignor in and to all contracts (expressly including unfilled
contracts for services), agreements, leases, commitments, arrangements or understandings, written or oral, pertaining to the operation of Assignor’s business. Assignee shall assume, effective as of the first date set forth above, and shall
satisfy or perform as they come due, only the CDIP Assumed Liabilities of Assignor. Assignee hereby accepts the Assignment and assumes and agrees, from and after the Closing, to discharge, to the extent provided in the Plan of Reorganization, all of
the CDIP Assumed Liabilities. 
 3. Terms of the Plan of Reorganization. The terms of the Plan of Reorganization, including but
not limited to Assignor’s representations, warranties, covenants and agreements are incorporated herein by this reference. Assignor acknowledges and agrees that the representations, warranties, covenants and agreement contained in the Plan of
Reorganization shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Plan of Reorganization and the terms hereof, the
terms of the Plan of Reorganization shall govern. 
 4. Release. Assignee, for good and valuable consideration, hereby
releases and discharges Assignor, its successors and assigns, from all actions, causes of action, suits, debts, dues, sums of money, accounts, reckonings, bonds, bills, specialties, covenants, contracts, controversies, agreements, promises,
variances, trespasses, damages, judgments, extents, executions, claims and demands whatsoever, in law, admiralty or equity, which against Assignor, Assignee and Assignee’s successors and assigns ever had, now have or hereafter can, shall or
may, have arising out of or related to the CDIP Assumed Liabilities. 

 5. Further Actions. Each of the parties hereto covenants and agrees, at its own expense, to
execute and deliver, at the request of the other party hereto, such further instruments of transfer and assignment to take such other action as such other party may reasonably request to more effectively consummate the assignments and assumptions
contemplated by this Assumption Agreement. 
 6. Successors and Assigns. This Assumption Agreement will be binding upon and
inure to the benefit of the successors and assigns of the parties hereto. 
 7. Binding Effect; Governing Law. This Assumption
Agreement shall be binding on and inure to the benefit of and be enforceable by Assignor and Assignee and their respective successors and assigns. This Assumption Agreement shall be governed, construed, and enforced in accordance with the laws of
the State of Delaware without regard to the choice of law principles thereof. 
 8. Counterparts. This Assumption Agreement may
be executed in counterparts, each of which shall be deemed an original and all of which, when taken together, shall constitute one and the same instrument. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Assignment, Release and Assumption
Agreement as of the date first written above. 
  

			
	“ASSIGNOR”
	
	CERTIFIED DIABETIC SERVICES, INC.
		
	By:	 	  

		 	Lowell M. Fisher, Jr.,
		 	Chief Executive Officer
	
	“ASSIGNEE”
	
	MEDICAL SOLUTIONS MANAGEMENT INC.
		
	By:	 	  

		 	Marshall Sterman,
		 	Chairman of the Board of Directors

 [Signature Page to the Assignment, Release and Assumption Agreement] 

 EXHIBIT 1.11(d) 
 FORM OF ASSIGNMENT, RELEASE AND ASSUMPTION AGREEMENT 
 This Assignment, Release and Assumption
Agreement (the “Assumption Agreement”) is made and entered into as of the      day of             , 2008, by and between Andover
Medical, Inc. a Delaware corporation (the “Assignor”) and Medical Solutions Management Inc., a Nevada corporation (the “Assignee”). 
 RECITALS 
 WHEREAS, Assignor, Assignee and Certified Diabetic Services,
Inc., a Delaware corporation entered into that certain Asset Purchase Agreement and Plan of Reorganization dated July     , 2008 (the “Plan of Reorganization”), pursuant to which Assignee has
purchased substantially all of the assets of Assignor; and 
 WHEREAS, pursuant to the Plan of Reorganization, Assignor has agreed to
assign certain rights and agreements to Assignee, and Assignee has agreed to assume certain Andover liabilities of Assignor, as set forth herein; 
 NOW, THEREFORE, for and in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged, the
parties do hereby agree as follows: 
 9. Capitalized Terms. Capitalized terms used but not defined herein shall have the
meanings for such terms that are set forth in the Plan of Reorganization. 
 10. Assignment and Assumption. Effective as of the
first date set forth above, Assignor hereby assigns, sells, transfers and sets over (collectively, the “Assignment”) to Assignee all right, title and interest of Assignor in and to all contracts (expressly including unfilled
contracts for services), agreements, leases, commitments, arrangements or understandings, written or oral, pertaining to the operation of Assignor’s business. Assignee shall assume, effective as of the first date set forth above, and shall
satisfy or perform as they come due, only the Andover Assumed Liabilities of Assignor. Assignee hereby accepts the Assignment and assumes and agrees, from and after the Closing, to discharge, to the extent provided in the Plan of Reorganization, all
of the Andover Assumed Liabilities. 
 11. Terms of the Plan of Reorganization. The terms of the Plan of Reorganization,
including but not limited to Assignor’s representations, warranties, covenants and agreements are incorporated herein by this reference. Assignor acknowledges and agrees that the representations, warranties, covenants and agreement contained in
the Plan of Reorganization shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Plan of Reorganization and the terms
hereof, the terms of the Plan of Reorganization shall govern. 
 12. Release. Assignee, for good and valuable consideration,
hereby releases and discharges Assignor, its successors and assigns, from all actions, causes of action, suits, debts, dues, sums of money, accounts, reckonings, bonds, bills, specialties, covenants, contracts, controversies, agreements, promises,
variances, trespasses, damages, judgments, extents, executions, claims and demands whatsoever, in law, admiralty or equity, which against Assignor, Assignee and Assignee’s successors and assigns ever had, now have or hereafter can, shall or
may, have arising out of or related to the Andover Assumed Liabilities. 

 13. Further Actions. Each of the parties hereto covenants and agrees, at its own expense,
to execute and deliver, at the request of the other party hereto, such further instruments of transfer and assignment to take such other action as such other party may reasonably request to more effectively consummate the assignments and assumptions
contemplated by this Assumption Agreement. 
 14. Successors and Assigns. This Assumption Agreement will be binding upon and
inure to the benefit of the successors and assigns of the parties hereto. 
 15. Binding Effect; Governing Law. This Assumption
Agreement shall be binding on and inure to the benefit of and be enforceable by Assignor and Assignee and their respective successors and assigns. This Assumption Agreement shall be governed, construed, and enforced in accordance with the laws of
the State of Delaware without regard to the choice of law principles thereof. 
 16. Counterparts. This Assumption Agreement
may be executed in counterparts, each of which shall be deemed an original and all of which, when taken together, shall constitute one and the same instrument. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Assignment, Release and Assumption
Agreement as of the date first written above. 
  

			
	“ASSIGNOR”
	
	ANDOVER MEDICAL, INC.
		
	By:	 	  

		 	Edwin A. Reilly,
		 	Chief Executive Officer
	
	“ASSIGNEE”
	
	MEDICAL SOLUTIONS MANAGEMENT INC.
		
	By:	 	  

		 	Marshall Sterman,
		 	Chairman of the Board of Directors

 [Signature Page to the Assignment, Release and Assumption Agreement] 

 EXHIBIT 1.11(e) 
 FORM OF ASSIGNMENT OF INTELLECTUAL PROPERTY 
 This Assignment of Intellectual Property (the
“Assignment”) effective as of                 , 2008, (the “Effective Date”), is between Certified Diabetic
Services, Inc., a Delaware corporation whose address is 3030 Horseshoe Drive South, Suite 200, Naples, Florida 34104 (the “Assignor”) and Medical Solutions Management Inc., a Nevada corporation, whose address is 237 Cedar
Hill Street, Marlboro, Massachusetts 01752 (the “Assignee”). Capitalized terms used and not otherwise defined herein shall have the meaning given to them in the Plan of Reorganization (as defined below). 
 WHEREAS, the Assignor, Assignee and Andover Medical, Inc. have entered into an Asset Purchase Agreement and Plan of Reorganization effective as of
July [*], 2008 (the “Plan of Reorganization”) pursuant to which the Assignor has agreed, inter alia, to assign to the Assignee the CDIP Purchased Assets including, without limitation, (i) the United States trademark
registrations and applications for registration identified and set forth on Schedule A, (ii) the foreign trademark registrations and applications for registration identified and set forth on Schedule B, (iii) the common law
trademarks, service marks and trade names identified and set forth on Schedule C (each of the foregoing collectively referred to herein as the “Marks”). 
 WHEREAS, execution of this Assignment is a condition to the consummation of the transactions contemplated by the Plan of Reorganization;

 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor
hereby sells, assigns, transfers, conveys, and sets over to Assignee the entire right, title, and interest, anywhere in the world, in and to the Marks, together with the goodwill of the business in connection with which the Marks are used, and the
right to obtain any renewals or extensions of such Marks, with full benefit of priority therein as may now or hereafter be granted to it by law, treaty, or other international convention, for Assignee’s own use and enjoyment, and for the use
and enjoyment of Assignee’s successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made; together with all income, royalties,
damages, or payments due or payable as of the Effective Date or thereafter, including, without limitation, all rights, interests, claims, and demands recoverable in law or in equity that Assignor has or may have in profits and damages by reason of
past, present or future infringement or other unauthorized use of the Marks, with the right to compromise, sue for, and collect the same for Assignee’s own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other
legal representatives. 
 Assignor will not object to or otherwise challenge any attempted registration of the Marks anywhere in the world.

 Assignor agrees to execute and deliver at the request of Assignee, its successors, assigns or other legal representatives, all papers,
instruments, documents, and conveyances prepared by Assignee and to perform at Assignee’s expense any other reasonable acts Assignee may require as necessary to vest all of Assignor’s right, title, and interest in and to the Marks to
Assignee, its successors, assigns, or other legal representatives. 
 In the event that after the Effective Date the Assignor or Assignee
identifies additional trademarks owned by Assignor or one of its Affiliates which is a CDIP Purchased Asset, the Assignor agrees to execute an additional assignment agreement in a form substantially similar to this Assignment and to transfer any and
all rights to such trademarks to the Assignee. 

 This Assignment may be signed in counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 IN TESTIMONY WHEREOF, the Assignor and Assignee have caused this Assignment
of Intellectual Property to be signed and executed by the undersigned officers thereunto duly authorized this      day of             , 2008. 

 

			
	“ASSIGNOR”
	
	CERTIFIED DIABETIC SERVICES, INC.
		
	By:	 	  

		 	Lowell M. Fisher, Jr.,
		 	Chief Executive Officer
	
	“ASSIGNEE”
	
	MEDICAL SOLUTIONS MANAGEMENT INC.
		
	By:	 	  

		 	Marshall Sterman,
		 	Chairman of the Board of Directors

			
	STATE OF                           	  	)
		  	) ss.:
	COUNTY OF                       	  	)

 On this      day of
             2008, there appeared before me, Lowell M. Fisher, Jr., personally known to me who acknowledged that he is the Chief Executive Officer of Certified Diabetic Services,
Inc., and that he signed the foregoing Assignment as his voluntary act and deed on behalf of, and with full authority of Certified Diabetic Services, Inc. 
  

	
	  

	Notary Public

			
	STATE OF                           	  	)
		  	) ss.:
	COUNTY OF                       	  	)

 On this      day of
             2008, there appeared before me, Marshall Sterman, personally known to me who acknowledged that he is the Chairman of the Board of Directors of Medical Solutions
Management Inc., and that he signed the foregoing Assignment as his voluntary act and deed on behalf of, and with full authority of Medical Solutions Management Inc. 
  

	
	  

	Notary Public

 SCHEDULE A 
 to the 
 INTELLECTUAL PROPERTY ASSIGNMENT 
 U.S. TRADEMARK REGISTRATIONS AND APPLICATIONS 
 Trademarks

  

					
	 Trademark (1)
	 	 Registration No./Application No.
	 	 Registration Date/Application Date

		 		 	

 SCHEDULE B 
 to the 
 INTELLECTUAL PROPERTY ASSIGNMENT 
 FOREIGN TRADEMARK REGISTRATIONS AND APPLICATIONS 

 SCHEDULE C 
 to the 
 INTELLECTUAL PROPERTY ASSIGNMENT 
 COMMON LAW TRADEMARKS, SERVICE MARKS AND TRADE NAMES 

 EXHIBIT 4.1 
 FORM OF SECOND AMENDED AND RESTATED ARTICLES OF 
 INCORPORATION 
 OF 
 MEDICAL SOLUTIONS MANAGEMENT INC.

 Pursuant to the provisions of the Nevada Revised Statutes, Chapter 78 (Section 78.010 et. seq.) (the “Act”), the
Amended and Restated Articles of Incorporation of Medical Solutions Management Inc., a Nevada corporation (the “Corporation”), are hereby amended and restated to read in their entirety as follows (as amended and restated hereby,
hereinafter the “Articles of Incorporation”): 
 ARTICLE I 
 The name of the corporation is Medical Solutions Management Inc. 
 ARTICLE II 
 The Corporation is organized to engage in any lawful acts, activities and pursuits for
which a corporation may be organized under the Act. 
 ARTICLE III 
 The total number of shares of all classes of stock which the Corporation shall have authority to issue is 2,200,000,000, of which 25,000,000 shares shall
be shares of Preferred Stock (hereinafter referred to as the “Preferred Stock”), par value of $0.0001 per share, and 2,175,000,000 shares shall be shares of common stock (hereinafter referred to as the “Common
Stock”), par value $0.0001 per share. 
 The preferences, limitations and relative rights of each class of shares (to the extent
established hereby), and the express grant of authority to the Board of Directors to amend these Articles of Incorporation to divide the Preferred Stock into series, to establish and modify the preferences, limitations and relative rights of each
share of Preferred Stock, and to otherwise impact the capitalization of the Corporation, subject to certain limitations and procedures and as permitted by the Act, are as follows: 
 A. Common Stock. 
 (1) Voting
Rights. Except as otherwise expressly provided by law or in this Article III and subject to the provisions of Section F(3)b of this Article III, each outstanding share of Common Stock shall be entitled to one (1) vote on each matter to be
voted on by the stockholders of the Corporation. 
 (2) Liquidation Rights. Subject to any prior, participating or superior rights on
liquidation as may be conferred upon any shares of Preferred Stock, and after payment or provision for payment of the debts and other liabilities of the Corporation, upon any voluntary or involuntary liquidation, dissolution or winding up of the
affairs of the Corporation, the holders of Common Stock then outstanding shall be entitled to receive all of the assets and funds of the Corporation remaining and available for distribution. Such assets and funds shall be divided among and paid to
the holders of Common Stock, on a pro-rata basis, according to the number of shares of Common Stock held by them. 
 (3) Dividends.
Dividends may be paid on the outstanding shares of Common Stock, as and when declared by the Board of Directors, out of funds legally available therefor; provided, however, that no dividends shall be made with respect to the Common Stock until any
preferred dividends required to be paid or set apart for any shares of Preferred Stock have been paid or set apart. 

 (4) Residual Rights. All rights accruing to the outstanding shares of the Corporation not
expressly provided for to the contrary herein or in the Corporation’s bylaws or in any amendment hereto or thereto shall be vested in the Common Stock. 
 (5) No Preemptive Rights. Unless otherwise provided in resolutions of the Board of Directors providing for the issue of any Common Stock or in these Articles of Incorporation with respect to any series of
Preferred Stock, no holder of shares of any class of the Corporation or any security or obligation convertible into, or any warrant, option, or right to purchase, subscribe for, or otherwise acquire, shares of any class of the Corporation, whether
now or hereafter authorized, shall, as such holder, have any preemptive right whatsoever to purchase, subscribe for, or otherwise acquire shares of any class of the Corporation, whether now or hereafter authorized. 
 B. Preferred Stock. Shares of Preferred Stock may be issued from time to time in one or more series as may from time to time be determined by the
Board of Directors without stockholder action. Each series shall be distinctly designated. The powers, preferences and relative, participating, optional and other rights of each such series, and the qualifications, limitations or restrictions
thereof, if any, may differ from those of any and all other series at any time outstanding. Except as hereinafter provided, the Board of Directors is hereby expressly granted authority to fix, by resolution or resolutions adopted prior to the
issuance of any shares of each particular series of Preferred Stock, the designation, powers, preferences and relative, participating, optional and other rights, and the qualifications, limitations and restrictions thereof, if any, of such series,
including but without limiting the generality of the forgoing, the following: 
 (1) the distinctive designation of, and the number of shares
of, Preferred Stock which shall constitute the series, which number may be increased (except as otherwise fixed by the Board of Directors) or decreased (but not below the number of shares thereof then outstanding) from time to time by action of the
Board of Directors; 
 (2) the rate and times at which, and the terms and conditions upon which, dividends, if any, on shares of the series
shall be paid, the extent of preferences or relations, if any, of such dividends to the dividends payable on any other class or classes of stock of the Corporation, or on any series of Preferred Stock or of any other class or classes of stock of the
Corporation, and whether such dividends shall be cumulative or non-cumulative; 
 (3) the right, if any, of the holders of shares of the
series to convert the same into, or exchange the same for, shares of any other class or classes of stock of the Corporation, or of any series of Preferred Stock or of any other class or classes of stock of the Corporation, and the terms and
conditions of such conversion or exchange; 
 (4) whether shares of the series shall be subject to redemption, and the redemption price or
prices including, without limitation, a redemption price or prices payable in shares of the Common Stock and the time or times at which, and the terms and conditions upon which, shares of the series may be redeemed; 
 (5) the rights, if any, of the holders of shares of the series upon voluntary or involuntary liquidation, merger, consolidation, distribution or sale of
assets, dissolution or winding up of the Corporation; 
 (6) the terms of the sinking fund or redemption or purchase account, if any, to be
provided for shares of the series; and 

 (7) the voting power, if any, of the holders of shares of the series which may, without limiting the
generality of the foregoing, include the right to more or less than one vote per share of any or all matters voted upon by the stockholders and the right to vote, as a series by itself or together with other series of Preferred Stock as a class,
upon such matters, under such circumstances and upon such conditions as the Board of Directors may fix, including, without limitation, the right, voting as a series by itself or together with other series of Preferred Stock or together with all
series of Preferred Stock as a class, to elect one or more directors of the Corporation in the event there shall have been a default in the payment of dividends on any one or more series of Preferred Stock or under such other circumstances and upon
such conditions as the Board of Directors may determine. 
 C. Series A Voting Convertible Preferred Stock. Of the shares of Preferred
Stock authorized hereunder, there is hereby created a series of Preferred Stock designated “Series A Voting Convertible Preferred Stock” (hereinafter “Series A Preferred Stock”). All Capitalized terms used in this
Article III, Section C without definition shall have the respective meanings ascribed to such terms in Article III, Section G. The number of shares constituting such series is Five Million Sixty-Five Thousand Eight Hundred (5,065,800). The Series A
Preferred Stock shall have the following rights, preferences, powers, privileges, restrictions, qualifications and limitations: 
 (1)
Stated Value. The par value of each issued share of Series A Preferred Stock shall be $.0001 per share, and the stated value of each issued share of Series A Preferred Stock shall be deemed to be One Dollar ($1.00) (the “Series A
Stated Value”), subject to increase set forth in Section 2. 
 (2) Dividends. 
 a. Dividends on Series A Preferred Stock. The holders of shares of Series A Preferred Stock shall be entitled to receive, and the Corporation
shall pay, a cumulative dividend for each such share at a rate per annum equal to six percent (6%) of the Series A Stated Value thereof, payable, beginning on June 30, 2009, semi-annually on June 30 and December 31 and on each
Conversion Date (with respect only to Series A Preferred Stock being converted) (each such date, a “Series A Dividend Payment Date”) (if any Series A Dividend Payment Date is not a Trading Day, the applicable payment shall be due on
the next succeeding Trading Day), by one of the following methods, as selected by the Corporation in its sole discretion: (i) in cash, to the extent funds are legally available therefor in accordance with applicable corporate law; or
(ii) in-kind, with shares of Common Stock, which such shares shall be valued solely for such purpose equal to the average VWAP for the five (5) consecutive Trading Days ending on the Trading Day that is immediately prior to the applicable
Series A Dividend Payment Date. Notwithstanding the foregoing, [A] if there are insufficient shares of Common Stock authorized and available for issuance to pay the dividend, then the Corporation shall make the dividend payment pursuant to
Section 2(a)(i) above, and [B] if funds are not legally available for payment of the dividend in accordance with applicable corporate law, then, at the election of such holder, such dividends shall accrue to the next Series A Dividend
Payment Date (subject to Section 2(b) below) or shall be accredited to, and increase, the outstanding Series A Stated Value. Dividends on the Series A Preferred Stock shall be calculated on the basis of a 360-day year, consisting of
twelve 30 calendar day periods, shall accrue daily commencing on the Original Issue Date, and shall be deemed to accrue from such date whether or not earned or declared and whether or not there are profits, surplus or other funds of the Corporation
legally available for the payment of dividends. Except as otherwise provided herein, if at any time the Corporation pays dividends partially in cash and partially in shares, then such payment shall be distributed ratably among the holders based upon
the number of shares of Series A Preferred Stock held by each holder on such Series A Dividend Payment Date. 
 b. Priority of
Payment. Upon the payment of any dividend pursuant to Section 2(a), the holders of shares of Series A Preferred Stock shall rank pari passu with the holders of 

 
shares of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock. In the event that full dividends are not paid under
Section 2(a) to the holders of all outstanding shares of Series A Preferred Stock so entitled to such payment and funds available for payment of dividends shall be insufficient to permit payment in full to the holders of shares of Series
A Preferred Stock and any other class or series of stock of the Corporation ranking on parity with the Series A Preferred Stock, including the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock, the full preferential
amounts to which they are then entitled, then the entire amount available for payment of dividends shall be distributed, first, ratably among all holders of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D
Preferred Stock and any other class or series of stock ranking with respect to dividends on parity with the Series A Preferred Stock in proportion to the full amount to which they would otherwise be respectively entitled and, second, only after the
holders of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock and any other class or series of stock ranking with respect to dividends on parity with the Series A Preferred Stock have received
the full amount of dividends to which they were entitled, ratably among all holders of other Preferred Stock and Common Stock ranking junior to the Series A Preferred Stock in proportion to the full amount to which they would otherwise be
respectively entitled. 
 (3) Voting. 
 a. Voting Rights. Except as otherwise provided herein or as otherwise required by law, each holder of shares of Series A Preferred Stock shall have the right to the number of votes equal to the number of
Conversion Shares then issuable upon conversion of the Series A Preferred Stock, without regard to the limitations set forth in Section 5(f) below, held by such holder in all matters as to which stockholders are required or permitted to
vote, and with respect to such vote, such holder shall have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, and shall be entitled, notwithstanding any provision in these Articles of Incorporation,
to vote, together with the holders of Common Stock and with the holders of any other series of Preferred Stock, which by its terms and/or by statute is entitled to vote on all matters to which holders of Common Stock are required or permitted to
vote, as a single class, with respect to any question upon which holders of Common Stock have the right to vote. To the extent permitted under applicable corporate law, but subject to Section 3(b) below, the Corporation’s
stockholders may take action by the affirmative vote of a majority of all stockholders of this Corporation entitled to vote on an action. 
 b. Limitations on Corporate Actions. Notwithstanding anything to the contrary in Section 3(a), so long as twenty percent (20%) of the shares of Series A Preferred Stock issued and outstanding on the Original Issue
Date remain issued and outstanding, the Corporation shall not, without the written consent or affirmative vote of the holders of at least a majority of the then-outstanding shares of Series A Preferred Stock consenting or voting (as the case may be)
as a separate class from the Common Stock, either directly or by amendment, merger, consolidation or otherwise: 
 (i) amend or otherwise
restate its articles of incorporation in any manner that adversely affects the rights of the holders of Series A Preferred Stock; 
 (ii)
alter or change adversely the voting or other powers, preferences, rights, privileges or restrictions of the Series A Preferred Stock contained herein; 
 (iii) increase the authorized number of shares of Preferred Stock or the Series B Preferred Stock, Series C Preferred Stock or Series D Preferred Stock; 
 (iv) redeem, purchase or otherwise acquire directly or indirectly any Junior Stock or any shares pari passu with the Series A
Preferred Stock; 

 (v) directly or indirectly pay or declare any dividend or make any distribution in respect of, any
Junior Stock, or set aside any monies for the purchase or redemption (through a sinking fund or otherwise) of any Junior Stock or any shares pari passu with the Series A Preferred Stock; 
 (vi) authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a Liquidation senior to or otherwise
pari passu with the Series A Preferred Stock; or 
 (vii) enter into any agreement with respect to any of the foregoing.

 (4) Liquidation, Dissolution or Winding Down. 
 a. Payments to Holders of Series A Preferred Stock. Upon any Liquidation of the Corporation, the holders of shares of Series A Preferred Stock shall rank pari passu with the holders of shares of
Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock and shall be paid in cash, before any payment shall be paid to the holders of Common Stock, or any other Junior Stock, an amount for each share of Series A Preferred
Stock held by such holder equal to the sum of (1) the Series A Stated Value thereof and (2) an amount equal to dividends accrued but unpaid thereon, computed to the date payment thereof is made available. If, upon such Liquidation of the
Corporation, the assets to be distributed among the holders of shares of Series A Preferred Stock and any class or series of stock ranking on parity with the Series A Preferred Stock, including the Series B Preferred Stock, Series C Preferred Stock
and Series D Preferred Stock, shall be insufficient to permit payment to the holders of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock and any other class or series of stock ranking on
liquidation on parity with the Series A Preferred Stock, the full preferential amount to which they shall be entitled, the holders of shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock
and any other class or series of stock ranking on liquidation on parity with the Series A Preferred Stock shall share ratably in any distribution of the remaining assets available for distribution in proportion to the respective amounts that would
otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. 
 b. Payments to Holders of Junior Stock. After the payment of all preferential amounts required to be paid to the holders of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and
Series D Preferred Stock and any other class or series of stock of the Corporation ranking on liquidation senior to or on parity with the Series A Preferred Stock, the holders of shares of Junior Stock then outstanding shall be entitled to receive
the remaining assets of the Corporation available for distribution to its stockholders as otherwise set forth in the Corporation’s articles of incorporation. 
 (5) Conversion. The holders of Series A Preferred Stock shall have the conversion rights as follows: 
 a. Right to Convert. Each share of Series A Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the Original Issue Date (subject to the limitations set forth in Section 5(f)
below), and without the payment of additional consideration by the holder thereof, into such number of fully-paid and nonassessable shares of Common Stock as is determined by dividing (1) the sum of (i) the Series A Stated Value per share
and (ii) all dividends accrued and unpaid on each such share to the date such share is converted, whether or not declared, and all other dividends declared and unpaid on each such share through the date of actual conversion, by (2) the
Series A Conversion Price in effect at the time of conversion. The “Series A Conversion Price” shall 

 
be $0.0817743417; provided, however, that the Series A Conversion Price, and the rate at which shares of Series A Preferred Stock may be converted into
shares of Common Stock, shall be subject to adjustment as provided in for Section 6. Shares of Series A Preferred Stock converted into Common Stock or redeemed in accordance with the terms hereof shall be canceled and shall not be
reissued. 
 b. Holders shall effect conversions by providing the Corporation with a Notice of Conversion setting forth the Conversion Date.
To effect conversions of shares of Series A Preferred Stock, a holder shall not be required to surrender the certificate(s) representing such shares of Series A Preferred Stock to the Corporation unless all of the shares of Series A Preferred Stock
represented thereby are so converted, in which case such holder shall deliver the certificate representing such shares of Series A Preferred Stock promptly following the Conversion Date at issue. Certificates representing the Series A Preferred
Stock shall have the following legend: 
 THE HOLDER AND ANY ASSIGNEE OR TRANSFEREE, BY ACCEPTANCE OF THIS STOCK CERTIFICATE, ACKNOWLEDGE
AND AGREE THAT, PURSUANT TO SECTION 5.B. OF THE CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES A VOTING CONVERTIBLE PREFERRED STOCK, THE NUMBER OF SHARES REFLECTED ON THE FACE OF THIS CERTIFICATE MAY NOT BE THE ACTUAL NUMBER OF
SHARES HELD BY THE HOLDER OR ASSIGNEE. PLEASE INQUIRE WITH THE CORPORATION AS TO THE ACTUAL NUMBER OF SHARES EVIDENCED BY THIS CERTIFICATE. 
 c. Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Series A Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay
cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board of Directors, or round-up to the next whole number of shares, at the Corporation’s option. Whether or not
fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series A Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common
Stock issuable upon such conversion. 
 d. Mechanics of Conversion. 
 (i) Delivery of Certificate Upon Conversion. Not later than the Share Delivery Date, the Corporation shall deliver, or cause to be delivered, to
the converting holder, a certificate or certificates which shall be free of restrictive legends and trading restrictions (other than those which may then be required by applicable securities laws) representing the number of shares of Common Stock
being acquired upon the conversion of shares of Series A Preferred Stock. The Corporation shall, upon request of such holder, use its reasonable efforts to deliver any certificate or certificates required to be delivered by the Corporation under
this section electronically through the Depository Trust Company or another established clearing corporation performing similar functions. If in the case of any Notice of Conversion such certificate or certificates are not delivered to or as
directed by the applicable holder by the Share Delivery Date, the applicable holder shall be entitled to elect by written notice to the Corporation at any time on or before its receipt of such certificate or certificates, to rescind such Notice of
Conversion by written notice to the Corporation, in which event the Corporation shall promptly return to such holder any original Series A Preferred Stock certificate delivered to the Corporation and such holder shall promptly return any Common
Stock certificates representing the shares of Series A Preferred Stock tendered for conversion to the Corporation. 
 (ii) Obligation
Absolute; Damages. The Corporation’s obligation to issue and deliver the Conversion Shares upon conversion of Series A Preferred Stock in accordance with 

 
the terms hereof are absolute and unconditional, irrespective of any action or inaction by a holder to enforce the same, any waiver or consent with respect
to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such holder or any other Person of any
obligation to the Corporation; provided, however, that such delivery shall not operate as a waiver by the Corporation of any such action that the Corporation may have against such holder. If the Corporation fails to deliver to a holder
such certificate or certificates pursuant to this section on the fifth Trading Day after the Share Delivery Date applicable to such conversion, the Corporation shall pay to such holder, in cash, as liquidated damages and not as a penalty, for each
$1,000 of Stated Value of Series A Preferred Stock being converted, $10 per Trading Day (increasing to $20 per Trading Day on the tenth Trading Day after the Share Delivery Date) for each Trading Day after such fifth Trading Day after the Share
Delivery Date until such certificates are delivered. 
 e. Reservation of Shares Issuable Upon Conversion. The Corporation covenants
that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series A Preferred Stock and payment of dividends on the Series A Preferred Stock,
each as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the holders of the Series A Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be
issuable upon the conversion of all outstanding shares of Series A Preferred Stock and payment of dividends hereunder. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly
issued, fully paid and nonassessable. 
 f. Beneficial Ownership Limitation. The Corporation shall not effect any conversion of the
Series A Preferred Stock, and a holder shall not have the right to convert any portion of the Series A Preferred Stock, to the extent that, after giving effect to the conversion set forth on the applicable Notice of Conversion, such holder (together
with such holder’s Affiliates, and any other person or entity acting as a group together with such holder or any of such holder’s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation. To the extent that the
limitation contained in this Section 5(f) applies, the determination of whether the Series A Preferred Stock is convertible (in relation to other securities owned by such holder together with any Affiliates) and of how many shares of
Series A Preferred Stock are convertible shall be in the sole discretion of such holder, and the submission of a Notice of Conversion shall be deemed to be such holder’s determination of whether the shares of Series A Preferred Stock may be
converted (in relation to other securities owned by such holder together with any Affiliates) and how many shares of the Series A Preferred Stock are convertible, in each case subject to such aggregate percentage limitations. To ensure compliance
with this restriction, each holder will be deemed to represent to the Corporation each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation shall
have no obligation to verify or confirm the accuracy of such determination. The Beneficial Ownership Limitation provisions of this section may be waived by such holder, at the election of such holder, upon not less than sixty-one
(61) days’ prior notice to the Corporation, to change the Beneficial Ownership Limitation to 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
conversion of Series A Preferred Stock held by the applicable holder and the provisions of this section shall continue to apply. Upon such a change by a holder of the Beneficial Ownership Limitation from such 4.99% limitation to such 9.99%
limitation, the Beneficial Ownership Limitation shall not be further waived by such holder. The limitations contained in this paragraph shall apply to a successor holder of Series A Preferred Stock. 
 (6) Certain Adjustments. 

 a. Stock Dividends and Stock Splits. If the Corporation, at any time while this Series A
Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall
not include any shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, this Series A Preferred Stock or the Series B Preferred Stock, Series C Preferred Stock or Series D Preferred Stock or any other class
or series of stock ranking with respect to dividends on parity with the Series A Preferred Stock); (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock
split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Series A Conversion Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of
shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 6(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. 
 b. Subsequent Equity Sales. If, at any time while this Series A Preferred Stock is outstanding, the Corporation or any Subsidiary, as applicable, sells, grants or otherwise issues any Common Stock or Common
Stock Equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then Series A Conversion Price (such lower price, the “Series A Base Conversion Price” and such
issuances collectively, a “Series A Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating
conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is lower than
the Series A Conversion Price, such issuance shall be deemed to have occurred for less than the Series A Conversion Price on such date of the Series A Dilutive Issuance), then the Series A Conversion Price shall be reduced to equal the Series A Base
Conversion Price. Notwithstanding the foregoing, no adjustment will be made under this Section 6(b) in connection with an Exempt Issuance. The Corporation shall notify the holders in writing, no later than the Business Day following the
issuance of any Common Stock or Common Stock Equivalents subject to this Section 6(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice,
the “Series A Dilutive Issuance Notice”). For purposes of clarification, whether or not the Corporation provides a Series A Dilutive Issuance Notice pursuant to this Section 6(b), upon the occurrence of any Series A
Dilutive Issuance, the holders are entitled to receive a number of Conversion Shares based upon the Series A Base Conversion Price on or after the date of such Series A Dilutive Issuance, regardless of whether a holder accurately refers to the
Series A Base Conversion Price in the Notice of Conversion. 
 c. Subsequent Rights Offerings. If the Corporation, at any time while
Series A Preferred Stock is outstanding, shall issue rights, options or warrants to all holders of Common Stock (and not to the holders of Series A Preferred Stock) entitling them to subscribe for or purchase shares of Common Stock at a price per
share less than the VWAP as of the record date described in the following sentence, then the Series A Conversion Price shall be multiplied by a fraction, of which the denominator shall be the number of shares of the Common Stock outstanding on the
date of issuance of such rights or warrants plus the number of additional shares of Common Stock offered for subscription or purchase, and of which the numerator shall be the number of shares of the Common Stock outstanding on the date of issuance
of such rights, options or warrants plus the number of shares which the aggregate offering price of the total number of shares so offered (assuming receipt by the Corporation in full of all 

 
consideration payable upon exercise of such rights, options or warrants) would purchase at such VWAP. Such adjustment shall be made whenever such rights,
options or warrants are issued, and shall become effective immediately after the record date for the determination of stockholders entitled to receive such rights, options or warrants. 
 d. Pro Rata Distributions. If the Corporation, at any time while Series A Preferred Stock is outstanding, distributes to all holders of Common
Stock (and not to the holders of Series A Preferred Stock) evidences of its indebtedness or assets (including cash and cash dividends) (other than stock dividends, which shall be subject to Section 6(a) and the dividends due pursuant to
Section 1 hereof), then, in each such case, the Series A Conversion Price shall be adjusted by multiplying such Series A Conversion Price in effect immediately prior to the record date fixed for determination of stockholders entitled to
receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which the numerator shall be such VWAP on such record date less the then fair market value at such record
date of the portion of such assets, evidence of indebtedness or rights or warrants so distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors of the Corporation in good faith. In either case the
adjustments shall be described in a statement delivered to the holders describing the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment shall be made
whenever any such distribution is made and shall become effective immediately after the record date mentioned above. 
 e. Fundamental
Transaction. If, at any time while this Series A Preferred Stock is outstanding the Corporation effects a Fundamental Transaction and a redemption of the Series A Preferred Stock, as contemplated by Section 7 is not effected, then,
upon any subsequent conversion of this Series A Preferred Stock, the holders shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental
Transaction, the Alternate Consideration. For purposes of any such conversion, the determination of the Series A Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Series A Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holders shall be given the same choice as to the
Alternate Consideration it receives upon any conversion of this Series A Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in
such Fundamental Transaction shall amend and restate its articles of incorporation or amend its articles of incorporation by filing an appropriate certificate of designation with the same terms and conditions and issue to the holders new preferred
stock consistent with the foregoing provisions and evidencing the holders’ right to convert such preferred stock into Alternate Consideration. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include
terms requiring any such successor or surviving entity to comply with the provisions of this Section 6(e) and ensuring that this Series A Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent
transaction analogous to a Fundamental Transaction. 
 f. Calculations. All calculations under this Section 6 shall be
made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 6, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of
shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding. 

 g. Notice to the Holders. 
 (i) Adjustment to Conversion Price. Whenever the Series A Conversion Price is adjusted pursuant to any provision of this Section 6,
the Corporation shall promptly mail to each holder a notice setting forth the conversion price after such adjustment and setting forth a brief statement of the facts requiring such adjustment. 
 (ii) Notice to Allow Conversion by Holder. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to
subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the Common Stock, any consolidation or
merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or
(E) the Corporation shall authorize the Liquidation of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of this Series A Preferred Stock, and shall
cause to be delivered to each holder at its last address as it shall appear upon the stock books of the Corporation, at least ten (10) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to
such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as
of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. The holder is entitled to convert the
Series A Preferred Stock (or any part hereof) during the ten (10) day period commencing on the date of such notice through the effective date of the event triggering such notice. 
 (7) Redemption Upon Triggering Events. At any time after the occurrence of a Triggering Event, but within thirty (30) days after the receipt
by the Corporation of a written request from the holders of not less than a majority of the then outstanding shares of Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock, voting together as a single class, that all or
some of such stockholders’ shares be redeemed, and concurrently with the surrender by such holders of the certificates representing such shares, the Corporation shall, to the extent it may legally do so, redeem the shares of Series A Preferred
Stock specified in such request by paying such holder in cash, a sum equal to the Series A Stated Value, plus all accrued and unpaid dividends (the “Series A Triggering Redemption Amount). For any redemption effected pursuant to this
Section 7, the holders of Series A Preferred Stock shall rank pari passu with the holders of Series C Preferred Stock and Series D Preferred Stock. If the Corporation does not have sufficient funds legally available to
satisfy the Series A Triggering Redemption Amount and of any other class or series of stock to be redeemed upon the occurrence of a Triggering Event, including the Series C Preferred Stock and Series D Preferred Stock, the Corporation shall redeem a
pro-rata portion of each holder’s redeemable shares of such stock out of funds legally available therefor, based on the respective amounts that would otherwise be payable in respect of the shares to be redeemed if the legally available funds
were sufficient to redeem all such shares, and shall redeem the remaining shares as soon as practicable after the Corporation has funds legally available therefor. If the Corporation fails to pay in full the Series A Triggering Redemption Amount
hereunder on 

 
the date such amount is due in accordance with this section, the Corporation will pay interest thereon at a rate equal to the lesser of eighteen percent
(18%) per annum or the maximum rate permitted by applicable law, accruing daily from such date until the Series A Triggering Redemption Amount, plus all such interest thereon, is paid in full. For purposes of this section, a share of Series A
Preferred Stock is outstanding until such date as the applicable holder has been paid the Series A Triggering Redemption Amount in cash. 
 D. Series B Voting Convertible Preferred Stock. Of the shares of Preferred Stock authorized hereunder, there is hereby created a series of Preferred Stock designated “Series B Voting Convertible Preferred Stock”
(hereinafter “Series B Preferred Stock”). All Capitalized terms used in this Article III, Section D without definition shall have the respective meanings ascribed to such terms in Article III, Section G. The number of shares
constituting such series is Four Hundred Sixty-Six Thousand (466,000). The Series B Preferred Stock shall have the following rights, preferences, powers, privileges, restrictions, qualifications and limitations: 
 (1) Stated Value. The par value of each issued share of Series B Preferred Stock shall be $.0001 per share, and the stated value of each issued
share of Series B Preferred Stock shall be deemed to be One Dollar ($1.00) (the “Series B Stated Value”), subject to increase set forth in Section 2. 
 (2) Dividends. 
 a. Dividends on
Series B Preferred Stock. The holders of shares of Series B Preferred Stock shall be entitled to receive, and the Corporation shall pay, a cumulative dividend for each such share at a rate per annum equal to eight percent (8%) of the Series
B Stated Value thereof, payable, beginning on June 30, 2009, semi-annually on June 30 and December 31 and on each Conversion Date (with respect only to Series B Preferred Stock being converted) (each such date, a “Series B
Dividend Payment Date”) (if any Series B Dividend Payment Date is not a Trading Day, the applicable payment shall be due on the next succeeding Trading Day), by one of the following methods, as selected by the Corporation in its sole
discretion: (i) in cash, to the extent funds are legally available therefor in accordance with applicable corporate law; or (ii) in-kind, with shares of Common Stock, which such shares shall be valued solely for such purpose equal to the
average VWAP for the five (5) consecutive Trading Days ending on the Trading Day that is immediately prior to the applicable Series B Dividend Payment Date. Notwithstanding the foregoing, [A] if there are insufficient shares of Common Stock
authorized and available for issuance to pay the dividend, then the Corporation shall make the dividend payment pursuant to Section 2(a)(i) above, and [B] if funds are not legally available for payment of the dividend in accordance with
applicable corporate law, then, at the election of such holder, such dividends shall accrue to the next Series B Dividend Payment Date (subject to Section 2(b) below) or shall be accredited to, and increase, the outstanding Series B
Stated Value. Dividends on the Series B Preferred Stock shall be calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, shall accrue daily commencing on the Original Issue Date, and shall be deemed to accrue from
such date whether or not earned or declared and whether or not there are profits, surplus or other funds of the Corporation legally available for the payment of dividends. Except as otherwise provided herein, if at any time the Corporation pays
dividends partially in cash and partially in shares, then such payment shall be distributed ratably among the holders based upon the number of shares of Series B Preferred Stock held by each holder on such Series B Dividend Payment Date. 

b. Priority of Payment. Upon the payment of any dividend pursuant to Section 2(a), the holders of shares of Series B Preferred
Stock shall rank pari passu with the holders of shares of Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock. In the event that full dividends are not paid under Section 2(a) to the holders of
all outstanding shares of Series B Preferred Stock so entitled to such payment and funds available for payment of dividends shall be 

 
insufficient to permit payment in full to the holders of shares of Series B Preferred Stock and any other class or series of stock of the Corporation ranking
on parity with the Series B Preferred Stock, including the Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock, the full preferential amounts to which they are then entitled, then the entire amount available for payment
of dividends shall be distributed, first, ratably among all holders of Series B Preferred Stock, Series A Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock and any other class or series of stock ranking with respect to
dividends on parity with the Series B Preferred Stock in proportion to the full amount to which they would otherwise be respectively entitled and, second, only after the holders of Series B Preferred Stock, Series A Preferred Stock, Series C
Preferred Stock and Series D Preferred Stock and any other class or series of stock ranking with respect to dividends on parity with the Series B Preferred Stock have received the full amount of dividends to which they were entitled, ratably among
all holders of other Preferred Stock and Common Stock ranking junior to the Series B Preferred Stock in proportion to the full amount to which they would otherwise be respectively entitled. 
 (3) Voting. 
 a. Voting
Rights. Except as otherwise provided herein or as otherwise required by law, each holder of the shares of Series B Preferred Stock shall have the right to the number of votes equal to the number of Conversion Shares then issuable upon conversion
of the Series B Preferred Stock held by such holder in all matters as to which stockholders are required or permitted to vote, and with respect to such vote, such holder shall have full voting rights and powers equal to the voting rights and powers
of the holders of Common Stock, and shall be entitled, notwithstanding any provision in these Articles of Incorporation, to vote, together with the holders of Common Stock and with the holders of any other series of Preferred Stock, which by its
terms and/or by statute is entitled to vote on all matters to which holders of Common Stock are required or permitted to vote, as a single class, with respect to any question upon which holders of Common Stock have the right to vote. To the extent
permitted under applicable corporate law, but subject to Section 3(b) below, the Corporation’s stockholders may take action by the affirmative vote of a majority of all stockholders of this Corporation entitled to vote on an action.

 b. Limitations on Corporate Actions. Notwithstanding anything to the contrary in Section 3(a) above, so long as at
least twenty percent (20%) of the shares of Series B Preferred Stock issued and outstanding on the Original Issue Date remain issued and outstanding, the Corporation shall not, without the written consent or affirmative vote of the holders of
at least a majority of the then-outstanding shares of Series B Preferred Stock consenting or voting (as the case may be) as a separate class from the Common Stock, either directly or by amendment, merger, consolidation or otherwise: 
 (i) amend or otherwise restate its articles of incorporation in any manner that adversely affects the rights of the holders of Series B Preferred Stock;
or 
 (ii) alter or change adversely the voting or other powers, preferences, rights, privileges or restrictions of the Series B Preferred
Stock contained herein. 
 (4) Liquidation, Dissolution or Winding-Down. 
 a. Payments to Holders of Series B Preferred Stock. Upon any Liquidation of the Corporation, the holders of the shares of Series B Preferred
Stock shall rank pari passu with the holders of the Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock and shall be paid in cash, before any payment shall be paid to the holders of Common Stock, or any
other Junior Stock, an amount for each share of Series B Preferred Stock held by such holder equal to the sum of (1) the Series B Stated Value thereof and (2) an amount equal to dividends accrued but unpaid thereon, 

 
computed to the date payment thereof is made available. If, upon such Liquidation of the Corporation, the assets to be distributed among the holders of
shares of Series B Preferred Stock and any class or series of stock ranking on parity with the Series B Preferred Stock, including the Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock, shall be insufficient to permit
payment to the holders of the Series B Preferred Stock, Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock and any other class or series of stock ranking on liquidation on parity with the Series B Preferred Stock, the
full preferential amount to which they shall be entitled, the holders of shares of Series B Preferred Stock, Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock and any other class or series of stock ranking on
liquidation on parity with the Series B Preferred Stock shall share ratably in any distribution of the remaining assets available for distribution in proportion to the respective amounts that would otherwise be payable in respect of the shares held
by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. 
 b. Payments to Holders of
Junior Stock. After the payment of all preferential amounts required to be paid to the holders of the Series B Preferred Stock, Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock and any other class or series of
stock of the Corporation ranking on liquidation senior to or on parity with the Series B Preferred Stock, the holders of shares of Junior Stock then outstanding shall be entitled to receive the remaining assets of the Corporation available for
distribution to its stockholders as otherwise set forth in the Corporation’s articles of incorporation. 
 (5) Conversion. The
holders of Series B Preferred Stock shall have the conversion rights as follows: 
 a. Right to Convert. Each share of Series B
Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the Original Issue Date, and without the payment of additional consideration by the holder thereof, into such number of fully-paid and nonassessable shares
of Common Stock as is determined by dividing (1) the sum of (i) the Series B Stated Value per share and (ii) all dividends accrued and unpaid on each such share to the date such share is converted, whether or not declared, and all
other dividends declared and unpaid on each such share through the date of actual conversion, by (2) the Series B Conversion Price in effect at the time of conversion. The “Series B Conversion Price” shall be $0.252148;
provided, however, that the Series B Conversion Price, and the rate at which shares of Series B Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided in Section 6. Shares of Series B
Preferred Stock converted into Common Stock or redeemed in accordance with the terms hereof shall be canceled and shall not be reissued. 
 b. Holders shall effect conversions by providing the Corporation with a Notice of Conversion setting forth the Conversion Date. To effect conversions of shares of Series B Preferred Stock, a holder shall not be required to surrender the
certificate(s) representing such shares of Series B Preferred Stock to the Corporation unless all of the shares of Series B Preferred Stock represented thereby are so converted, in which case such holder shall deliver the certificate representing
such shares of Series B Preferred Stock promptly following the Conversion Date at issue. Certificates representing the Series B Preferred Stock shall have the following legend: 
 THE HOLDER AND ANY ASSIGNEE OR TRANSFEREE, BY ACCEPTANCE OF THIS STOCK CERTIFICATE, ACKNOWLEDGE AND AGREE THAT, PURSUANT TO SECTION 5.B. OF THE
CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES B VOTING CONVERTIBLE PREFERRED STOCK, THE NUMBER OF SHARES REFLECTED ON THE FACE OF THIS CERTIFICATE MAY NOT BE THE ACTUAL NUMBER OF SHARES HELD BY THE HOLDER OR 

 
ASSIGNEE. PLEASE INQUIRE WITH THE CORPORATION AS TO THE ACTUAL NUMBER OF SHARES EVIDENCED BY THIS CERTIFICATE. 
 c. Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Series B Preferred Stock. In lieu of any
fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board of Directors, or
round-up to the next whole number of shares, at the Corporation’s option. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series B Preferred Stock the
holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. 
 d.
Reservation of Shares Issuable Upon Conversion. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the
Series B Preferred Stock and payment of dividends on the Series B Preferred Stock, each as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the holders of the Series B Preferred Stock,
not less than such aggregate number of shares of the Common Stock as shall be issuable upon the conversion of all outstanding shares of Series B Preferred Stock and payment of dividends hereunder. The Corporation covenants that all shares of Common
Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable. 
 (6) Certain
Adjustments. 
 a. Stock Dividends and Stock Splits. If the Corporation, at any time while this Series B Preferred Stock is
outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any
shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, this Series B Preferred Stock or the Series A Preferred Stock, Series C Preferred Stock or Series D Preferred Stock or any other class or series of
stock ranking with respect to dividends on parity with the Series B Preferred Stock); (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding
shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Series B Conversion Price shall be multiplied by
a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock
outstanding immediately after such event. Any adjustment made pursuant to this Section 6(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. 
 b.
Fundamental Transaction. If, at any time while this Series B Preferred Stock is outstanding the Corporation effects a Fundamental Transaction, then, upon any subsequent conversion of this Series B Preferred Stock, the holders shall have the
right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the Alternate Consideration. For purposes of any such conversion, the determination
of the Series B Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Corporation shall apportion the Series B Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative 

 
value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to
be received in a Fundamental Transaction, then the holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series B Preferred Stock following such Fundamental Transaction. To the extent
necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall amend and restate its articles of incorporation or amend its articles of incorporation by filing an
appropriate certificate of designation with the same terms and conditions and issue to the holders new preferred stock consistent with the foregoing provisions and evidencing the holders’ right to convert such preferred stock into Alternate
Consideration. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 6(b) and ensuring that
this Series B Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. 
 E. Series C Voting Convertible Preferred Stock. Of the shares of Preferred Stock authorized hereunder, there is hereby created a series of Preferred Stock designated “Series C Voting Convertible
Preferred Stock” (hereinafter “Series C Preferred Stock”). All Capitalized terms used in this Article III, Section E without definition shall have the respective meanings ascribed to such terms in Article III, Section G.
The number of shares constituting such series is Thirteen Million Nine Hundred Fifty Thousand (13,950,000). The Series C Preferred Stock shall have the following rights, preferences, powers, privileges, restrictions, qualifications and limitations:

 (1) Stated Value. The par value of each issued share of Series C Preferred Stock shall be $.0001 per share, and the stated value of
each issued share of Series C Preferred Stock shall be deemed to be One Dollar ($1.00) (the “Series C Stated Value”), subject to increase set forth in Section 2. 
 (2) Dividends. 
 a. Dividends on
Series C Preferred Stock. The holders of shares of Series C Preferred Stock shall be entitled to receive, and the Corporation shall pay, a cumulative dividend for each such share at a rate per annum equal to ten percent (10%) of the Series
C Stated Value, payable, beginning on June 30, 2009, semi-annually on June 30 and December 31 and on each Conversion Date (with respect only to Series C Preferred Stock being converted) (each such date, a “Series C Dividend
Payment Date”) (if any Series C Dividend Payment Date is not a Trading Day, the applicable payment shall be due on the next succeeding Trading Day), by one of the following methods, as selected by the Corporation in its sole discretion:
(i) in cash, to the extent funds are legally available therefor in accordance with applicable corporate law; or (ii) in-kind, with shares of Common Stock, which such shares shall be valued solely for such purpose at a ten percent
(10%) discount to average VWAP for the 5 consecutive Trading Days ending on the Trading Day that is immediately prior to the applicable Series C Dividend Payment Date. Notwithstanding the foregoing, [A] if there are insufficient shares of
Common Stock authorized and available for issuance to pay the dividend, then the Corporation shall make the dividend payment pursuant to Section 2(a)(i) above, and [B] if funds are not legally available for payment of the dividend in
accordance with applicable corporate law, then, at the election of such holder, such dividends shall accrue to the next Series C Dividend Payment Date (subject to Section 2(b) below) or shall be accredited to, and increase, the
outstanding Series C Stated Value. Dividends on the Series C Preferred Stock shall be calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, shall accrue daily commencing on the Original Issue Date, and shall be
deemed to accrue from such date whether or not earned or declared and whether or not there are profits, surplus or other funds of the Corporation legally available for the payment of dividends. Except as otherwise provided herein, if at any time the
Corporation pays dividends partially in cash and partially in shares, then such payment shall 

 
be distributed ratably among the holders based upon the number of shares of Series C Preferred Stock held by each holder on such Series C Dividend Payment
Date. 
 b. Priority of Payment. Upon the payment of any dividend pursuant to Section 2(a), the holders of shares of
Series C Preferred Stock shall rank pari passu with the holders of shares of Series A Preferred Stock, Series B Preferred Stock and Series D Preferred Stock. In the event that full dividends are not paid under Section 2(a)
to the holders of all outstanding shares of Series C Preferred Stock so entitled to such payment and funds available for payment of dividends shall be insufficient to permit payment in full to the holders of shares of Series C Preferred Stock and
any other class or series of stock of the Corporation ranking on parity with the Series C Preferred Stock, including the Series A Preferred Stock, Series B Preferred Stock and Series D Preferred Stock, all such stock of the full preferential amounts
to which they are then entitled, then the entire amount available for payment of dividends shall be distributed, first, ratably among all holders of Series C Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series D Preferred
Stock and any other class or series of stock ranking with respect to dividends on parity with the Series C Preferred Stock, in proportion to the full amount to which they would otherwise be respectively entitled and, second, only after the holders
of Series C Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series D Preferred Stock and any other class or series of stock ranking with respect to dividends on parity with the Series C Preferred Stock have received the full
amount of dividends to which they were entitled, ratably among all holders of other Preferred Stock and Common Stock ranking junior to the Series C Preferred Stock in proportion to the full amount to which they would otherwise be respectively
entitled. 
 (3) Voting. 
 a. Voting Rights. Except as otherwise provided herein or as otherwise required by law, each holder of the shares of Series C Preferred Stock shall have the right to the number of votes equal to the number of Conversion Shares then
issuable upon conversion of the Series C Preferred Stock, without regard to the limitations set forth in Section 5(f) below, held by such holder in all matters as to which stockholders are required or permitted to vote, and with respect
to such vote, such holder shall have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, and shall be entitled, notwithstanding any provision in these Articles of Incorporation, to vote, together with
the holders of Common Stock and with the holders of any other series of Preferred Stock, which by its terms and/or by statute is entitled to vote on all matters to which holders of Common Stock are required or permitted to vote, as a single class,
with respect to any question upon which holders of Common Stock have the right to vote. To the extent permitted under applicable corporate law, but subject to Section 3(b) below, the Corporation’s stockholders may take action by the
affirmative vote of a majority of all stockholders of this Corporation entitled to vote on an action. 
 b. Limitations on Corporate
Actions. Notwithstanding anything to the contrary in Section 3(a) above, so long as at least twenty percent (20%) of the shares of Series C Preferred Stock issued and outstanding on the Original Issue Date remain issued and
outstanding, the Corporation shall not, without the written consent or affirmative vote of the holders of at least a majority of the then-outstanding shares of Series C Preferred Stock consenting or voting (as the case may be) as a separate class
from the Common Stock, either directly or by amendment, merger, consolidation or otherwise: 
 (i) amend or otherwise restate its articles of
incorporation in any manner that adversely affects the rights of the holders of Series C Preferred Stock; 
 (ii) alter or change adversely
the voting or other powers, preferences, rights, privileges, or restrictions of the Series C Preferred Stock contained herein; 

 (iii) increase the authorized number of shares of Preferred Stock or the Series A Preferred Stock,
Series B Preferred Stock or Series D Preferred Stock; 
 (iv) redeem, purchase or otherwise acquire directly or indirectly any Junior Stock
or any shares pari passu with the Series C Preferred Stock; 
 (v) directly or indirectly pay or declare any dividend or
make any distribution in respect of, any Junior Stock, or set aside any monies for the purchase or redemption (through a sinking fund or otherwise) of any Junior Stock or any shares pari passu with the Series C Preferred Stock;

 (vi) authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a Liquidation senior to or
otherwise pari passu with the Series C Preferred Stock; or 
 (vii) enter into any agreement with respect to any of the
foregoing. 
 (4) Liquidation, Dissolution or Winding-Down. 
 a. Payments to Holders of Series C Preferred Stock. Upon any Liquidation of the Corporation, the holders of the shares of Series C Preferred Stock
shall rank pari passu with the holders of the Series A Preferred Stock, Series B Preferred Stock and Series D Preferred Stock and shall be paid in cash, before any payment shall be paid to the holders of Common Stock, or any other
Junior Stock, an amount for each share of Series C Preferred Stock held by such holder equal to the sum of (1) the Series C Stated Value thereof and (2) an amount equal to dividends accrued but unpaid thereon, computed to the date payment
thereof is made available. If, upon such Liquidation of the Corporation, the assets to be distributed among the holders of shares of Series C Preferred Stock and any class or series of stock ranking on parity with the Series C Preferred Stock,
including the Series A Preferred Stock, Series B Preferred Stock and Series D Preferred Stock, shall be insufficient to permit payment to the holders of Series C Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series D
Preferred Stock and any other class or series of stock ranking on liquidation on parity with the Series C Preferred Stock, the full preferential amount to which they shall be entitled, the holders of shares of Series C Preferred Stock, Series A
Preferred Stock, Series B Preferred Stock and Series D Preferred Stock and any other class or series of stock ranking on liquidation on parity with the Series C Preferred Stock shall share ratably in any distribution of the remaining assets
available for distribution in proportion to the respective amounts that would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. 

b. Payments to Holders of Junior Stock. After the payment of all preferential amounts required to be paid to the holders of the Series C
Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series D Preferred Stock and any other class or series of stock of the Corporation ranking on liquidation senior to or on parity with the Series C Preferred Stock, the holders
of shares of Junior Stock then outstanding shall be entitled to receive the remaining assets of the Corporation available for distribution to its stockholders as otherwise set forth in the Corporation’s articles of incorporation. 
 (5) Conversion. The holders of Series C Preferred Stock shall have the conversion rights as follows: 
 a. Right to Convert. Each share of Series C Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the
Original Issue Date (subject to the 

 
limitations set forth in Section 5(f) below), and without the payment of additional consideration by the holder thereof, into such number of
fully-paid and nonassessable shares of Common Stock as is determined by dividing (1) the sum of (i) the Series C Stated Value per share and (ii) all dividends accrued and unpaid on each such share to the date such share is converted,
whether or not declared, and all other dividends declared and unpaid on each such share through the date of actual conversion, by (2) the Series C Conversion Price in effect at the time of conversion. The “Series C Conversion
Price” shall be $0.04210818; provided, however, that the Series C Conversion Price, and the rate at which shares of Series C Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided in
Section 6 below. Shares of Series C Preferred Stock converted into Common Stock or redeemed in accordance with the terms hereof shall be canceled and shall not be reissued. 
 b. Holders shall effect conversions by providing the Corporation with a Notice of Conversion setting forth the Conversion Date. To effect conversions of
shares of Series C Preferred Stock, a holder shall not be required to surrender the certificate(s) representing such shares of Series C Preferred Stock to the Corporation unless all of the shares of Series C Preferred Stock represented thereby are
so converted, in which case such holder shall deliver the certificate representing such shares of Series C Preferred Stock promptly following the Conversion Date at issue. Certificates representing the Series C Preferred Stock shall have the
following legend: 
 THE HOLDER AND ANY ASSIGNEE OR TRANSFEREE, BY ACCEPTANCE OF THIS STOCK CERTIFICATE, ACKNOWLEDGE AND AGREE THAT,
PURSUANT TO SECTION 5.B. OF THE CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES C VOTING CONVERTIBLE PREFERRED STOCK, THE NUMBER OF SHARES REFLECTED ON THE FACE OF THIS CERTIFICATE MAY NOT BE THE ACTUAL NUMBER OF SHARES HELD BY THE
HOLDER OR ASSIGNEE. PLEASE INQUIRE WITH THE CORPORATION AS TO THE ACTUAL NUMBER OF SHARES EVIDENCED BY THIS CERTIFICATE. 
 c.
Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Series C Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to
such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board of Directors, or round-up to the next whole number of shares, at the Corporation’s option. Whether or not fractional shares
would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series C Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon
such conversion. 
 d. Mechanics of Conversion. 
 (i) Delivery of Certificate Upon Conversion. Not later than the Share Delivery Date, the Corporation shall deliver, or cause to be delivered, to the converting holder a certificate or certificates which shall
be free of restrictive legends and trading restrictions (other than those which may then be required by applicable securities laws) representing the number of shares of Common Stock being acquired upon the conversion of shares of Series C Preferred
Stock. The Corporation shall, upon request of such holder, use its reasonable efforts to deliver any certificate or certificates required to be delivered by the Corporation under this section electronically through the Depository Trust Company or
another established clearing corporation performing similar functions. If in the case of any Notice of Conversion such certificate or certificates are not delivered to or as directed by the applicable holder by the Share Delivery Date, the
applicable holder shall be entitled to elect by written notice to the Corporation at any time on or before its receipt of such certificate or certificates, to rescind such Conversion Notice by written notice to the Corporation, in which event the
Corporation shall 

 
promptly return to such holder any original Series C Preferred Stock certificate delivered to the Corporation and such holder shall promptly return any
Common Stock certificates representing the shares of Series C Preferred Stock tendered for conversion to the Corporation. 
 (ii)
Obligation Absolute; Damages. The Corporation’s obligation to issue and deliver the Conversion Shares upon conversion of Series C Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any
action or inaction by a holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or
termination, or any breach or alleged breach by such holder or any other Person of any obligation to the Corporation; provided, however, that such delivery shall not operate as a waiver by the Corporation of any such action that the
Corporation may have against such holder. If the Corporation fails to deliver to a holder such certificate or certificates pursuant to this section on the fifth Trading Day after the Share Delivery Date applicable to such conversion, the Corporation
shall pay to such holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Stated Value of Series C Preferred Stock being converted, $10 per Trading Day (increasing to $20 per Trading Day on the tenth Trading Day after the
Share Delivery Date) for each Trading Day after such fifth Trading Day after the Share Delivery Date until such certificates are delivered. 
 e. Reservation of Shares Issuable Upon Conversion. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon
conversion of the Series C Preferred Stock and payment of dividends on the Series C Preferred Stock, each as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the holders of the Series
C Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable upon the conversion of all outstanding shares of Series C Preferred Stock and payment of dividends hereunder. The Corporation covenants that
all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable. 
 f. Beneficial Ownership Limitation. The Corporation shall not effect any conversion of the Series C Preferred Stock, and a holder shall not have the right to convert any portion of the Series C Preferred Stock, to the extent that,
after giving effect to the conversion set forth on the applicable Notice of Conversion, such holder (together with such holder’s Affiliates, and any other person or entity acting as a group together with such holder or any of such holder’s
Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation. To the extent that the limitation contained in this section applies, the determination of whether the Series C Preferred Stock is convertible (in relation to other
securities owned by such holder together with any Affiliates) and of how many shares of Series C Preferred Stock are convertible shall be in the sole discretion of such holder, and the submission of a Notice of Conversion shall be deemed to be such
holder’s determination of whether the shares of Series C Preferred Stock may be converted (in relation to other securities owned by such holder together with any Affiliates) and how many shares of the Series C Preferred Stock are convertible,
in each case subject to such aggregate percentage limitations. To ensure compliance with this restriction, each holder will be deemed to represent to the Corporation each time it delivers a Notice of Conversion that such Notice of Conversion has not
violated the restrictions set forth in this paragraph and the Corporation shall have no obligation to verify or confirm the accuracy of such determination. The Beneficial Ownership Limitation provisions of this section may be waived by such holder,
at the election of such holder, upon not less than sixty-one (61) days’ prior notice to the Corporation, to change the Beneficial Ownership Limitation to 9.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon conversion of Series C Preferred Stock held by the applicable holder and the provisions of this section shall continue to apply. Upon such a change by a holder of the Beneficial Ownership
Limitation from such 4.99% limitation to such 9.99% limitation, the Beneficial 

 
Ownership Limitation shall not be further waived by such holder. The limitations contained in this paragraph shall apply to a successor holder of Series C
Preferred Stock. 
 (6) Certain Adjustments. 
 a. Stock Dividends and Stock Splits. If the Corporation, at any time while this Series C Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable
in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, this
Series C Preferred Stock or the Series A Preferred Stock, Series B Preferred Stock or Series D Preferred Stock or any other class or series of stock ranking with respect to dividends on parity with the Series C Preferred Stock); (ii) subdivides
outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a
reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Series C Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any
treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this
Section 6(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of
a subdivision, combination or re-classification. 
 b. Subsequent Equity Sales. If, at any time while this Series C Preferred Stock
is outstanding, the Corporation or any Subsidiary, as applicable, sells, grants or otherwise issues any Common Stock or Common Stock Equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower
than the then Series C Conversion Price (such lower price, the “Series C Base Conversion Price” and such issuances collectively, a “Series C Dilutive Issuance”) (if the holder of the Common Stock or Common Stock
Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in
connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is lower than the Series C Conversion Price, such issuance shall be deemed to have occurred for less than the conversion price on such
date of the Series C Dilutive Issuance), then the Series C Conversion Price shall be reduced to equal the Series C Base Conversion Price. Notwithstanding the foregoing, no adjustment will be made under this Section 6(b) in connection
with an Exempt Issuance. The Corporation shall notify the holders in writing, no later than the Business Day following the issuance of any Common Stock or Common Stock Equivalents subject to this Section 6(b), indicating therein the
applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the “Series C Dilutive Issuance Notice”). For purposes of clarification, whether or not the Corporation
provides a Series C Dilutive Issuance Notice pursuant to this Section 6(b), upon the occurrence of any Series C Dilutive Issuance, the holders are entitled to receive a number of Conversion Shares based upon the Series C Base Conversion
Price on or after the date of such Series C Dilutive Issuance, regardless of whether a holder accurately refers to the Series C Base Conversion Price in the Notice of Conversion. 
 c. Subsequent Rights Offerings. If the Corporation, at any time while Series C Preferred Stock is outstanding, shall issue rights, options or
warrants to all holders of Common Stock (and not to the holders of Series C Preferred Stock) entitling them to subscribe for or purchase shares of Common Stock at a price per share less than the VWAP as of the record date described in the following
sentence, then the Series C Conversion Price shall be multiplied by a fraction, of which the 

 
denominator shall be the number of shares of the Common Stock outstanding on the date of issuance of such rights or warrants plus the number of additional
shares of Common Stock offered for subscription or purchase, and of which the numerator shall be the number of shares of the Common Stock outstanding on the date of issuance of such rights, options or warrants plus the number of shares which the
aggregate offering price of the total number of shares so offered (assuming receipt by the Corporation in full of all consideration payable upon exercise of such rights, options or warrants) would purchase at such VWAP. Such adjustment shall be made
whenever such rights, options or warrants are issued, and shall become effective immediately after the record date for the determination of stockholders entitled to receive such rights, options or warrants. 
 d. Pro Rata Distributions. If the Corporation, at any time while this Series C Preferred Stock is outstanding, distributes to all holders of
Common Stock (and not to the holders of Series C Preferred Stock) evidences of its indebtedness or assets (including cash and cash dividends) (other than stock dividends, which shall be subject to Section 6(a) and the dividends due
pursuant to Section 1 hereof), then, in each such case, the Series C Conversion Price shall be adjusted by multiplying such conversion price in effect immediately prior to the record date fixed for determination of stockholders entitled
to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which the numerator shall be such VWAP on such record date less the then fair market value at such record
date of the portion of such assets, evidence of indebtedness or rights or warrants so distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors of the Corporation in good faith. In either case the
adjustments shall be described in a statement delivered to the holders describing the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment shall be made
whenever any such distribution is made and shall become effective immediately after the record date mentioned above. 
 e. Fundamental
Transaction. If, at any time while this Series C Preferred Stock is outstanding the Corporation effects a Fundamental Transaction and a redemption of the Series C Preferred Stock, as contemplated by Section 7 is not effected, then,
upon any subsequent conversion of this Series C Preferred Stock, the holders shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental
Transaction, the Alternate Consideration. For purposes of any such conversion, the determination of the Series C Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Series C Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holders shall be given the same choice as to the
Alternate Consideration it receives upon any conversion of this Series C Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in
such Fundamental Transaction shall amend and restate its articles of incorporation or amend its articles of incorporation by filing an appropriate certificate of designation with the same terms and conditions and issue to the holders new preferred
stock consistent with the foregoing provisions and evidencing the holders’ right to convert such preferred stock into Alternate Consideration. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include
terms requiring any such successor or surviving entity to comply with the provisions of this Section 6(e) and ensuring that this Series C Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent
transaction analogous to a Fundamental Transaction. 

 f. Calculations. All calculations under this Section 6 shall be made to the nearest
cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 6, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common
Stock (excluding any treasury shares of the Corporation) issued and outstanding. 
 g. Notice to the Holders. 
 (i) Adjustment to Conversion Price. Whenever the Series C Conversion Price is adjusted pursuant to any provision of this Section 6,
the Corporation shall promptly mail to each holder a notice setting forth the conversion price after such adjustment and setting forth a brief statement of the facts requiring such adjustment. 
 (ii) Notice to Allow Conversion by Holder. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to
subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the Common Stock, any consolidation or
merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or
(E) the Corporation shall authorize the Liquidation of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of this Series C Preferred Stock, and shall
cause to be delivered to each holder at its last address as it shall appear upon the stock books of the Corporation, at least ten (10) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to
such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as
of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. The holder is entitled to convert the
Series C Preferred Stock (or any part hereof) during the ten (10) day period commencing on the date of such notice through the effective date of the event triggering such notice. 
 (7) Redemption Upon Triggering Events. At any time after the occurrence of a Triggering Event, but within thirty (30) days after the receipt
by the Corporation of a written request from the holders of not less than a majority of the then outstanding shares of Series C Preferred Stock, Series A Preferred Stock and Series D Preferred Stock, voting together as a single class, that all or
some of such stockholders’ shares be redeemed, and concurrently with the surrender by such holders of the certificates representing such shares, the Corporation shall, to the extent it may legally do so, redeem the shares of Series C Preferred
Stock specified in such request by paying such holder in cash, a sum equal to the Series C Stated Value, plus all accrued and unpaid dividends (the “Series C Triggering Redemption Amount). For any redemption effected pursuant to this
Section 7, the holders of Series C Preferred Stock shall rank pari passu with the holders of Series A Preferred Stock and Series D Preferred Stock. If the Corporation does not have sufficient funds legally available to
satisfy the Series C Triggering Redemption Amount and of any other class or series of stock to be redeemed upon the occurrence of a Triggering Event, including the Series A Preferred Stock and Series D Preferred Stock, the Corporation shall redeem

 
a pro-rata portion of each holder’s redeemable shares of such stock out of funds legally available therefor, based on the respective amounts that would
otherwise be payable in respect of the shares to be redeemed if the legally available funds were sufficient to redeem all such shares, and shall redeem the remaining shares to have been redeemed as soon as practicable after the Corporation has funds
legally available therefor. If the Corporation fails to pay in full the Series C Triggering Redemption Amount hereunder on the date such amount is due in accordance with this section, the Corporation will pay interest thereon at a rate equal to the
lesser of eighteen percent (18%) per annum or the maximum rate permitted by applicable law, accruing daily from such date until the Series C Triggering Redemption Amount, plus all such interest thereon, is paid in full. For purposes of this
section, a share of Series C Preferred Stock is outstanding until such date as the applicable holder has been paid the Series C Triggering Redemption Amount in cash. 
 F. Series D Voting Convertible Preferred Stock. Of the shares of Preferred Stock authorized hereunder, there is hereby created a series of Preferred Stock designated “Series D Voting Convertible
Preferred Stock” (hereinafter “Series D Preferred Stock”). All Capitalized terms used in this Article III, Section F without definition shall have the respective meanings ascribed to such terms in Article III, Section G.
The number of shares constituting such series is Seven Hundred Ninety-Eight Thousand Nine Hundred Six (798,906). The Series D Preferred Stock shall have the following rights, preferences, powers, privileges, restrictions, qualifications and
limitations: 
 (1) Stated Value. The par value of each issued share of Series D Preferred Stock shall be $.0001 per share, and the
stated value of each issued share of Series D Preferred Stock shall be deemed to be Ten Dollars ($10.00) (the “Series D Stated Value”), subject to increase set forth in Section 2. 
 (2) Dividends. 
 a. Dividends on
Series D Preferred Stock. The holders of shares of Series D Preferred Stock shall be entitled to receive, and the Corporation shall pay, a cumulative dividend for each such share at a rate per annum equal to ten percent (10%) of the Series
D Stated Value, payable, beginning on June 30, 2009, semi-annually on June 30 and December 31 and on each Conversion Date (with respect only to Series D Preferred Stock being converted) (each such date, a “Series D Dividend
Payment Date”) (if any Series D Dividend Payment Date is not a Trading Day, the applicable payment shall be due on the next succeeding Trading Day), by one of the following methods, as selected by the Corporation in its sole discretion:
(i) in cash, to the extent funds are legally available therefor in accordance with applicable corporate law; or (ii) in-kind, with shares of Common Stock, which such shares shall be valued solely for such purpose at a ten percent
(10%) discount to average VWAP for the 5 consecutive Trading Days ending on the Trading Day that is immediately prior to the applicable Series D Dividend Payment Date. Notwithstanding the foregoing, [A] if there are insufficient shares of
Common Stock authorized and available for issuance to pay the dividend, then the Corporation shall make the dividend payment pursuant to Section 2(a)(i) above, and [B] if funds are not legally available for payment of the dividend in
accordance with applicable corporate law, then, at the election of such holder, such dividends shall accrue to the next Series D Dividend Payment Date (subject to Section 2(b) below) or shall be accredited to, and increase, the
outstanding Series D Stated Value. Dividends on the Series D Preferred Stock shall be calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, shall accrue daily commencing on the Original Issue Date, and shall be
deemed to accrue from such date whether or not earned or declared and whether or not there are profits, surplus or other funds of the Corporation legally available for the payment of dividends. Except as otherwise provided herein, if at any time the
Corporation pays dividends partially in cash and partially in shares, then such payment shall be distributed ratably among the holders based upon the number of shares of Series D Preferred Stock held by each holder on such Series D Dividend Payment
Date. 

 b. Priority of Payment. Upon the payment of any dividend pursuant to Section 2(a),
the holders of shares of Series D Preferred Stock shall rank pari passu with the holders of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock. In the event that full dividends are not paid under
Section 2(a) to the holders of all outstanding shares of Series D Preferred Stock so entitled to such payment and funds available for payment of dividends shall be insufficient to permit payment in full to the holders of shares of Series
D Preferred Stock and any other class or series of stock of the Corporation ranking on parity with the Series D Preferred Stock, including the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, all such stock of the
full preferential amounts to which they are then entitled, then the entire amount available for payment of dividends shall be distributed, first, ratably among all holders of Series D Preferred Stock, Series A Preferred Stock, Series B Preferred
Stock and Series C Preferred Stock and any other class or series of stock ranking with respect to dividends on parity with the Series D Preferred Stock in proportion to the full amount to which they would otherwise be respectively entitled and,
second, only after the holders of Series D Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock and any other class or series of stock ranking with respect to dividends on parity with the Series D
Preferred Stock have received the full amount of dividends to which they were entitled, ratably among all holders of other Preferred Stock and Common Stock ranking junior to the Series D Preferred Stock in proportion to the full amount to which they
would otherwise be respectively entitled. 
 (3) Voting. 
 a. Voting Rights. Except as otherwise provided herein or as otherwise required by law, each holder of the shares of Series D Preferred Stock shall
have the right to the number of votes equal to the number of Conversion Shares then issuable upon conversion of the Series D Preferred Stock, without regard to the limitations set forth in Section 5(f) below, held by such holder in all
matters as to which stockholders are required or permitted to vote, and with respect to such vote, such holder shall have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, and shall be entitled,
notwithstanding any provision in these Articles of Incorporation, to vote, together with the holders of Common Stock and with the holders of any other series of Preferred Stock, which by its terms and/or by statute is entitled to vote on all matters
to which holders of Common Stock are required or permitted to vote, as a single class, with respect to any question upon which holders of Common Stock have the right to vote. To the extent permitted under applicable corporate law, but subject to
Section 3(c) below, the Corporation’s stockholders may take action by the affirmative vote of a majority of all stockholders of this Corporation entitled to vote on an action. 
 b. So long as fifty percent (50%) of the shares of Series D Preferred Stock issued and outstanding on the Original Issue Date remain issued and
outstanding, the holders of record of the shares of Series D Preferred Stock, exclusively and as a separate class, shall be entitled to elect four (4) directors of the Corporation (the “Series D Directors”) by affirmative vote
of the holders of a majority of the then-outstanding shares of the Series D Preferred Stock consenting or voting (as the case may be), given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written
consent of such stockholders. Any director elected pursuant to this Section 3(b) may be removed without cause by, and only by, affirmative vote of the holders of a majority of the then-outstanding shares of the Series D Preferred Stock
consenting or voting (as the case may be) as a separate class from the Common Stock, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of such stockholders. The holders of record of
the shares of Common Stock and of any other class or series of voting stock (including the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock), exclusively and voting together as a single class,
shall, subject to any other rights of any additional series of Preferred Stock that may be established from time to time, be entitled to elect the balance of the total number of directors of the Corporation. At any meeting held for the purpose
of electing a director, the presence in person or by proxy of the holders of a 

 
majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such
director. A vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected
by the holders of such class or series pursuant to this Section 3(b). 
 c. Limitations on Corporate Actions.
Notwithstanding anything to the contrary in Section 3(a) above, so long as at least twenty percent (20%) of the shares of Series D Preferred Stock issued and outstanding on the Original Issue Date remain issued and outstanding, the
Corporation shall not, without the written consent or affirmative vote of the holders of at least a majority of the then-outstanding shares of Series D Preferred Stock consenting or voting (as the case may be) as a separate class from the Common
Stock, either directly or by amendment, merger, consolidation or otherwise: 
 (i) amend or otherwise restate its articles of incorporation
in any manner that adversely affects the rights of the holders of Series D Preferred Stock; 
 (ii) alter or change adversely the voting or
other powers, preferences, rights, privileges, or restrictions of the Series D Preferred Stock contained herein; 
 (iii) increase the
authorized number of shares of Preferred Stock or the Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock; 
 (iv) redeem, purchase or otherwise acquire directly or indirectly any Junior Stock or any shares pari passu with the Series D Preferred Stock; 
 (v) directly or indirectly pay or declare any dividend or make any distribution in respect of, any Junior Stock, or set aside any monies for the
purchase or redemption (through a sinking fund or otherwise) of any Junior Stock or any shares pari passu with the Series D Preferred Stock; 
 (vi) authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a Liquidation senior to or otherwise pari passu with the Series D Preferred Stock; or

 (vii) enter into any agreement with respect to any of the foregoing. 
 (4) Liquidation, Dissolution or Winding-Down. 
 a. Payments to Holders of Series D Preferred Stock. Upon any Liquidation of the Corporation, the holders of the shares of Series D Preferred Stock shall rank pari passu with the holders of the Series A
Preferred Stock, Series B Preferred Stock and Series C Preferred Stock and shall be paid in cash, before any payment shall be paid to the holders of Common Stock, or any other Junior Stock, an amount for each share of Series D Preferred Stock held
by such holder equal to the sum of (1) the Series D Stated Value thereof and (2) an amount equal to dividends accrued but unpaid thereon, computed to the date payment thereof is made available. If, upon such Liquidation of the Corporation,
the assets to be distributed among the holders of shares of Series D Preferred Stock and any class or series of stock ranking on parity with the Series D Preferred Stock, including the Series A Preferred Stock, Series B Preferred Stock and Series C
Preferred Stock, shall be insufficient to permit payment to the holders of Series D Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock and any other class or series of stock ranking on liquidation on
parity with the Series D 

 
Preferred Stock, the full preferential amount to which they shall be entitled, the holders of shares of Series D Preferred Stock, Series A Preferred Stock,
Series B Preferred Stock and Series C Preferred Stock and any other class or series of stock ranking on liquidation on parity with the Series D Preferred Stock shall share ratably in any distribution of the remaining assets available for
distribution in proportion to the respective amounts that would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. 
 b. Payments to Holders of Junior Stock. After the payment of all preferential amounts required to be paid to the holders of the Series D
Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock and any other class or series of stock of the Corporation ranking on liquidation senior to or on parity with the Series D Preferred Stock, the holders
of shares of Junior Stock then outstanding shall be entitled to receive the remaining assets of the Corporation available for distribution to its stockholders as otherwise set forth in the Corporation’s articles of incorporation. 
 (5) Conversion. The holders of Series D Preferred Stock shall have the conversion rights as follows: 
 a. Right to Convert. Each share of Series D Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the
Original Issue Date (subject to the limitations set forth in Section 5(f) below), and without the payment of additional consideration by the holder thereof, into such number of fully-paid and nonassessable shares of Common Stock as is
determined by dividing (1) the sum of (i) the Series D Stated Value per share and (ii) all dividends accrued and unpaid on each such share to the date such share is converted, whether or not declared, and all other dividends declared
and unpaid on each such share through the date of actual conversion, by (2) the Series D Conversion Price in effect at the time of conversion. The “Series D Conversion Price” shall be ten cents ($0.10); provided, however, that
the Series D Conversion Price, and the rate at which shares of Series D Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided in Section 6 below. Shares of Series D Preferred Stock
converted into Common Stock or redeemed in accordance with the terms hereof shall be canceled and shall not be reissued. 
 b. Holders shall
effect conversions by providing the Corporation with a Notice of Conversion setting forth the Conversion Date. To effect conversions of shares of Series D Preferred Stock, a holder shall not be required to surrender the certificate(s) representing
such shares of Series D Preferred Stock to the Corporation unless all of the shares of Series D Preferred Stock represented thereby are so converted, in which case such holder shall deliver the certificate representing such shares of Series D
Preferred Stock promptly following the Conversion Date at issue. Certificates representing the Series D Preferred Stock shall have the following legend: 
 THE HOLDER AND ANY ASSIGNEE OR TRANSFEREE, BY ACCEPTANCE OF THIS STOCK CERTIFICATE, ACKNOWLEDGE AND AGREE THAT, PURSUANT TO SECTION 5.B. OF THE CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES D
VOTING CONVERTIBLE PREFERRED STOCK, THE NUMBER OF SHARES REFLECTED ON THE FACE OF THIS CERTIFICATE MAY NOT BE THE ACTUAL NUMBER OF SHARES HELD BY THE HOLDER OR ASSIGNEE. PLEASE INQUIRE WITH THE CORPORATION AS TO THE ACTUAL NUMBER OF SHARES EVIDENCED
BY THIS CERTIFICATE. 
 c. Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Series
D Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair 

 
market value of a share of Common Stock as determined in good faith by the Board of Directors, or round-up to the next whole number of shares, at the
Corporation’s option. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series D Preferred Stock the holder is at the time converting into Common Stock and
the aggregate number of shares of Common Stock issuable upon such conversion. 
 d. Mechanics of Conversion. 
 (i) Delivery of Certificate Upon Conversion. Not later than the Share Delivery Date, the Corporation shall deliver, or cause to be delivered, to
the converting holder a certificate or certificates which shall be free of restrictive legends and trading restrictions (other than those which may then be required by applicable securities laws) representing the number of shares of Common Stock
being acquired upon the conversion of shares of Series D Preferred Stock. The Corporation shall, upon request of such holder, use its reasonable efforts to deliver any certificate or certificates required to be delivered by the Corporation under
this section electronically through the Depository Trust Company or another established clearing corporation performing similar functions. If in the case of any Notice of Conversion such certificate or certificates are not delivered to or as
directed by the applicable holder by the Share Delivery Date, the applicable holder shall be entitled to elect by written notice to the Corporation at any time on or before its receipt of such certificate or certificates, to rescind such Conversion
Notice by written notice to the Corporation, in which event the Corporation shall promptly return to such holder any original Series D Preferred Stock certificate delivered to the Corporation and such holder shall promptly return any Common Stock
certificates representing the shares of Series D Preferred Stock tendered for conversion to the Corporation. 
 (ii) Obligation Absolute;
Damages. The Corporation’s obligation to issue and deliver the Conversion Shares upon conversion of Series D Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a
holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any
breach or alleged breach by such holder or any other Person of any obligation to the Corporation; provided, however, that such delivery shall not operate as a waiver by the Corporation of any such action that the Corporation may have
against such holder. If the Corporation fails to deliver to a holder such certificate or certificates pursuant to this section on the fifth Trading Day after the Share Delivery Date applicable to such conversion, the Corporation shall pay to such
holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Stated Value of Series D Preferred Stock being converted, $10 per Trading Day (increasing to $20 per Trading Day on the tenth Trading Day after the Share Delivery Date)
for each Trading Day after such fifth Trading Day after the Share Delivery Date until such certificates are delivered. 
 e. Reservation
of Shares Issuable Upon Conversion. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series D
Preferred Stock and payment of dividends on the Series D Preferred Stock, each as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the holders of the Series D Preferred Stock, not less
than such aggregate number of shares of the Common Stock as shall be issuable upon the conversion of all outstanding shares of Series D Preferred Stock and payment of dividends hereunder. The Corporation covenants that all shares of Common Stock
that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable. 
 f. Beneficial Ownership
Limitation. The Corporation shall not effect any conversion of the Series D Preferred Stock, and a holder shall not have the right to convert any portion of 

 
the Series D Preferred Stock, to the extent that, after giving effect to the conversion set forth on the applicable Notice of Conversion, such holder
(together with such holder’s Affiliates, and any other person or entity acting as a group together with such holder or any of such holder’s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation. To the extent
that the limitation contained in this section applies, the determination of whether the Series D Preferred Stock is convertible (in relation to other securities owned by such holder together with any Affiliates) and of how many shares of Series D
Preferred Stock are convertible shall be in the sole discretion of such holder, and the submission of a Notice of Conversion shall be deemed to be such holder’s determination of whether the shares of Series D Preferred Stock may be converted
(in relation to other securities owned by such holder together with any Affiliates) and how many shares of the Series D Preferred Stock are convertible, in each case subject to such aggregate percentage limitations. To ensure compliance with this
restriction, each holder will be deemed to represent to the Corporation each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation shall have no
obligation to verify or confirm the accuracy of such determination. The Beneficial Ownership Limitation provisions of this section may be waived by such holder, at the election of such holder, upon not less than sixty-one (61) days’ prior
notice to the Corporation, to change the Beneficial Ownership Limitation to 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon conversion of Series D Preferred
Stock held by the applicable holder and the provisions of this section shall continue to apply. Upon such a change by a holder of the Beneficial Ownership Limitation from such 4.99% limitation to such 9.99% limitation, the Beneficial Ownership
Limitation shall not be further waived by such holder. The limitations contained in this paragraph shall apply to a successor holder of Series D Preferred Stock. 
 (6) Certain Adjustments. 
 a. Stock Dividends and Stock Splits. If the Corporation, at any
time while this Series D Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for
avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, this Series D Preferred Stock or the Series A Preferred Stock, Series B Preferred Stock or Series C Preferred
Stock or any other class or series of stock ranking with respect to dividends on parity with the Series D Preferred Stock); (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way
of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Series D
Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 6(a) shall become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. 
 b. Subsequent Equity Sales. If, at any time while this Series D Preferred Stock is outstanding, the Corporation or any Subsidiary, as applicable, sells, grants or otherwise issues any Common Stock or Common
Stock Equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then Series D Conversion Price (such lower price, the “Series D Base Conversion Price” and such
issuances collectively, a “Series D Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating
conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in 

 
connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is lower than the Series D Conversion
Price, such issuance shall be deemed to have occurred for less than the conversion price on such date of the Series D Dilutive Issuance), then the Series D Conversion Price shall be reduced to equal the Series D Base Conversion Price.
Notwithstanding the foregoing, no adjustment will be made under this Section 6(b) in connection with an Exempt Issuance. The Corporation shall notify the holders in writing, no later than the Business Day following the issuance of any
Common Stock or Common Stock Equivalents subject to this Section 6(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the
“Series D Dilutive Issuance Notice”). For purposes of clarification, whether or not the Corporation provides a Series D Dilutive Issuance Notice pursuant to this Section 6(b), upon the occurrence of any Series D Dilutive
Issuance, the holders are entitled to receive a number of Conversion Shares based upon the Series D Base Conversion Price on or after the date of such Series D Dilutive Issuance, regardless of whether a holder accurately refers to the Series D Base
Conversion Price in the Notice of Conversion. 
 c. Subsequent Rights Offerings. If the Corporation, at any time while Series D
Preferred Stock is outstanding, shall issue rights, options or warrants to all holders of Common Stock (and not to the holders of Series D Preferred Stock) entitling them to subscribe for or purchase shares of Common Stock at a price per share less
than the VWAP as of the record date described in the following sentence, then the Series D Conversion Price shall be multiplied by a fraction, of which the denominator shall be the number of shares of the Common Stock outstanding on the date of
issuance of such rights or warrants plus the number of additional shares of Common Stock offered for subscription or purchase, and of which the numerator shall be the number of shares of the Common Stock outstanding on the date of issuance of such
rights, options or warrants plus the number of shares which the aggregate offering price of the total number of shares so offered (assuming receipt by the Corporation in full of all consideration payable upon exercise of such rights, options or
warrants) would purchase at such VWAP. Such adjustment shall be made whenever such rights, options or warrants are issued, and shall become effective immediately after the record date for the determination of stockholders entitled to receive such
rights, options or warrants. 
 d. Pro Rata Distributions. If the Corporation, at any time while this Series D Preferred Stock is
outstanding, distributes to all holders of Common Stock (and not to the holders of Series D Preferred Stock) evidences of its indebtedness or assets (including cash and cash dividends) (other than stock dividends, which shall be subject to
Section 6(a) and the dividends due pursuant to Section 1 hereof), then, in each such case, the conversion price shall be adjusted by multiplying such conversion price in effect immediately prior to the record date fixed for
determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which the numerator shall be such VWAP on such record date less the
then fair market value at such record date of the portion of such assets, evidence of indebtedness or rights or warrants so distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors of the
Corporation in good faith. In either case the adjustments shall be described in a statement delivered to the holders describing the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of
Common Stock. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above. 
 e. Fundamental Transaction. If, at any time while this Series D Preferred Stock is outstanding the Corporation effects a Fundamental Transaction and a redemption of the Series D Preferred Stock, as contemplated
by Section 7 is not effected, then, upon any subsequent conversion of this Series D Preferred Stock, the holders shall have the right to receive, for each of the Conversion Shares that would have been issuable upon such conversion
immediately prior to the occurrence of such 

 
Fundamental Transaction, the Alternate Consideration. For purposes of any such conversion, the determination of the Series D Conversion Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Series D
Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series D Preferred Stock following such Fundamental Transaction. To the
extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file amend and restate its articles of incorporation or amend its articles of incorporation by filing
an appropriate certificate of designation with the same terms and conditions and issue to the holders new preferred stock consistent with the foregoing provisions and evidencing the holders’ right to convert such preferred stock into Alternate
Consideration. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 6(e) and insuring that
this Series D Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. 
 f. Calculations. All calculations under this Section 6 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 6, the number
of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding. 
 g. Notice to the Holders. 
 (i)
Adjustment to Conversion Price. Whenever the Series D Conversion Price is adjusted pursuant to any provision of this Section 6, the Corporation shall promptly mail to each holder a notice setting forth the conversion price after
such adjustment and setting forth a brief statement of the facts requiring such adjustment. 
 (ii) Notice to Allow Conversion by
Holder. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
(C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the
Corporation shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, of any
compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or (E) the Corporation shall authorize the Liquidation of the Corporation, then, in each case, the Corporation shall cause to be filed at
each office or agency maintained for the purpose of conversion of this Series D Preferred Stock, and shall cause to be delivered to each holder at its last address as it shall appear upon the stock books of the Corporation, at least ten
(10) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if
a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the 

 
Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. The holder is entitled to convert the Series D Preferred Stock
(or any part hereof) during the ten (10) day period commencing on the date of such notice through the effective date of the event triggering such notice. 
 (7) Redemption Upon Triggering Events. At any time after the occurrence of a Triggering Event, but within thirty (30) days after the receipt by the Corporation of a written request from the holders of not
less than a majority of the then outstanding shares of Series D Preferred Stock, Series A Preferred Stock and Series C Preferred Stock, voting together as a single class, that all or some of such stockholders’ shares be redeemed, and
concurrently with the surrender by such holders of the certificates representing such shares, the Corporation shall, to the extent it may legally do so, redeem the shares of Series D Preferred Stock specified in such request by paying such holder in
cash, a sum equal to the Series D Stated Value, plus all accrued and unpaid dividends (the “Series D Triggering Redemption Amount). For any redemption effected pursuant to this Section 7, the holders of Series D Preferred
Stock shall rank pari passu with the holders of Series A Preferred Stock and Series C Preferred Stock. If the Corporation does not have sufficient funds legally available to satisfy the Series D Triggering Redemption Amount and of any other
class or series of stock to be redeemed upon the occurrence of a Triggering Event, including the Series A Preferred Stock and Series C Preferred Stock, the Corporation shall redeem a pro-rata portion of each holder’s redeemable shares of such
stock out of funds legally available therefor, based on the respective amounts that would otherwise be payable in respect of the shares to be redeemed if the legally available funds were sufficient to redeem all such shares, and shall redeem the
remaining shares to have been redeemed as soon as practicable after the Corporation has funds legally available therefor. If the Corporation fails to pay in full the Series D Triggering Redemption Amount hereunder on the date such amount is due in
accordance with this section, the Corporation will pay interest thereon at a rate equal to the lesser of eighteen percent (18%) per annum or the maximum rate permitted by applicable law, accruing daily from such date until the Series D
Triggering Redemption Amount, plus all such interest thereon, is paid in full. For purposes of this section, a share of Series D Preferred Stock is outstanding until such date as the applicable holder has been paid the Series D Triggering Redemption
Amount in cash. 
 G. Definitions. As used in this Article III, the following terms shall have the following meanings: 
 (1) “Act” shall mean the Nevada Revised Statutes, Chapter 78 (Section 78.010 et. seq.). 
 (2) “Affiliate” shall mean any Person that, directly or indirectly through one (1) or more intermediaries, controls or is
controlled by or is under common control with a Person, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a holder, any investment fund or managed account that is managed on a discretionary basis by the
same investment manager as such holder will be deemed to be an Affiliate of such holder. 
 (3) “Alternate Consideration”
shall mean the kind and amount of securities, cash or property a holder would have been entitled to receive upon the occurrence of a Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share
of Common Stock. 
 (4) “Bankruptcy Event” shall mean any of the following events: (a) the Corporation or any
Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) thereof commences a case or other proceeding under any bankruptcy, reorganization, arrangement, adjustment of debt, relief of 

 
debtors, dissolution, insolvency or Liquidation or similar law of any jurisdiction relating to the Corporation or any Subsidiary thereof; (b) there is
commenced against the Corporation or any Subsidiary thereof any such case or proceeding that is not dismissed within 60 days after commencement; (c) the Corporation or any Subsidiary thereof is adjudicated. 
 (5) “Beneficial Ownership Limitation” shall mean 4.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon conversion of the Series A Preferred Stock, the Series C Preferred Stock or the Series D Preferred Stock, as applicable, held by the respective holder. For purposes of calculating the
Beneficial Ownership Limitation, the number of shares of Common Stock beneficially owned by such holder and its Affiliates shall include the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock, the Series C
Preferred Stock or the Series D Preferred Stock, as applicable, with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted
Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock or Series D Preferred Stock, as applicable, beneficially owned by such holder or any of its Affiliates and (B) exercise or conversion of the unexercised or unconverted
portion of any other securities of the Corporation subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by such holder or any of its Affiliates. Except as set forth in the preceding
sentence, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act. For purposes of calculating the Beneficial Ownership Limitation, in determining the number of outstanding shares of Common Stock, a holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the
following: (A) the Corporation’s most recent Form 10-Q or Form 10-K, as the case may be, (B) a more recent public announcement by the Corporation or (C) a more recent notice by the Corporation or the Corporation’s transfer
agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a holder, the Corporation shall within two Trading Days confirm orally and in writing to such holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including the Series A Preferred Stock, the Series B
Preferred Stock, the Series C Preferred Stock and Series D Preferred Stock, as applicable, by such holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. 
 (6) “Business Day” shall mean any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. 
 (7) “Common Stock” shall mean the Corporation’s common stock, par value $.0001 per share. 
 (8)
“Common Stock Equivalents” shall mean any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock,
rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 
 (9) “Conversion Date” shall mean the date set forth in the Notice of Conversion, which date may not be prior to the date the applicable holder delivers the Notice of Conversion to the Corporation. If
no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion is received by the Corporation. 

 (10) “Conversion Shares” shall mean, collectively, the shares of Common Stock issuable
upon conversion of the shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock or Series D Preferred Shares, as applicable. 
 (11) “Corporation” shall mean Medical Solutions Management Inc., a Nevada corporation. 
 (12) “Exempt Issuance” shall mean: (a) shares of Common Stock or options to purchase Common Stock issued to employees, officers, directors or consultants of the Corporation pursuant to any stock or option plan duly
adopted by a majority of the non-employee members of the Board of Directors of the Corporation or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of Common Stock issued or deemed
issued as a dividend or distribution on the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock or Series D Preferred Stock; (c) shares of Common Stock issued upon exercise or conversion of the Series A Preferred Stock,
Series B Preferred Stock, Series C Preferred Stock or Series D Preferred Stock; (d) shares of Common Stock issued upon the exercise or conversion of Common Stock Equivalents outstanding on the Original Issue Date; (e) shares of Common
Stock issued or issuable by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock that is covered by Article III Sections C(6)(a), D(6)(a), E(6)(a) and F(6)(a) above; (f) securities issued pursuant
to acquisitions or strategic transactions approved by a majority of the directors, provided that any such issuance shall only be to a Person which is, itself or through its subsidiaries, an operating company in a business synergistic with the
business of the Corporation, as determined by a majority of the directors, and in which the Corporation receives benefits in addition to the investment of funds, but shall not include a transaction in which the Corporation is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities; (g) securities issued to financial institutions or lessors, pursuant to a commercial credit arrangement, equipment financing
transaction, accounts receivable financing or a similar transaction, provided that in each such instance said issuance is approved by a majority of the directors; and (h) securities sold in connection with a firm commitment underwritten public
offering of shares of Common Stock that is intended, pursuant to the Board of Directors resolution, to produce minimum proceeds (after payment of underwriter’s fees and commissions) of not less than $30,000,000. 
 (13) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 (14) “Exchange” shall mean a national securities exchange. 
 (15) “Fundamental Transaction” shall mean a transaction in which (a) the Corporation effects any merger or consolidation of the
Corporation with or into another Person, and, after giving effect to such transaction, the stockholders of the Corporation immediately prior to such transaction own less than sixty-six percent (66%) of the aggregate voting power of the
Corporation or the successor entity of such transaction (b) the Corporation effects any sale of all or substantially all of its assets in one transaction or a series of related transactions, and the stockholders of the Corporation immediately
prior to such transaction own less than sixty-six percent (66%) of the aggregate voting power of the acquiring entity immediately after the transaction (c) any tender offer or exchange offer (whether by the Corporation or another Person)
is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, (d) the Corporation effects any reclassification of the Common Stock or any compulsory share
exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property; or (e) the execution by the Corporation of an agreement to which the Corporation is a party or by which it is bound,
providing for any of the events set forth in clauses (a) through (d) herein. 

 (16) “Junior Stock” shall mean the Common Stock and all other Common Stock Equivalents
of the Corporation other than those securities which are explicitly senior or pari passu to the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock in dividend rights or
Liquidation preference. 
 (17) “Liquidation” shall mean any liquidation, dissolution or winding down of the Corporation,
whether voluntary or involuntary. 
 (18) “NASDAQ” shall mean the National Association of Securities Dealers Automated
Quotations System. 
 (19) “Notice of Conversion” shall mean a written notice that shall specify the number of shares of
Preferred Stock to be converted, the number of shares of Preferred Stock owned prior to the conversion at issue, the number of shares of Preferred Stock owned subsequent to the conversion at issue and the Conversion Date on which such conversion is
to be effected. 
 (20) “Original Issue Date” shall mean the date the Corporation initially issues the shares of Series A
Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock regardless of the number of times transfer of such share is made on the stock records maintained by or for the Corporation and regardless of the number
of certificates which may be issued to evidence such share. 
 (21) “OTCBB” shall mean the Over the Counter Bulletin Board,
or any other successor organization 
 (22) “Person” shall mean any individual, partnership, firm, corporation, association,
trust, unincorporated organization or other entity, as well as any syndicate or group that would be deemed to be a person under Section 13(d)(3) of the Exchange Act. 
 (23) “Preferred Stock” shall have the meaning set forth in Article III. 
 (24)
“Rule 144” shall mean Rule 144 promulgated by the SEC under the Securities Act. 
 (25) “SEC” shall
mean the United States Securities and Exchange Commission. 
 (26) “Securities Act” shall mean the Securities Act of 1933,
as amended, and the rules and regulations promulgated thereunder. 
 (27) “Series A Base Conversion Price” shall have the
meaning set forth in Article III, Section C(6)(b). 
 (28) “Series A Conversion Price” shall have the meaning set forth in
Article III, Section C(5)(a). 
 (29) “Series A Dilutive Issuance” shall have the meaning set forth in Article III, Section
C(6)(b). 
 (30) “Series A Dilutive Issuance Notice” shall have the meaning set forth in Article III, Section C(6)(b).

 (31) “Series A Dividend Payment Date” shall have the meaning set forth in Article III,
Section C(2)(a). 
 (32) “Series A Preferred Stock” shall have the meaning set forth in Article III, Section C. 

(33) “Series A Stated Value” shall have the meaning set forth in Article III, Section C(1). 
 (34) “Series A Triggering Redemption Amount” shall have the meaning set forth in Article III, Section C(7). 
 (35) “Series B Conversion Price” shall have the meaning set forth in Article III, Section D(5)(a). 
 (36) “Series B Dividend Payment Date” shall have the meaning set forth in Article III, Section D(2)(a). 
 (37) “Series B Preferred Stock” shall have the meaning set forth in Article III, Section D. 
 (38) “Series B Stated Value” shall have the meaning set forth in Article III, Section D(1). 
 (39) “Series C Base Conversion Price” shall have the meaning set forth in Article III, Section E(6)(b). 
 (40) “Series C Conversion Price” shall have the meaning set forth in Article III, Section E(5)(a). 
 (41) “Series C Dilutive Issuance” shall have the meaning set forth in Article III, Section E(6)(b). 
 (42) “Series C Dilutive Issuance Notice” shall have the meaning set forth in Article III, Section E(6)(b). 
 (43) “Series C Dividend Payment Date” shall have the meaning set forth in Article III, Section E(2)(a). 
 (44) “Series C Preferred Stock” shall have the meaning set forth in Article III, Section E. 
 (45) “Series C Stated Value” shall have the meaning set forth in Article III, Section E(1). 
 (46) “Series C Triggering Redemption Amount” shall have the meaning set forth in Article III, Section E(7). 
 (47) “Series D Base Conversion Price” shall have the meaning set forth in Article III, Section F(6)(b). 
 (48) “Series D Conversion Price” shall have the meaning set forth in Article III, Section F(5)(a). 

 (49) “Series D Dilutive Issuance” shall have the meaning set forth in Article III,
Section F(6)(b). 
 (50) “Series D Dilutive Issuance Notice” shall have the meaning set forth in Article III, Section
F(6)(b). 
 (51) “Series D Directors” shall have the meaning set forth in Article III, Section F(3)(b). 
 (52) “Series D Dividend Payment Date” shall have the meaning set forth in Article III, Section F(2)(a). 
 (53) “Series D Preferred Stock” shall have the meaning set forth in Article III, Section F. 
 (54) “Series D Stated Value” shall have the meaning set forth in Article III, Section F(1). 
 (55) “Series D Triggering Redemption Amount” shall have the meaning set forth in Article III, Section F(7). 
 (56) “Share Delivery Date” shall mean the fifth Trading Day following the Conversion Date. 
 (57) “Subsidiary” shall mean any corporation, association, partnership, limited liability company or other business entity of which more
than fifty percent (50%) of the total voting power is, at the time, owned or controlled, directly or indirectly, by the Corporation or one or more of the other Subsidiaries of the Corporation or a combination thereof. 
 (58) “Trading Day” shall mean a day on which the securities exchange, association, or quotation system on which shares of Common Stock
are listed or quoted for trading shall be open for business or, if the shares of Common Stock shall not be listed on such exchange, association, or quoted on a quotation system for such day, a day with respect to which trades in the United States
domestic over-the-counter market shall be reported. 
 (59) “Trading Market” shall mean the following markets or exchanges
on which the Common Stock is listed or quoted for trading on the date in question: the NASDAQ Capital Market, the American Stock Exchange, the New York Stock Exchange, the NASDAQ National Market, the OTC Bulletin Board, or “Pink Sheets”
published by Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of reporting prices). 
 (60)
“Triggering Event” shall mean any one or more of the following events (whatever the reason and whether it shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court,
or any order, rule or regulation of any administrative or governmental body): 
 a. the Corporation effects a Fundamental Transaction;

 b. the Corporation shall fail to have available a sufficient number of authorized and unreserved shares of Common Stock to issue to such
holder upon a conversion hereunder; 
 c. unless specifically addressed elsewhere in these Articles of Incorporation as a Triggering Event,
the Corporation shall fail to observe or perform any other covenant, agreement or warranty contained in these Articles of Incorporation, and such failure or breach shall not, if subject to the 

 
possibility of a cure by the Corporation, have been cured within 20 calendar days after the date on which written notice of such failure or breach shall have
been delivered; 
 d. there shall have occurred a Bankruptcy Event; or 
 e. any monetary judgment, writ or similar final process shall be entered or filed against the Corporation, any Subsidiary or any of their respective
property or other assets for greater than $250,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or unstayed for a period of 30 calendar days. 
 (61) “VWAP” of a share of Common Stock as of a particular date (the “Determination Date”) shall mean the price
determined by the first of the following clauses that applies: (a) if shares of Common Stock are traded on an Exchange, the weighted average of the closing sale price of a share of the Common Stock of the Corporation on the last five
(5) Trading Days prior to the Determination Date reported on such Exchange as reported in The Wall Street Journal (weighted with respect to the trading volume with respect to each such day); (b) if shares of Common Stock are not traded on
an Exchange but trade in the over-the-counter market and such shares are quoted on NASDAQ, the weighted average of the closing sale price of a share of the Common Stock of the Corporation on the last five (5) Trading Days prior to the
Determination Date reported on NASDAQ as reported in The Wall Street Journal (weighted with respect to the trading volume with respect to each such day); (c) if such shares are an issue for which last sale prices are not reported on NASDAQ, the
average of the closing sale price, in each case on the last five (5) Trading Days (or if the relevant price or quotation did not exist on any of such days, the relevant price or quotation on the next preceding Business Day on which there was
such a price or quotation) prior to the Determination Date as reported by the OTCBB; (d) if no closing sales price is reported for the Common Stock by the OTCBB or any other successor organization for such day, the average of the closing sale
price, in each case on the last five (5) Trading Days (or if the relevant price or quotation did not exist on any of such days, the relevant price or quotation on the next preceding Business Day on which there was such a price or quotation)
prior to the Determination Date as reported by the “pink sheets” by the Pink Sheets, LLC, or any successor organization, (e) if no closing sales price is reported for the Common Stock by the OTCBB or any other successor organization
for such day, then the average of the high and low bid and asked price of any of the market makers for the Common Stock as reported on the OTCBB or in the “pink sheets” by the Pink Sheets, LLC on the last five (5) Trading Days; or
(f) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holder and reasonably acceptable to the Corporation. 
 ARTICLE IV 
 Subject to any additional vote expressly
required by these Articles of Incorporation or the Act, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the
Corporation. 
 ARTICLE V 
 Subject to any additional vote expressly required by these Articles of Incorporation or the Act, the Corporation reserves the right to amend, alter, change or repeal any provision contained in these Articles of Incorporation, in the manner
now or hereafter prescribed by statute, and all rights conferred upon stockholders are granted subject to this reservation. 
 ARTICLE VI

 The Corporation shall indemnify and advance expenses to, in accordance with and to the full extent now or
hereafter permitted by law, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative, by reason of the fact
that he is or was a director or an officer of the Corporation (and the Corporation, in the discretion of the Board of Directors, may so indemnify a person by reason of the fact that he is or was an employee or agent of the Corporation or is or was
serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, or other enterprise for or on behalf of the Corporation) against any liability or expense (including
attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in respect thereof. Such indemnification is not exclusive of any other right to indemnification provided by law or otherwise.

 ARTICLE VII 
 The
Corporation elects not to be governed by Sections 78.411 to 78.444 of the Act and Sections 78.378 through 78.3793 of the Act. 
 ARTICLE
VIII 
 No contract or other transaction between the Corporation and any other company, whether or not a majority of the equity interest
of such other company is owned by the Corporation, and no act of the Corporation shall in any way be affected or invalidated by the fact that any of the directors of this Corporation are pecuniarily or otherwise interested in, or are directors or
officers of such other company. Any director of this Corporation, individually, or any company of which such director may be an Affiliate, may be a party to, or may be pecuniarily or otherwise interested in any contract or transaction of the
Corporation; provided, however, the fact that he or such company is so interested shall be disclosed or shall have been known to the Board of Directors of this Corporation, or a majority thereof; and any director of this Corporation who is also an
Affiliate of such other company, or who is so interested, may be counted in determining the existence of a quorum at any meeting of the Board of Directors of this Corporation that shall authorize such contract or transaction, and may vote thereat to
authorize such contract or transaction, with like force and effect as if he were not such director or officer of such other corporation or so interested. 
 [The remainder of this page is left intentionally blank.] 

 These Second Amended and Restated Articles of Incorporation were duly adopted by the Board of Directors
of the Corporation and by the stockholders holding shares in the Corporation entitling them to exercise at least a majority of the voting power as required under the Nevada Revised Statutes, Chapter 78. 
 These Second Amended and Restated Articles of Incorporation have been duly executed on this      day of
             2008. 
  

			
	MEDICAL SOLUTIONS MANAGEMENT INC.
		
	By:	 	  

		 	Lowell M. Fisher, Jr., Chief Executive OfficerSecurities Purchase Agreement

 EXHIBIT 10.2 
 SECURITIES PURCHASE AGREEMENT 
 This Securities Purchase Agreement (this
“Agreement”) is dated as of July 30, 2008 between Medical Solutions Management Inc., a Nevada corporation (the “Company”), and Vicis Capital Master Fund, a sub-trust of Vicis Capital Series Master Trust, a unit
trust organized and existing under the laws of the Cayman Islands (the “Purchaser”). 
 WHEREAS, the Purchaser is the holder
of interest bearing promissory notes in the principal amount, together with accrued interest, and has advanced the Company funds, as set forth on Exhibit A attached hereto (individually, an “Existing Debt” and collectively,
the “Existing Debts”); 
 WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to
Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 promulgated thereunder, the Company desires to issue and sell to Purchaser, and the Purchaser desires to purchase from the Company, the
securities of the Company as more fully described in Section 2.1 of this Agreement for the consideration as more fully described in Section 2.1 of this Agreement and the Company desires to issue the warrants as more fully described in
Section 2.2 of this Agreement. 
 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other
good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and Purchaser agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 1.1 Definitions. In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Series D Designations
(as defined herein), and (b) the following terms have the meanings indicated in this Section 1.1: 
 “Affiliate” means any Person that, directly or indirectly through one (1) or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under
Rule 144 under the Securities Act. With respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser.

 “Business Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in
the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. 

 “Charter Amendment” means the proposed Second Amended and Restated Articles of
Incorporation of the Company to be filed with the Nevada Secretary of State to, among other things, increase the number of authorized but unissued shares of Common Stock from 200,000,000 to 2,175,000,000 shares. 
 “Closing” means the closing of the purchase and sale of the Securities pursuant to Section 2.3. 

“Closing Date” means the Trading Day when all of the Transaction Documents have been executed and delivered by the
applicable parties thereto, and all conditions precedent to (i) the Purchaser’s obligations to pay the Cash Purchase Price and deliver and discharge the Existing Debts and (ii) the Company’s obligations to deliver the Securities
have been satisfied or waived. 
 “Commission” means the Securities and Exchange Commission. 
 “Common Stock” means the common stock of the Company, par value $.0001 per share, and any other class of securities into
which such securities may hereafter be reclassified or changed into. 
 “Common Stock Equivalents” means any
securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time
convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 
 “Disclosure Schedules” shall have the meaning ascribed to such term in Section 3.1. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 “Exempt Issuance” means: (a) shares of Common Stock or options to purchase Common Stock issued to employees, officers, directors or consultants of the Company pursuant to any stock or option plan
duly adopted by a majority of the non-employee members of the Board of Directors of the Company or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities issued upon the exercise or
exchange of or conversion of any Securities issued hereunder and/or other securities (including the stock rights set forth on Schedule 3.1(g)) exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding
on the date of this Agreement, provided that, unless set forth on Schedule 3.1(g), such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise, exchange or
conversion price of any such securities, (c) shares of Common Stock issued or deemed issued as a dividend or distribution on the Series D Convertible Preferred Stock, and/ or other securities issued and outstanding on the date of this
Agreement, provided that such stock dividend or distribution shall be issued pursuant to the terms of such other securities as of the date of this Agreement, (d) securities issued pursuant to acquisitions or strategic transactions 

  

 2 

 
approved by a majority of the directors, provided that any such issuance shall only be to a Person which is, itself or through its subsidiaries, an operating
company in a business synergistic with the business of the Company, as determined by a majority of the directors, and in which the Company receives benefits in addition to the investment of funds, but shall not include a transaction in which the
Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, (e) securities sold in connection with a firm commitment underwritten public offering of shares of
Common Stock that is intended, pursuant to the Company’s Board of Directors resolution, to produce minimum proceeds (after payment of underwriter’s fees and commissions) of not less than $30,000,000 and (f) securities issued in
connection with that certain Asset Purchase Agreement and Plan of Reorganization dated as of July 25, 2008 by and among the Company, Andover Medical, Inc. and Certified Diabetic Services, Inc. 
 “Existing Debts” shall have the meaning ascribed to such term in the preamble above. 
 “Interim Balance Sheet” means the most recent quarterly report filed on Form 10-Q by the Company under the Exchange Act.

 “Liens” means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or
other restriction. 
 “Material Adverse Effect” shall have the meaning assigned to such term in
Section 3.1(b). 
 “Person” means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 
 “Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation
or partial proceeding, such as a deposition), whether commenced or threatened. 
 “Registration Rights
Agreement” means the Registration Rights Agreement, dated the date hereof, between the Company and the Purchaser, in the form of Exhibit B attached hereto. 
 “Registration Statement” means a registration statement meeting the requirements set forth in the Registration Rights
Agreement and covering the resale of the Underlying Shares by Purchaser as provided for in the Registration Rights Agreement. 
 “Required Approvals” shall have the meaning ascribed to such term in Section 3.1(e). 
 “Required Minimum” means, as of any date, 110% of the maximum aggregate number of shares of Common Stock then issued or potentially issuable in the future pursuant to the Transaction Documents, including any Underlying
Shares issuable upon 

  

 3 

 
exercise or conversion in full of all Warrants and Series D Preferred Stock (including a reasonable reserve for Underlying Shares issuable as payment of
dividends), ignoring any conversion or exercise limits set forth therein. 
 “Rule 144” means Rule 144
promulgated by the Commission pursuant to the Securities Act, as such rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 
 “Securities” means the Series D Preferred Stock, the Warrants, the Warrant Shares and the Underlying Shares. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated hereunder.

 “Series D Conversion Price” shall have the meaning ascribed to such term in the Series D Designations.

 “Series D Convertible Preferred Stock” means the Series D Convertible Preferred Stock of the Company and
such designations, preferences and limitations as are set forth in the Series D Designations. 
 “Series D
Designations” means the Certificate of Designation, Preferences and Rights of Series D Convertible Preferred Stock as filed with the State of Nevada on July 29, 2008 in the form attached hereto as Exhibit C. 
 “Short Sales” shall include all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act
(but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock). 
 “Stated
Value” shall have the meaning ascribed to such term in the Series D Designations. 
 “Subsidiary”
means any subsidiary of the Company as set forth on Schedule 3.1(a). 
 “Trading Day” means a day on
which the Common Stock is traded on a Trading Market. 
 “Trading Market” means the following markets or
exchanges on which the Common Stock is listed or quoted for trading on the date in question: the Nasdaq Capital Market, the American Stock Exchange, the New York Stock Exchange, the Nasdaq National Market, the OTC Bulletin Board, or “Pink
Sheets” published by Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of reporting prices). 
 “Transaction Documents” means this Agreement, the Series D Designations, the Warrants, the Registration Rights Agreement, the Letter Agreement, and any other 

  

 4 

 
documents or agreements executed in connection with the transactions contemplated hereunder. 
 “Underlying Shares” means the shares of Common Stock issued and issuable upon conversion or redemption of the Series D
Preferred Stock and upon exercise of the Warrants and issued and issuable in lieu of the cash payment of dividends on the Series D Preferred Stock in accordance with the terms of the Series D Preferred Stock. 
 “VWAP” of a share of Common Stock as of a particular date (the “Determination Date”) shall mean the
price determined by the first of the following clauses that applies: (a) if shares of Common Stock are traded on a national securities exchange (an “Exchange”), the weighted average of the closing sale price of a share of the
Common Stock of the Company on the last five (5) Trading Days prior to the Determination Date reported on such Exchange as reported in The Wall Street Journal (weighted with respect to the trading volume with respect to each such day);
(b) if shares of Common Stock are not traded on an Exchange but trade in the over-the-counter market and such shares are quoted on the National Association of Securities Dealers Automated Quotations System (“NASDAQ”), the
weighted average of the closing sale price of a share of the Common Stock of the Company on the last five (5) Trading Days prior to the Determination Date reported on NASDAQ as reported in The Wall Street Journal (weighted with respect to the
trading volume with respect to each such day); (c) if such shares are an issue for which last sale prices are not reported on NASDAQ, the average of the closing sale price, in each case on the last five (5) Trading Days (or if the relevant
price or quotation did not exist on any of such days, the relevant price or quotation on the next preceding Business Day on which there was such a price or quotation) prior to the Determination Date as reported by the Over the Counter Bulletin Board
(the “OTCBB”), or any other successor organization; (d) if no closing sales price is reported for the Common Stock by the OTCBB or any other successor organization for such day, the average of the closing sale price, in each case on
the last five (5) Trading Days (or if the relevant price or quotation did not exist on any of such days, the relevant price or quotation on the next preceding business day on which there was such a price or quotation) prior to the Determination
Date as reported by the “pink sheets” by the Pink Sheets, LLC, or any successor organization, (e) if no closing sales price is reported for the Common Stock by the OTCBB or any other successor organization for such day, then the
average of the high and low bid and asked price of any of the market makers for the Common Stock as reported on the OTCBB or in the “pink sheets” by the Pink Sheets, LLC on the last five (5) Trading Days; or (e) in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holder and reasonably acceptable to the Company. 
 “Warrants” shall have the meaning assigned to such term in Section 2.2. 
 “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Warrants. 
  

 5 

 ARTICLE II 
 PURCHASE AND SALE 
 2.1 Purchased Securities. On the Closing Date, upon the terms and subject
to the conditions set forth herein, concurrent with the execution and delivery of this Agreement by the parties hereto: 
 (a)
the Purchaser agrees to purchase, and the Company agrees to sell, for a cash purchase price of $3,000,000 (the “Cash Purchase Price”), Series D Preferred Stock having an aggregate Stated Value of $3,000,000. 
 (b) the Purchaser agrees to tender, deliver and forgive the Existing Debts to the Company for cancellation of all the Existing Debts on
Exhibit A in the principal amount of $4,760,204.91 and accrued interest of $228,856.63, and the Company shall issue and deliver to the Purchaser Series D Preferred Stock having an aggregate Stated Value of $4,989,061.54. 
 2.2 Issuance of Warrants. Immediately upon and subject to the effectiveness of the Charter Amendment in the State of Nevada, MSMI will issue (i) a
common stock purchase warrant exercisable for 90,000,000 shares of Common Stock, with an exercise price equal to $0.10 and a term of exercise of five (5) years and (ii) a common stock purchase warrant exercisable for 149,671,846
shares of Common Stock, with an exercise price equal to $0.10 and a term of exercise of five (5) years. 
 The warrants described in
this Section 2.2 are referred to herein individually as a “Warrant” and collectively as the “Warrants.” 
 2.3 Closing. Subject to satisfaction of the conditions set forth in Sections 2.4, 2.5, and 2.6, the Closing shall occur at the offices of the Company’s counsel, Bush Ross, P.A., 1801
North Highland Avenue, Tampa, Florida 33602, or such other location as the parties shall mutually agree. At the Closing, (a) the Purchaser shall deliver (i) via wire transfer or a certified check immediately available funds equal to the
Cash Purchase Price, and (ii) the Existing Debts held by such Purchaser, together with all documents necessary to validly and duly tender, assign and convey such Existing Debts to the Company for cancellation thereof, and (b) the Company
shall deliver to the Purchaser the Series D Preferred Stock, free and clear of all liens and restrictions of any kind (except for those imposed by applicable securities laws), and a letter agreement providing for the issuance of the warrants
referred to in Section 2.2. 
 2.4 Cancellation of Existing Debts; Guarantees; Termination of Security Interest. Upon
receipt from Purchaser of the Existing Debts in accordance with Sections 2.1, 2.2 and 2.3 hereof, the Company shall cancel each Existing Debt immediately. The Company and Purchaser agree that upon such cancellation of each Existing
Debts: (a) the obligations of the Company, or its subsidiaries, as applicable, to pay the principal of, interest on or redemption premium and otherwise in respect of, such Existing Debts surrendered by the Purchaser to the Company shall
terminate; (b) all obligations of the Purchaser pursuant to the Existing Debts shall terminate; (c) all obligations of the Company, or its subsidiaries, as applicable, in respect of the cancelled Existing Debts shall
terminate, and (d) all obligations of guarantors guarantying repayment of the 

  

 6 

 
Existing Debts shall terminate. In addition, upon receipt from the Purchaser of the Existing Debts in accordance with Section 2.3 hereof, the Purchaser
agrees and acknowledges that (x) all security interests and other liens granted to or held by Purchaser in any collateral as security for such Existing Debts shall be forever and irrevocably satisfied, released and discharged, (y) all
share pledge agreements and charges shall be forever and irrevocably terminated, cancelled, released and satisfied, and (z) all mortgages of any trademarks, copyrights, patents and other intellectual property shall be forever and irrevocably
terminated, cancelled, released and satisfied. Further, Purchaser agrees, at Company’s expense, to take all reasonable additional steps requested by the Company as may be necessary to release its security interests in the collateral that may be
identified after the date hereof, including but not limited to the recording, filing and entering into any agreements, documents, forms or papers needed to accomplish such release. 
 2.5 Deliveries. 
 (a)
On the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following: 
 (i) this Agreement
duly executed by the Company; 
 (ii) a certificate for the Series D Preferred Stock having an aggregate Stated Value of
$7,989,061.54; 
 (iii) a letter agreement providing for the issuance of the Warrants described in Section 2.2 above (the
“Letter Agreement”); and 
 (iv) the Registration Rights Agreement duly executed by the Company. 

(b) On the Closing Date, the Purchaser shall deliver or cause to be delivered to the Company the following: 
 (i) this Agreement duly executed by such Purchaser; 
 (ii) the Cash Purchase Price by wire transfer to the account as specified in writing by the Company; 
 (iii) the Existing Debts for cancellation; and 
 (iv) the Registration Rights Agreement duly executed by such Purchaser. 
 2.6 Closing Conditions. 
 (a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met: 
 (i) the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Purchaser contained herein; 
  

 7 

 (ii) all obligations, covenants and agreements of the Purchaser required to be performed
at or prior to the Closing Date shall have been performed; and 
 (iii) the delivery by the Purchaser of the items set forth
in Section 2.5(b) of this Agreement. 
 (b) The obligations of the Purchaser hereunder in connection with the
Closing are subject to the following conditions being met: 
 (i) the accuracy in all material respects on the Closing Date of
the representations and warranties of the Company contained herein; 
 (ii) all obligations, covenants and agreements of the
Company required to be performed at or prior to the Closing Date shall have been performed; 
 (iii) the delivery by the
Company of the items set forth in Section 2.5(a) of this Agreement; and 
 (iv) there shall have been no Material
Adverse Effect with respect to the Company since the date of the Interim Balance Sheet [NOT DEFINED]. 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES 
 3.1
Representations and Warranties of the Company. Except as set forth under the corresponding section of the disclosure schedules delivered to the Purchaser concurrently herewith (the “Disclosure Schedules”) which Disclosure
Schedules shall be deemed a part hereof and to qualify any representation or warranty otherwise made herein to the extent of such disclosure, the Company hereby makes the representations and warranties set forth below to Purchaser. 
 (a) Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1(a). The Company
owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid,
non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no Subsidiaries, then all other references in the Transaction Documents to the Subsidiaries or any of them will be disregarded.

 (b) Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or
otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the requisite corporate power and authority to own and use its properties and assets and to
carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.
The Company and each of the Subsidiaries is duly qualified to conduct 

  

 8 

 
business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in (i) a material adverse effect on the legality, validity
or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a
material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”) and no
Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such corporate power and authority or qualification. 
 (c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the
transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of the Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary corporate action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection therewith
other than in connection with the Required Approvals. Each Transaction Document has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid
and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and
contribution provisions may be limited by applicable law. 
 (d) No Conflicts. The execution, delivery and performance
of the Transaction Documents by the Company and the consummation by the Company of the other transactions contemplated hereby and thereby do not and will not: (i) subject to the Required Approvals, conflict with or violate any provision of the
Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) subject to the Required Approvals, conflict with, or constitute a default (or an event that with
notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party
or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or
other restriction of any court or governmental authority to which the Company or a Subsidiary is subject 

  

 9 

 
(including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except
in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect. 
 (e) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other
federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than (i) the filing with the Commission of the Registration
Statement, (ii) the notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the listing of the Underlying Shares for trading thereon in the time and manner required thereby, (iii) the
filing of Form D with the Commission and such filings as are required to be made under applicable state securities laws and (iv) the delivery of the notices and the receipt of the approvals set forth on Schedule 3.1(e) (collectively, the
“Required Approvals”). 
 (f) Issuance of the Securities. The Securities are duly authorized and, when
issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the
Transaction Documents. The Underlying Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved
from its duly authorized capital stock a number of shares of Common Stock for issuance of the Underlying Shares at least equal to the Required Minimum on the date hereof. 
 (g) Capitalization. Immediately before the Closing, the capitalization of the Company is as set forth on Schedule 3.1(g).
Except as set forth on Schedule 3.1(g), no Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result
of the purchase and sale of the Securities or as set forth on Schedule 3.1(g), there are no outstanding options, warrants, script rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. Except as set forth on Schedule 3.1(g), the issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or
other securities to any Person (other than the Purchaser) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of
capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. Except as set forth on Schedule 3.1(g), no further approval or 

  

 10 

 
authorization of any stockholder, the Board of Directors of the Company or others is required for the issuance and sale of the Securities. Except as set
forth on Schedule 3.1(g), there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or
among any of the Company’s stockholders. 
 (h) SEC Reports; Financial Statements. Except as set forth on
Schedule 3.1(h), the Company has filed all SEC Reports required to be filed by it under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for two years preceding the Closing Date (or such
shorter period as the Company was required by law or regulation to file such materials) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the
“SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, each SEC Report (i) were
prepared in accordance and complied in all material respects with the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations of the SEC thereunder applicable to such SEC Reports, and (ii) did
not at the time they were filed (or if amended or superseded by a filing prior the date of this Agreement then on the date of such filing) contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. None of the Subsidiaries are required to file any forms, reports or other documents with the SEC. The consolidated
financial statements of the Company and the Subsidiaries included in the SEC Reports complied in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of
filing. Such financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and fairly present in all material respects the consolidated financial position of the Company and the Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject,
in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. 
 (i) Material Changes. Since
the date of the Interim Balance Sheet, except as specifically disclosed on Schedule 3.1(i), (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect,
(ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not
required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not materially altered its method of accounting, (iv) the Company has not declared
or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has 

  

 11 

 
not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option or stock grant plans. 
 (j) Litigation. Except as set forth on Schedule 3.1(j), there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory
authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or
(ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor, to the knowledge of the Company, any director or officer thereof, is or has
been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. 
 (k) Certain Fees. Except as set forth on Schedule 3.1(s), no brokerage or finder’s fees or commissions are or will be
payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchaser shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.

 (l) Disclosure. All disclosure furnished by or on behalf of the Company to the Purchaser regarding the Company, its
business and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, with respect to the representations and warranties made herein are true and correct with respect to such representations and warranties and do
not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges and
agrees that Purchaser has not made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof. 
 (m) Acknowledgment Regarding Purchaser’s Purchase of Securities. The Company acknowledges and agrees that the Purchaser is
acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of
the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by Purchaser or any of their respective representatives or agents in connection with the Transaction
Documents and the transactions contemplated thereby is merely incidental to the Purchaser’s purchase of the Securities. The Company further represents to Purchaser that the Company’s decision to enter into this Agreement and the other

  

 12 

 
Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 3.2 Representations and Warranties of the Purchaser. Purchaser hereby represents and warrants as of the date hereof and as of the
Closing Date to the Company as follows: 
 (a) Organization; Authority. Purchaser is an entity duly organized, validly
existing and in good standing under the laws of the jurisdiction of its organization with full right, corporate or partnership power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and
otherwise to carry out its obligations hereunder and thereunder. The execution, delivery and performance by such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or similar action on
the part of Purchaser. Each Transaction Document to which it is a party has been duly executed by Purchaser, and when delivered by Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of Purchaser,
enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law. 
 (b) Own Account. Purchaser understands that the Securities are “restricted securities”
and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with a view to or for distributing or reselling such Securities or any part thereof
in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant to the Registration
Statement or otherwise in compliance with applicable federal and state securities laws) in violation of the Securities Act or any applicable state securities law. Purchaser is acquiring the Securities hereunder in the ordinary course of its
business. 
 (c) Purchaser Status. At the time Purchaser was offered the Securities, it was, and at the date hereof it
is, and on each date on which it exercises any Warrants or converts any Series D Preferred Stock it will be either: (i) an “accredited investor” as defined in Rule 501 under the Securities Act or (ii) a “qualified
institutional buyer” as defined in Rule 144A(a) under the Securities Act. Such Purchaser is not required to be registered as a broker-dealer under Section 15 of the Exchange Act. 
 (d) Experience of Such Purchaser. Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. 

  

 13 

 
Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such
investment. 
 (e) General Solicitation. Purchaser is not purchasing the Securities as a result of any advertisement,
article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

 (f) Short Sales and Confidentiality Prior To The Date Hereof. Other than the transaction contemplated hereunder,
Purchaser has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with Purchaser, executed any disposition, including Short Sales, in the securities of the Company during the period commencing
from the time that Purchaser first received a term sheet (written or oral) from the Company or any other Person setting forth the material terms of the transactions contemplated hereunder until the date hereof (“Discussion Time”).
Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of Purchaser’s assets and the portfolio managers have no direct knowledge of the
investment decisions made by the portfolio managers managing other portions of Purchaser’s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the
investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement, Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction). 
 (g) Risk Factors. Purchaser hereby agrees and acknowledges that it has
been informed of the following: (i) there are factors relating to the subsequent transfer of any Securities acquired hereunder that could make the resale of such Securities difficult; and (ii) there is no guarantee that Purchaser will
realize any gain from the purchase of the Securities. The purchase of the Securities involves a high degree of risk and is subject to many uncertainties. These risks and uncertainties may adversely affect the Company’s business, operating
results and financial condition. In such an event, the trading price for the Common Stock could decline substantially and Purchaser could lose all or part of its investment. 
 (h) Due Diligence. Purchaser hereby agrees and acknowledges that Purchaser has had an opportunity to meet with representatives of
the Company and to ask questions and receive answers to Purchaser’s satisfaction regarding the Company’s proposed business and the Company’s financial condition in order to assist Purchaser in evaluating the merits and risks of
purchasing the Securities. All material documents and information pertaining to the Company and the purchase of Securities hereunder that have been requested by Purchaser have been made available to Purchaser. 
 (i) Certain Fees. Except for investment banking fees payable to Midtown Partners & Co., LLC, Purchaser has not employed
any broker or finder or incurred any liability for any brokerage or investment banking fees, commissions, finders’ structuring 

  

 14 

 
fees, financial advisory fees or other similar fees in connection with the Transaction Documents. 
 ARTICLE IV 
 OTHER AGREEMENTS OF THE PARTIES 
 4.1 Transfer Restrictions. 
 (a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an
Affiliate of Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act. As a condition of
transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights of a Purchaser under this Agreement and the Registration Rights Agreement. 
 (b) The Purchaser agrees to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities
in the following form: 
 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE] [CONVERTIBLE] HAVE BEEN
REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT
BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON [EXERCISE]
[CONVERSION] OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES. 
 The Company acknowledges and agrees that Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial
institution that is an “accredited investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and the Registration Rights Agreement 

  

 15 

 
and, if required under the terms of such arrangement, Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge
or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At
Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the Securities
are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to
appropriately amend the list of selling stockholders thereunder. 
 4.2 Integration. The Company shall not sell, offer for sale or
solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the
Securities Act of the sale of the Securities to the Purchaser. 
 4.3 Use of Proceeds. Except as set forth on Schedule 4.5
attached hereto, the Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and not for the satisfaction of any portion of the Company’s debt (other than payment of trade payables in the
ordinary course of the Company’s business and prior practices, including attorney’s and professional fees), to redeem any Common Stock or Common Stock Equivalents or to settle any outstanding litigation. 
 4.4 Reimbursement. If Purchaser becomes involved in any capacity in any Proceeding by or against any Person who is a stockholder of the Company
(except as a result of sales, pledges, margin sales and similar transactions by such Purchaser to or with any other stockholder), solely as a result of Purchaser’s acquisition of the Securities from the Company under this Agreement, the Company
will reimburse Purchaser for its reasonable legal and other expenses (including the cost of any investigation preparation and travel in connection therewith) incurred in connection therewith, as such expenses are incurred. The reimbursement
obligations of the Company under this paragraph shall be in addition to any liability which the Company may otherwise have, shall extend upon the same terms and conditions to any Affiliates of the Purchaser who are actually named in such action,
proceeding or investigation, and partners, directors, agents, employees and controlling persons (if any), as the case may be, of the Purchaser and any such Affiliate, and shall be binding upon and inure to the benefit of any successors, assigns,
heirs and personal representatives of the Company, the Purchaser and any such Affiliate and any such Person. The Company also agrees that neither the Purchaser nor any such Affiliates, partners, directors, agents, employees or controlling persons
shall have any liability to the Company or any Person asserting claims on behalf of or in right of the Company solely as a result of acquiring the Securities under this Agreement. 
 4.5 Indemnification of Purchaser. Subject to the provisions of this Section 4.5, the Company will indemnify and hold Purchaser and its
directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls
Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of 

  

 16 

 
the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling person (each, a “Purchaser Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to
(a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against Purchaser, or any of its Affiliates, by any
stockholder of the Company who is not an Affiliate of such Purchaser, solely as a result of such Purchaser’s acquisition of the Securities pursuant to this Agreement (unless such action is based upon a breach of such Purchaser’s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser may have with any such stockholder or any violations by the Purchaser of state or federal securities laws or any conduct by
such Purchaser which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party
shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ
separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically
authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of such separate counsel, a
material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one (1) such separate
counsel. The Company will not be liable to any Purchaser Party under this Agreement (i) for any settlement by a Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or
(ii) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this
Agreement or in the other Transaction Documents. 
 4.6 Participation in Future Financing. 
 (a) From the date hereof until the date that is the one (1) year anniversary of the Closing Date, upon any issuance by the Company or
any of its Subsidiaries of Common Stock or Common Stock Equivalents other than an Exempt Issuance (a “Subsequent Financing”), Purchaser shall have the pro-rata right to participate (with any other holders identified as having a
contractual right of first refusal on Schedule 3.1(g)) in the Subsequent Financing on the same terms, conditions and price provided for in the Subsequent Financing. 
 (b) At least ten (10) Trading Days prior to the closing of the Subsequent Financing, the Company shall deliver to Purchaser a written
notice of its intention to effect a Subsequent Financing (“Pre-Notice”), which Pre-Notice shall ask Purchaser if it 

  

 17 

 
wants to review the details of such financing (such additional notice, a “Subsequent Financing Notice”). Upon the request of Purchaser, and
only upon a request by such Purchaser, for a Subsequent Financing Notice, the Company shall promptly, but no later than one (1) Trading Day after such request, deliver a Subsequent Financing Notice to Purchaser. The Subsequent Financing Notice
shall describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised thereunder, the Person or Persons through or with whom such Subsequent Financing is proposed to be effected, and
attached to which shall be a term sheet or similar document relating thereto. 
 (c) Any Purchaser desiring to participate in
such Subsequent Financing must provide written notice to the Company by not later than 5:30 p.m. (New York City time) on the 10th Trading Day after all of the Purchaser have received the Pre-Notice that the Purchaser is willing to participate in the
Subsequent Financing, the amount of the Purchaser’s participation, and that the Purchaser has such funds ready, willing, and available for investment on the terms set forth in the Subsequent Financing Notice. If the Company receives no notice
from a Purchaser as of such tenth (10th) Trading Day, such Purchaser shall be deemed to have notified the Company that it does not elect to participate. 
 (d) If by 5:30 p.m. (New York City time) on the tenth (10th) Trading Day after all of the Purchaser have received the Pre-Notice,
notifications by Purchaser of its willingness to participate in the Subsequent Financing (or to cause their designees to participate) is, in the aggregate, less than the total amount of the Subsequent Financing, then the Company may effect the
remaining portion of such Subsequent Financing on the terms and with the Persons set forth in the Subsequent Financing Notice. 
 (e) Notwithstanding the foregoing, this Section 4.6 shall not apply in respect of (i) an Exempt Issuance, and (ii) shares of Common Stock issued solely in connection with dividends required to be paid under the terms
and conditions of the Series D Convertible Preferred Stock or the Series D Convertible Preferred Stock. 
 4.7 Form D; Blue Sky
Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof, promptly upon request of Purchaser. The Company shall take such action as the Company shall
reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchaser at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall
provide evidence of such actions promptly upon request of Purchaser. 
 ARTICLE V 
 MISCELLANEOUS 
 5.1 Fees and
Expenses. At the Closing, the Company has agreed to reimburse the Purchaser the non-accountable sum of $50,000 for its legal fees and expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and 

  

 18 

 
performance of this Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery
of any Securities to the Purchaser. 
 5.2 Entire Agreement. The Transaction Documents, together with the exhibits and schedules
thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged
into such documents, exhibits and schedules. 
 5.3 Notices. Any and all notices or other communications or deliveries required or
permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the
signature pages attached hereto prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on
the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. 
 5.4 Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and the Purchaser or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right
hereunder in any manner impair the exercise of any such right. 
 5.5 Headings. The headings herein are for convenience only, do not
constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 
 5.6 Successors and
Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of Purchaser (other than by merger). Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided such transferee agrees in writing to be bound, with respect to
the transferred Securities, by the provisions of the Transaction Documents that apply to the “Purchaser”. 
 5.7 No Third-Party
Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 
 5.8 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be
governed by and construed and 

  

 19 

 
enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that
all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in Hillsborough County, Florida. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in Hillsborough County, Florida for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an
inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of
the Transaction Documents, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and
prosecution of such action or proceeding. 
 5.9 Survival. The representations, warranties, covenants and other agreements contained
herein shall survive the Closing and the delivery, exercise and/or conversion of the Securities, as applicable for a period of two (2) years from the date of this Agreement. 
 5.10 Execution. This Agreement may be executed in two (2) or more counterparts, all of which when taken together shall be considered one and
the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered
by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an original thereof. 
 5.11 Severability. If any term, provision,
covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and
effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that
may be hereafter declared invalid, illegal, void or unenforceable. 
  

 20 

 5.12 Remedies. In addition to being entitled to exercise all rights provided herein or granted by
law, including recovery of damages, the Purchaser and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of
any breach of obligations contained in the Transaction Documents and hereby agrees to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. 
 5.13 Construction. The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the
Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.

 (Remainder of Page Intentionally Left Blank) 
 (Signature Pages Follow) 
  

 21 

 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed
by their respective authorized signatories as of the date first indicated above. 
  

					
	Medical Solutions Management Inc.	  	Address for Notice:
			
	By:	 	 /s/ Lowell M. Fisher
	  	 237 Cedar Hill Street
 Marlboro, MA 01752

	Name:	 	Lowell M. Fisher	  
	Title:	 	Interim Chief Executive Officer	  	

 With a copy to (which shall not constitute notice): 
 (Remainder of Page Intentionally Left Blank) 
 (Signature Page For Purchaser
Follows) 
  

 22 

 [PURCHASER SIGNATURE PAGES TO SECURITIES 
 PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities
Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser: VICIS CAPITAL MASTER FUND
		
	Signature of Authorized Signatory of Purchaser:	  	/s/ Chris Phillips

			
		
	Name of Authorized Signatory:	  	/s/ Chris Phillips, Managing Director

			
		
	Title of Authorized Signatory:	  	Vicis Capital, LLC , sole voting unitholder of Vicis Capital Master Fund and delegate of Caledonian Bank & Trust Limited

			
		
	Email Address of Purchaser:	  	  

			
		
	Facsimile Number of Purchaser:	  	(212) 909-4601

			
		
	Jurisdiction of Organization of Purchaser:	  	a trust organized under the laws of the Cayman Islands

 Address for Notice of Purchaser: 
 Vicis Capital Master Fund 
 Attn: Keith Hughes 
 445 Park Avenue, 16th Floor 
 New York, NY 10022 
 Address for Delivery of Securities for Purchaser (if not same as above): 
 Vicis Capital Master Fund 
 Attn: Keith Hughes 
 445 Park Avenue, 16th Floor 
 New York, NY 10022 
  

 23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]